# P U B L I C A T I O N S

## Prof. Dr. med. Dr.h.c. Michael Oellerich

**FADLM, FAMM, FFPath (RCPI), FRCPath**

**Distinguished Research Professor**

**of Clinical Chemistry**

**Department of Clinical Pharmacology**

**George-August-University Göttingen**

**Germany**

 **https://klinpharm.umg.eu/oellerich/**

Table of Content

[P U B L I C A T I O N S 1](file:///Y:\Publikationsliste\Publikationsliste%202018\Publikationsliste%2025.05.18.docx#_Toc515472969)

[Prof. Dr. med. Dr.h.c. Michael Oellerich 1](file:///Y:\Publikationsliste\Publikationsliste%202018\Publikationsliste%2025.05.18.docx#_Toc515472970)

[ORIGINAL ARTICLES 4](#_Toc515472971)

[Clinical chemistry - analytical methods 4](#_Toc515472972)

[Hypoglycemic substances 10](#_Toc515472973)

[Liver function, liver transplantation 12](#_Toc515472974)

[Lipoproteins, plasminogen, oxidant stress, liver and small bowel injury, inflammation, prenatal programming 17](#_Toc515472975)

[Therapeutic drug monitoring (pharmacokinetics, pharmacogenetics, pharmacodynamics) 20](#_Toc515472976)

[Proteomics 35](#_Toc515472977)

[Molecular diagnostics 38](#_Toc515472978)

[BOOK CHAPTERS 44](#_Toc515472979)

[REVIEWS 53](#_Toc515472980)

[MULTICENTRE STUDIES 62](#_Toc515472981)

[BOOKS EDITED 64](#_Toc515472982)

[EDITORIALS, LETTERS TO THE EDITOR, QUESTIONS AND ANSWERS 66](#_Toc515472983)

[GUEST EDITOR 70](#_Toc515472984)

[GENE BANK ENTRIES 71](#_Toc515472985)

[PROTEOME ENTRIES 72](#_Toc515472986)

[COMMITTEE RECOMMENDATIONS 75](#_Toc515472987)

[NEWSLETTER 76](#_Toc515472988)

[ABSTRACTS 77](#_Toc515472989)

**Dissertation**:

"**Über die Freisetzung von Magnesium- und Calcium-Ionen aus einer Mikrosomenfraktion der Meerschweinchenleber unter Einwirkung von Phenyläthylbiguanid**".

Ludolf-Krehl-Klinik Heidelberg

(Direktor: Prof.Dr.G.Schettler)

Ruprecht-Karl-Universität, Heidelberg 1970

**Habilitation**:

"**Untersuchungen über die blutglucosesenkende Wirkung der 2-(Phenyläthylhydrazano)- und 2-(2-Cyclohexyläthylhydrazono)-propi­onsäure**".

Institut für Klinische Chemie

(Direktor: Prof.Dr.Dr.J.Büttner)

Medizinische Hochschule Hannover, Hannover 1978

# ORIGINAL ARTICLES

# Clinical chemistry - analytical methods

1. Haeckel R, Haindl H, Hultsch E, Mariss P, **Oellerich M**. Com­parison of 8 different colorimetric, radiochemical and immu­nological procedures for the determination of iron binding capacity. Z Klin Chem Klin Biochem 1973; 11:529-534.
2. **Oellerich M**, Külpmann WR, Haeckel R. Drug screening by enzyme immunoassay (EMIT) and thin-layer chromatography (Drug Skreen). J Clin Chem Clin Biochem 1977; 15:275-283.
3. **Oellerich M**, Külpmann WR, Haeckel R, Heyer R. Determination of phenobarbital and phenytoin in serum by a mechanized immu­noassay (EMIT) in comparison with a gas-liquid chromatogra­phic method. J Clin Chem Clin Biochem 1977; 15:353-358.
4. **Oellerich M**, Haindl H, Haeckel R. Die Bestimmung von Digoxin im Serum mit Enzymimmunotests. Internist 1978; 19:188-190.
5. **Oellerich M**, Sybrecht GW, Haeckel R. Monitoring of serum theophylline concentrations by a fully mechanized enzyme immunoassay (EMIT). J Clin Chem Clin Biochem 1979; 17:299-302.
6. **Oellerich M**, Haindl H, Haeckel R. Evaluation of enzyme immu­noassays for determination of thyroxine (EMIT, ENZYMUN) and of thyroxine binding index. J Clin Chem Clin Biochem 1979; 17:483-488.
7. Borner K, Colombo JP, Bachman C, Haeckel R, **Oellerich M**, Westerink D, Fischer M, Wimmer P, Vogt W, Tausch A, Knedel M, Minder W, Blum J, Portenhauser R. Die Bestimmung von Thyroxin im Serum mit einem heterogenen Enzymimmunoassay: Ergebnisse einer gemeinsamen Erprobung. J Clin Chem Clin Biochem 1979; 17:471-481.
8. **Oellerich M**, Engelhardt P, Schaadt M, Diehl V. Determination of methotrexate in serum by a rapid, fully mechanized enzyme immunoassay (EMIT). J Clin Chem Clin Biochem 1980; 18:169-174.
9. Haeckel R, **Oellerich M**. Evaluation of the 30°C-version of the ACA (Automatic Clinical Analyzer). Dt Ges f Klin Chem e V - Mitteilungen 1980; 11:74-95.
10. **Oellerich M**, Haindl H. Determination of triiodothyronine in serum by enzyme- and radioimmunoassay - a comparative study. J Clin Chem Clin Biochem 1981; 19:447-451.
11. Braun S, Vogt W, Borner K, Delcourt R, Eber O, Ederveen AB, Haas H, Kagedal B, Kaltwasser F, Löund H, **Oellerich M**, Haidl H, Wagner H. Bestimmung von Trijodthyronin im Serum mit einem heterogenen Enzymimmunoassay: Ergebnisse einer gemeinsamen Erprobung. J Clin Chem Clin Biochem 1981; 19:911-918.
12. Külpmann WR, **Oellerich M**. Monitoring of therapeutic serum concentrations of antiepileptic drugs by a newly developed gas chromatographic procedure and enzyme immunoassay (EMIT): a comparative study. J Clin Chem Clin Biochem 1981; 19:249-258.
13. **Oellerich M**, Külpmann WR, Beneking M, Sybrecht GW, Staib AH, Schuster R. Determination of theophylline in serum by non-isotopic immunoassays (EMIT, SLFIA, NIIA) and HPLC - a compa­rative study. Fresenius Z Anal Chem 1982; 311:355-356.
14. **Oellerich M**, Haeckel R, Haindl H. Evaluation of EMIT adapted to the Cobas Bio centrifugal analyzer. J Clin Chem Clin Biochem 1982; 20:756-772.
15. **Oellerich M**, Hannemann P, Külpmann WR, Beneking M, Sybrecht GW. Die Bestimmung von Theophyllin im Serum mit radioaktivi­tätsfreien Immunotests und Hochdruck-Flüssigkeits-Chromato­graphie. Internist 1982; 23:641-646.
16. **Oellerich M**, Seiler D, Nagel D, Weidemann G, Weiss L, Hoff­mann GE, Temme H, Henkel E, Colombo JP, Peheim E, Hagemann P, Bayer PM, Gibitz JH, Malqvist E, Dati F, Habenstein K. Test­streifen für den schnellen Nachweis der α-Amylase im Urin. Eine kooperative Studie. Dtsch med. Wschr 1983; 108:1308-1311 (engl. u. japan. Übersetzung 1983).
17. Schumann G, Isberner I, **Oellerich M**. Highly specific HPLC method for the determination of theophylline in serum. Fre­senius Z Anal Chem 1984; 317:677.
18. Külpmann WR, Gey S, Beneking M, Kohl B, **Oellerich M**. Determi­nation of total and free phenytoin in serum by non-isotopic immunoassays and gas chromatography. J Clin Chem Clin Biochem 1984; 22:773-779.
19. Kessler A Ch, Rudorff KH, **Oellerich M**, Horn K, Mattersberger J, Hesch RD. Medizinische und klinische Evaluation einer neuen enzymimmunologischen Meßmethode zur Bestimmung des Thy­roxin bindenden Globulins (TBG) und des T4/TBG-Quotienten: Eine multizentrische Studie. J Clin Chem Clin Biochem 1985; 23:117-127.
20. Niemann A, **Oellerich M**, Schumann G, Sybrecht GW. Determina­tion of theophylline in saliva, using fluorescence polariza­tion immunoassay (FPIA). J Clin Chem Clin Biochem 1985; 23:725-732.
21. Schumann G, **Oellerich M**, Wonigeit K, Wrenger M. Ciclosporin: HPLC routine method with column switching. Fresenius Z Anal Chem 1986; 324:328-329.
22. Wrenger M, **Oellerich M**, Raude E, Riedmann M. HPLC methods for therapeutic drug monitoring involving direct serum injection, column switching and simple mobile phase adjustments. Fre­senius Z Anal Chem 1986; 324:350-351.
23. Raude E, **Oellerich M**, Wrenger M. Methotrexate: specific HPLC routine method involving column switching. Fresenius Z Anal Chem 1988; 330:384-385.
24. Martz W, **Oellerich M**. Flucytosine: determination in serum by HPLC and dosage individualization. Fresenius J Anal Chem 1990; 337:122.
25. Martz W, **Oellerich** **M**, Schumann G. Determination of methotre­xate in serum: the aca MTHO immunoassay and HPLC compared. J Clin Chem Clin Biochem 1990; 28:951-953.
26. Wieland E, Diedrich F, Schettler V, Schuff-Werner P, **Oellerich M**. Lipid hydroperoxide determination in serum by HPLC and iodometry. Fresenius J Anal Chem 1992; 343:62-63.
27. Wieland E, Schettler V, Diedrich F, Schuff-Werner P, **Oellerich M**. Determination of lipid hydroperoxides in serum. Iodometry and high performance liquid chromatography compared. Eur J Clin Chem Clin Biochem 1992; 30:363-369.
28. Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, **Oellerich M**, Schauer A. Determination of a fragment of the c-*erb*B-2 translational product p185 in serum of breast cancer patients. J Cancer Res Clin Oncol 1993; 119:249-252.
29. Petersen D, Demertzis S, Freund M, Schumann G, **Oellerich M**. Individualization of 5-Fluorocytosine Therapy. Chemotherapy 1994; 40:149-156.
30. Zielmann S, Mielck F, Roth AT, Lüdtke R, Sydow M, **Oellerich M.** Die Bestimmung von Gesamteiweiß eignet sich nicht zur Diagnose der therapie-bedürftigen Hypoalbuminämie bei Intensivpatienten. Anaesthesist 1995; 44:700-704.
31. Heller C, Hinzmann R, Hofmann M, Kaufhold S, Henkel E, **Oellerich M**. Lipid interference in the determination of the concentration of haemoglobin in plasma using the ACA SX analyzer. Eur J Clin Chem Clin Biochem 1996; 34:811-816.
32. Scholer A, Boecker J, Engelmayer U, Feldmann K, Hannak D, Kattermann R, **Oellerich M**, Raith H, Schlebusch H, Wieland H, Willems D, Jarausch J, Domke I. Comparability of a new turbidimetric digoxin test with other immunochemical tests and with HPLC - a multicenter evaluation. Clin Chem 1997; 43:92-99.
33. Andreeva M, Niedmann PD, Schütz E, Wieland E, Armstrong VW, **Oellerich M**. Determination of MEGX by HPLC with fluorescence detection. Clin Chem 1997; 43:1081-1083.
34. Andreeva M, Niedmann PD, Binder L, Armstrong VW, Meden H, Binder M, **Oellerich M**. A simple and reliable reverse-phase high-performance liquid chromatographic procedure for determination of paclitaxel (taxol) in human serum. Ther Drug Monit 1997; 19: 327-332.
35. Schütz E, Shipkova M, Niedmann PD, Wieland E, Armstrong VW, **Oellerich M**. Determination of monoethylglycinexylidide by fluorescence polarization immunoassay in highly icteric serum samples: modified precipitation procedure and HPLC compared. Clin Chem 1998; 44:1269-1274.
36. Shipkova M, Niedmann PD, Armstrong VW, Schütz E, Wieland E, Shaw LM, **Oellerich M**. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem 1998; 44:1481-1488.
37. Schütz E, Svinarov D, Shipkova M, Niedmann PD, Armstrong VW, Wieland E, **Oellerich M**. Cyclosporin whole blood immunoassays AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC. Clin Chem 1998; 44:2158-2164.
38. Meyer T, Binder L, Graeber T, Luthe H, Kreuzer H, **Oellerich M**, Buchwald AB. Superiority of combined CK-MB and Troponin I measurements for the early risk stratification of unselected patients presenting with acute chest pain. Cardiology 1999; 90:286-294.
39. Streit F, Niedmann PD, Shipkova M, Armstrong VW, **Oellerich M**. Rapid and sensitive liquid chromatography-tandem mass spectrometric method for determination of monoethylglycinexylidide. Clin Chem 2001; 47: 1853-1856.
40. von Ahsen N, Ehrlich B, Scott CS, Riggert J, **Oellerich M**. Cryoglobulins interfere with platelet counts by optical and impedance methods but not with the CD61 immunoplatelet count. Clin Chem 2001; 47: 1858-1860.
41. Streit F, Armstrong VW, **Oellerich M**. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem 2002; 48: 955-958.
42. Streit F, Shipkova M, Armstrong VW, **Oellerich M**. Validation of a rapid and sensitive liquid chromatography tandem mass spectrometry method for free and total mycophenolic acid. Clin Chem 2004; 50:152-159.
43. Shipkova M, Niedmann PD, Armstrong VW, **Oellerich M**, Wieland E. Determination of thiopurine methyltransferase activity in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by sulfasalazine. Clin Chem 2004; 50: 438-441.
44. Brandhorst G, Engelmayer J, Götze S, **Oellerich M**, von Ahsen N. Pre-analytical effects of different lithium heparin plasma separation tubes in the routine clinical chemistry laboratory.Clin Chem Lab Med 2011; 49: 1473-1477.
45. Petrova DT, Cocisiu GA, Eberle C, Rhode KH, Brandhorst G, Walson PD, **Oellerich M**. Can the Roche hemolysis index be used for automated determination of cell-free haemoglobin? A comparison to photometric assays. Clin Biochem 2013; 46: 1298-1301.

# Hypoglycemic substances

1. **Oellerich M**, Haeckel R. Inhibition of gluconeogenesis and of cell respiration by 1-(2-pyrimidinyl)-4-imino-1,4-dihydropy­ridinium chloride in perfused guinea pig liver. Biochem Phar­macol 1975; 24:1085-1088.
2. Haeckel R, **Oellerich M**. Inhibition of gluconeogenesis by sodium nitroprusside in the perfused guinea pig liver. Arzneim-Forsch (Drug Res) 1976; 26:2052-2054.
3. Haeckel R, **Oellerich M**. The influence of hydrazine, phenel­zine and nialamide on gluconeogenesis and cell respiration in the perfused guinea pig liver. Eur J Clin Invest 1977; 7:393-400.
4. Haeckel R, **Oellerich M**. Hydrazonopropionic acids, a new class of non-hormonal hypoglycaemic compounds. Biochem Soc Transac­tions 1979; 7:749-752.
5. Haeckel R, **Oellerich M**. Hydrazonopropionic acids, a new class of hypoglycemic substances. 1. Hypoglycemic effect of 2-(phenylethylhydrazono)- and 2-(2-cyclohexylethylhydrazono)-propionic acid. Horm Metab Res 1979; 11:606-611.
6. **Oellerich M**, Haeckel R. Hydrazonopropionic acids, a new class of hypoglycemic substances. 2. Influence of 2-(phenylethylhydrazono)- and 2-(2-cyclohexylethylhydrazono)-propionic acid on redox systems, acid base status and mono­amino oxidase activity. Horm Metab Res 1980; 12:182-189.
7. Haeckel R, Terlutter H, Schumann G, **Oellerich M**. Hydrazono­propionic acids, a new class of hypoglycemic substances. 3. Inhibition of jejunal glucose uptake in the rat and guinea pig. Horm Metabol Res 1984; 16:423-427.
8. **Oellerich M**, Haeckel R, Wirries KH, Schumann G, Beneking M. Hydrazonopropionic acids, a new class of hypoglycemic sub­stances. 4. Hypoglycemic effects of 2-(3-methylcinnamylhydra­zono)-propionate in the rat and guinea pig. Horm Metabol Res 1984; 16:619-625.
9. Haeckel R, **Oellerich M**, Schumann G, Beneking M. Hydrazonopro­pionic acids, a new class of hypoglycemic substances. 6. Inhibition of hepatic gluconeogenesis by 2-(3-methylcinnamyl-hydrazono)-propionate in the rat and guinea pig. Horm Metabol Res 1985; 17:115-122.
10. Beneking M, **Oellerich M**, Haeckel R, Binder L. Inhibition of mitochondrial carnitine acylcarnitine translocase-mediated uptake of carnitine 2-(3-methyl-cinnamyl-hydrazono)-propio­nate. Hydrazonopropionic acids, a new class of hypoglyaemic substances, VI. J Clin Chem Clin Biochem 1987; 25:467-471.
11. Haeckel R, Fink PC, **Oellerich M**. Influence of 2-(3-methyl-cinnamyl-hydrazono)-propionate on glucose and palmitate oxi­dation in human mononuclear leukocytes. Hydrazonopropionic acids, a new class of hypoglycaemic substances, VII. J Clin Chem Clin Biochem 1987; 25:561-566.
12. Binder L, **Oellerich M**, Haeckel R, Beneking M. Effects of 2-(3-methyl-cinnamyl-hydrazono)-propionate on fatty acid and glucose oxidation in the isolated rat diaphragm using 14C-labelled substrates. Hydrazonopropionic acids, a new class of hypoglycaemic substances, VIII. J Clin Chem Clin Biochem 1988; 26:815-819.
13. Beneking M, **Oellerich M**, Binder L, Choitz GF, Haeckel R. Inhibiton of mitochondrial carnitine acylcarnitine translo­case by hypoglycaemia-inducing substances. J Clin Chem Clin Biochem 1990; 28:323-327.
14. Haeckel R, Colic D, Binder L, **Oellerich M**. Stimulation of glucose metabolism in human blood cells by inhibitors of car­nitine-dependent fatty acid transport. J Clin Chem Clin Biochem 1990; 28:329-333.

# Liver function, liver transplantation

1. **Oellerich M**, Raude E, Burdelski M, Schulz M, Schmidt FW, Ringe B, Lamesch P, Pichlmayr R, Raith H, Scheruhn M, Wrenger M, Wittekind Ch. Monoethylglycinexylidide formation kinetics: A novel approach to assessment of liver function. J Clin Chem Clin Biochem 1987; 25:845-853.
2. Burdelski M, **Oellerich M**, Lamesch P, Raude E, Ringe B, Neu­haus P, Bortfeld S, Kämmerling C, Raith H, Scheruhn M, West­phal C, Worm M, Pichlmayr R. Evaluation of quantitative liver function test in liver donors. Transplant Proc 1987; 19:3838-3839.
3. Burdelski M, **Oellerich M**, Raude E, Lamesch P, Ringe B, Raith H, Scheruhn M, Westphal C, Worm M, Bortfeld S, Schulz M, Wittekind C, Hoyer PF, Pichlmayr R. A novel approach to assessment of liver function in donors. Transplant Proc 1988; 20, Suppl. 1:591-593.
4. 63. Lamesch P, Ringe B, Neuhaus P, Burdelski M, **Oellerich M**, Pichlmayr R. Qualitative assessment of liver function after hypovolemic, hypoxemic, and ischemic shock in a transplanta­tion model. Transplant Proc 1988; 20:994-995.
5. Burdelski M, **Oellerich M**, Bornscheuer A, Luebbe N, Ringe B, Lamesch P, Raude E, Raith H, Scheruhn M, Gubernatis G, Pichl­mayr R. Donor rating in human liver transplantation: correla­tion of oxygen consumption after revascularization with MEGX formation in donors. Transplant Proc 1989; 21:2392-2393.
6. Gubernatis G, Bornscheuer A, Taki Y, Farle M, Lübbe N, Yamaoka Y, Beneking M, Burdelski M, **Oellerich M**. Total oxygen consumption, ketone body ratio and a special score are early indicators of irreversible liver allograft dysfunction. Transplant Proc 1989; 21:2279-2281.
7. **Oellerich M**, Burdelski M, Ringe B, Lamesch P, Gubernatis G, Bunzendahl H, Pichlmayr R, Herrmann H. Lignocaine metabolite formation as a measure of pre-transplant liver function. Lancet 1989; i:640-642.
8. **Oellerich M**, Burdelski M, Lautz HU, Schulz M, Schmidt FW, Herrmann H. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. Ther Drug Monit 1990; 12:219-226.
9. Taki Y, Gubernatis G, Yamaoka Y, **Oellerich M**, Yamamoto Y, Ringe B, Okamoto R, Bunzendahl H, Beneking M, Burdelski M, Bornscheuer A, Pichlmayr R. Significance of arterial ketone body ratio measurement in human transplantation. Transplanta­tion 1990; 49:535-539.
10. Yamaoka Y, Taki Y, Gubernatis G, Nakatani T, Okamoto R, Yama­moto Y, Ishikawa Y, Ringe B, Bunzendahl H, **Oellerich M**, Koba­yashi K, Ozawa K, Pichlmayr R. Evaluation of the liver graft before procurement. Significance of arterial ketone body ratio in brain-dead patients. Transplant Int 1990; 3:78-81.
11. Lamesch P, Ringe B, **Oellerich M**, Burdelski M, Beyrau R, Gubernatis G, Pichlmayr R. Assessment of liver function in the early postoperative period after liver transplantation with ICG, MEGX, and GAL tests. Transplant Proc 1990; 22:1539-1541.
12. **Oellerich M**, Burdelski M, Lautz HU, Rodeck B, Duewel J, Schulz M, Schmidt FW, Brodehl J, Pichlmayr R. Assessment of pre-transplant prognosis in patients with cirrhosis. Trans­plantation 1991; 51:801-806.
13. **Oellerich M**, Burdelski M, Ringe B, Wittekind Ch, Lamesch P, Lautz HU, Gubernatis G, Beyrau R, Pichlmayr R. Functional state of the donor liver and early outcome of transplanta­tion. Transplant Proc 1991; 23:1575-1578.
14. Lautz HU, **Oellerich M**, Burdelski M, Bürger M, Engelmayer U, Pirlich M, Knoke A, Schmidt FW. Assessment of short-term prognosis in transplant candidates with postnecrotic or biliary cirrhosis. Transplant Proc 1991; 23:1572-1574.
15. Ozaki N, Ringe B, Bunzendahl H, Taki Y, Gubernatis G, **Oelle­rich M**, Kuse ER, Kinchi T, Yamanchi K, Takada Y, Yamaguchi T, Ozawa K, Pichlmayr R. Ketone body ratio as an indicator of early graft survival in clinical liver transplantation. Clin Transplantation 1991; 5:48-54.
16. **Oellerich M**, Burdelski M, Lautz HU, Binder L, Pichlmayr R. Predictors of one-year pretransplant survival in patients with cirrhosis. Hepatology 1991; 14:1029-1034.
17. Ozaki N, Gubernatis G, Ringe B, **Oellerich M**, Washida M, Yamaoka Y, Ozawa K, Pichlmayr R. Arterial blood ketone body ratio as an indicator for viability of donor livers. Transplant Proc 1991; 23:2487-2489.
18. Goeschen K, **Oellerich M**, Wedeking H, Elling D. Überprüfung der Leberfunktion in der Schwangerschaft mit Hilfe des MEGX-Tests unter besonderer Berücksichtigung der SIH und des HELLP-Syndrom. Gyn Comp 1991; 2:65.
19. Lehmann U, **Oellerich M**, Pape D, Sturm JA, Regel G. Leberfunktionsdiagnostik bei polytraumatisierten Patienten mittels MEGX-Test. In: Chirurgisches Forum 1992 f. experim. u. klinische Forschung. Gall, Berger, Ungeheuer (Hrsg.), Springer-Verlag Berlin 1992: 437-440.
20. Burdelski M, **Oellerich M**, Düwel J, Raith H, Scheruhn M, Ringe B, Rodeck B, Latta A, Pichlmayr R, Brodehl J. Pre- and post-transplant assessment of liver function in pediatric liver transplantation. Eur J Pediatr 1992; 151 [Suppl.1]: 39-43.
21. Yamaoka Y, Washida M, Manaka D, Gubernatis G, Ringe B, Ozaki N, Yamaguchi T, Takada Y, **Oellerich M**, Ozawa K, Pichlmayr R. Arterial ketone body ratio as a predictor of donor liver viability in human liver transplantation. Transplantation 1993; 55: 92-95.
22. **Oellerich M**, Hartmann H, Ringe B, Burdelski M, Lautz HU, Pichlmayr R. Assessment of prognosis in transplant candidates by use of the Pugh-MEGX score. Transplant Proc 1993; 25:1116-1119.
23. Ozaki N, Ringe B, Gubernatis G, Takada Y, Yamaguchi T, Yamaoka Y, **Oellerich M**, Ozawa K, Pichlmayr R. Changes in energy substrates in relation to arterial ketone body ratio after human orthotopic liver transplantation. Surgery 1993; 113: 403-409.
24. **Oellerich M**, Schütz E, Polzien F, Ringe B, Armstrong VW, Hartmann H, Burdelski M. Influence of gender on the monoethylglycinexylidide test in normal subjects and liver donors. Ther Drug Monit 1994; 16:225-231.
25. Christians U, Kohlhaw K, Esselmann H, Sürig T, Luy M, Kaltefleiter M, Beyrau R, Linck A, Ringe B, **Oellerich M**, Sewing KFR. The Yin and Yang of lidocaine and cyclosprorine metabolism in liver graft recipients. Transplant Proc 1994; 26:2827-2828.
26. Armstrong VW, Kaltefleiter M, Luy-Kaltefleiter M, Schütz E, Wieland E, Loss M, Winkler M, Ringe B, **Oellerich M**. Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine. Transplant Proc 1995; 27:1201-1203.
27. Lehmann U, Armstrong VW, Schütz E, Regel G, Pape D, **Oellerich M**. Monoethylglycinexylidide as an early predictor of posttraumatic multiple organ failure. Ther Drug Monit 1995; 17:125-132.
28. Armstrong VW, Schütz E, Kaltefleiter M, Luy M, Helmhold M, Wieland E, Ringe B, **Oellerich M**. Relationship of apolipoproteins AI, B and lipoprotein Lp(a) to hepatic function of liver recipients during the early post-transplant period. Eur J Clin Invest 1995; 25:485-493.
29. Schütz E, Luy-Kaltefleiter M, Kaltefleiter M, Burdelski M, Ringe B, Armstrong VW, **Oellerich M**. The value of serial determination of MEGX and hyaluronic acid after orthotopic liver transplantation. Eur J Clin Invest 1996; 26:907-916.
30. Burdelski M, Schütz E, Nolte-Buchholtz S, Armstrong VW, **Oellerich M**. Prognostic value of the monoethylglycinexylidide test in pediatric liver transplant candidates. Ther Drug Monit 1996; 18:378-382.
31. Autschbach R, Falk V, Lange H, **Oellerich M**, Walther T, Mohr FW, Dalichau H. Assessment of metabolic liver function and hepatic blood flow during cardiopulmonary bypass. Thorac. cardiovasc.Surgeon 1996; 44:76-80.
32. El Desoky ES, Ahmed AM, Nafeh MA, Ahmed HA, Schütz E, Armstrong VW, **Oellerich M**. Assessment of liver function by the MEGX test in patients with schistosomiasis and cirrhosis. Clin Biochem 1999; 32:207-212.
33. Igonin AA, Armstrong VW, Shipkova M, Kukes VG, **Oellerich M**. The monoethylglycinexylidide (MEGX) test as a marker of hepatic dysfunction in septic patients with pneumonia. Clin Chem Lab Med 2000; 38:1125-1128.
34. Hein OV, Öhring R, Schilling A, **Oellerich M**, Armstrong VW, Kox WJ, Spies C. N-acetylcysteine decreases lactate signal intensities in liver tissue and improves liver function in septic shock patients, as shown by magnetic resonance spectroscopy: extended case report. Critical Care 2004; 8:R66-R71.
35. Braun JP, Schroeder T, Buehner S, Dohmen P, Moshirzadeh M, Grosse J, Streit F, Schlaefke A, Armstrong VW, **Oellerich M**, Lochs H, Konertz W, Kox WJ, Spies C. Splanchnic oxygen transport, hepatic function and gastrointestinal barrier after normothermic cardiopulmonary bypass. Acta Anaesthesiol Scand 2004; 48: 697-703.
36. Dresing K, Armstrong VW, Leip CL, Streit F, Burchardi H, Stürmer KM, **Oellerich M**. Real-time assessment of hepatic function is related to clinical outcome in critically ill patients after polytrauma. Clin Biochem 2007; 40: 1194-1200.
37. Lorf T, Schnitzbauer AA, Schaefers SKH, Scherer MN, Schlitt HJ, **Oellerich M**, Becker H, Obed A. Prognostic value of the monoethylglycinexylidide (MEGX)-test prior to liver resection. Hepatogastroenterol 2008; 55: 539-43.
38. Neumann S, Frenz M, Streit F, **Oellerich M**. Formation of monoethylglycinexylidide (MEGX) in clinically healthy dogs. Can J Vet Res 2011; 75: 317-20.
39. Nörthen A, Asendorf T, Walson PD, **Oellerich M.** Diagnostic value of alpha-1-fetoprotein (AFP) as a biomarker for hepatocellular carcinoma recurrence after liver transplantation. Clin Biochem 2018; 52: 20-25.

# Lipoproteins, plasminogen, oxidant stress, liver and small bowel injury, inflammation, prenatal programming

1. Wieland E, Brandes A, Armstrong VW, **Oellerich M**. Oxidative modification of low density lipoproteins by human polymorphonuclear leukocytes. Eur J Clin Chem Clin Biochem 1993; 31:725-731.
2. Wieland E, Schütz E, Armstrong VW, Ringe B, **Oellerich M**. QSA 10 (Idebenone) or probucol supplementation of organ preservation solutions prevents oxygen radical-mediated injury of hepatic microsomes. Transplant Proc 1995; 27:738-740.
3. Wieland E, Schütz E, Armstrong VW, Küthe F, Heller C, **Oellerich M**. Idebenone protects hepatic microsomes against oxygen radical-mediated damage in organ preservation solutions. Transplantation 1995; 60:444-451.
4. von Ahsen N, Helmhold M, Eisenhauer T, Armstrong VW, **Oellerich M**. Decrease in lipoprotein(a) after renal transplantation is related to the glucocorticoid dose. Eur J Clin Invest 1996; 26:668-675.
5. Schütz E, Wieland E, Heine L, Hensel A, Schmiedl A, Armstrong VW, Richter J, Schuff-Werner P, Günther E, **Oellerich M**. Acceleration of hepatocellular energy by idebenone during early reperfusion after cold preservation ameliorates heat shock protein70 gene expression in a pig liver model. Transplantation 1997; 64:901-907.
6. Schütz E, Wieland E, Hensel A, Niedmann PD, Dreiss A, Armstrong VW, Schuff-Werner P, **Oellerich M**. Suppression of leukocyte-enhanced cold ischemia/reperfusion injury of liver endothelium with the benzoquinone antioxidant idebenone. Clin. Biochem. 1997; 30:619-624.
7. Osmers RGW, Schütz E, Diedrich F, Wehry B, Krauß T, **Oellerich M**, Kuhn W. Increased serum levels of hyaluronic acid in pregnancies complicated by preeclampsia or hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Obstet Gynecol 1998; 178:341-345.
8. Braun F, Schütz E, Laabs S, Hanack U, Sattler B, Lorf T, Wieland E, **Oellerich M**, Ringe B. Development of a porcine small bowel ex vivo perfusion model. Transplant Proc 1998; 30:2613-5.
9. Binder C, Schulz M, Hiddemann W, **Oellerich M**. Caspase-activation and induction of inducible nitric oxide-synthase during TNF-α-triggered apoptosis. Anticancer Research 1999; 19: 1715-1720.
10. Binder C, Schulz M, Hiddemann W, **Oellerich M**. Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-α-induced apoptosis in MCF-7 and other epithelial tumor cells. Laboratory Investigation 1999; 79:1703-1712.
11. Wieland E, **Oellerich M**, Braun F, Schütz E. c-fos and c-jun mRNA expression in a pig liver model of ischemia/reperfusion: effect of extended cold storage and the antioxidant idebenone. Clin Biochem 2000; 33: 285-290.
12. Schettler V, Kuhn W, Kleinoeder T, Armstrong VW, **Oellerich M**, Müller GA, Wieland E. No acute impact of haemodialysis treatment on free radical scavenging enzyme gene expression in white blood cells. J Intern Med 2003; 253: 201-207.
13. Igonin AA, Armstrong VW, Shipkova M, Lazareva NB, Kukes VG, **Oellerich M**. Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia. Clin Biochem 2004; 37: 204-209.
14. Zerr I, Bodemer M, Kaboth U, Kretzschmar H, **Oellerich M**, Armstrong VW. Plasminogen activities and concentrations in patients with sporadic Creutzfeldt-Jacob disease. Neuroscience Letters 2004; 371: 163-166.
15. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. Marmoset glutathione peroxidases: cDNA sequences, molecular evolution, and gene expression. J Med Primatol 2006; 35: 155-164.
16. Heller T, Geide A, Bonitz U, Wegner U, Gröne HJ, Armstrong VW, **Oellerich M**. Effect of the antioxidant idebenone on adverse events under mycophenolate mofetil therapy in a rat model. Transplantation 2008; 85: 739-747.
17. Atanasova S, Wieland E, Schlumbohm C, Korecka M, Shaw L, von Ahsen N, Fuchs E, **Oellerich M**, Armstrong V. Prenatal dexamethasone exposure in the common marmoset monkey enhances gene expression of antioxidant enzymes in the aorta of adult offspring. Stress 2009; 12: 215-224.
18. Bramlage CP, Schlumbohm C, Pryce CR, Mirza S, Schnell C, Amann K, Armstrong VW, Eitner F, Zapf A, Feldon J, **Oellerich M**, Fuchs E, Müller GA, Strutz F. Prenatal dexamethasone exposure does not alter blood pressure and nephron number in the young adult marmoset monkey. Hypertension 2009; 54: 1115-1122.
19. Nyirenda NJ, Carter R, Tang JI, de Vries A, Schlumbohn C, Hillier SG, Streit F, **Oellerich M**, Armstrong VW, Fuchs E, Seckl JR. Prenatal programming of metabolic syndrome in the common marmoset is associated with increased expression of 11beta-hydroxysteroid dehydrogenase type 1. Diabetes 2009; 58: 2873-9.
20. Brandhorst G, Weigand S, Eberle C, Raddatz D, Karaus M, **Oellerich M**, Walson PD. CD4+ Immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity. Clin Chim Acta 2013; 421: 31-33.
21. Wagner NM, Brandhorst G, Czepluch F, Lankeit M, Eberle C, Herzberg S, Faustin V, Riggert J, **Oellerich M**, Hasenfuss G, Konstantinides S, Schäfer K. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity 2013; 21: 461-468.

# Therapeutic drug monitoring (pharmacokinetics, pharmacogenetics, pharmacodynamics)

1. Kley HK, **Oellerich M**, Wiegelmann W, Herrmann J, Rudorff KH, Nieschlag E, Krüskemper HL. The effect of methadone on hypo­physeal and peripheral glandular hormones during withdrawl. Horm Metab Res 1977; 9:484-488.
2. Külpmann WR, **Oellerich M**, Blume U, Schmidt E, Bartels M. Ver­gleichende in vitro Untersuchungen zur Hämoperfusion mit ver­schiedenen Adsorbentien. Klin Wochenschr 1978; 56:1171-1178.
3. Wettengel R, **Oellerich M**, Schnitker J. Vergleichende Untersu­chung der Theophyllin-Serum-Konzentration und der broncho­spasmolytischen Wirkung von Cholintheophyllinat (EuspiraxR) und Theophyllin-Äthylendiamin (Euphyllin retardR) bei Patien­ten mit obstruktiver Atemwegserkrankung. Prax Pneumol 1979; 33:1125-1131.
4. Wemhöner S, **Oellerich M**, Sybrecht G. Optimierung der Therapie mit Theophyllin-Präparaten bei obstruktiven Ventilationsstö­rungen. 1. Bioverfügbarkeit und Pharmakokinetik verschiedener Theophyllin-Präparate. Prax Pneumol 1981; 35:36-41.

Optimisation of theophylline therapy in obstructive respira­tory disorders: bioavailability and pharmacokinetics of various theophylline preparations. Brit J Clin Pract 1981; Supplement 10:28-34.

1. Wemhöner S, **Oellerich M**, Sybrecht G. Optimierung der Therapie mit Theophyllin-Präparaten bei obstruktiven Ventilationsstö­rungen. 2. Anwendung von Theophyllin-retard-Präparaten in der Dauertherapie bei Nichtrauchern mit und ohne Herzinsuffi­zienz. Prax Pneumol 1981; 35:42-46.

Optimisation of theophylline therapy in obstructive respira­tory disorders: theophylline-retard preparations for the long term treatment of non-smokers with or without cardiac insuf­ficiency. Brit J Clin Pract 1981: Supplement 10:35-39.

1. Ranke C, Schmidt G, **Oellerich M**, Sybrecht GW. Optimierung der Therapie mit Theophyllin-Präparaten bei obstruktiven Ventila­tionsstörungen. 3. Vorhersage der Theophyllin-Clearance mit einer einfachen pharmakokinetischen Methode und Vergleich der Bioverfügbarkeit verschiedener Theophyllin-retard-Präparate. Prax Klin Pneumol 1983; 37:99-108.
2. Schmidt G, Ranke C, Creutzig H, **Oellerich M**, Sybrecht GW. Op­timierung der Therapie mit Theophyllin-Präparaten bei obstruktiven Ventilationsstörungen. 4. Einfluß von Theophyl­lin auf mukoziliare Clearance und den maximalen inspiratori­schen Mundokklusionsdruck. Prax Klin Pneumol 1983; 37:154-160. Therapiewoche 33:979-987.

Influence of theophylline on mucociliary clearance and maxi­mum inspiratory mouth occlusion pressure. Brit J Clin Pract 1983; Suppl 23:15-21.

1. **Oellerich M**, Ranke C, Schmidt G, Sybrecht GW. Optimierte Do­sierung von Theophyllin durch Abschätzung der Clearance mit einer einfachen pharmakokinetischen Methode. Therapiewoche 1983; 33:1131-1137.

Optimised theophylline dosage by estimation of clearance using a simple pharmacokinetic method. Brit J Clin Pract 1983; Suppl 23:37-41.

1. **Oellerich M**, Müller-Vahl H. The EMITR Free LevelTM ultrafil­tration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of pheny­toin. Clin Pharmacokinetics 1984; 9, Suppl. 1:61-70.
2. Wilkens JH, Neuenkirchen H, Sybrecht GW, **Oellerich M**. Indivi­dualizing theophylline dosage: evaluation of a single point maintenance dose prediction method. Eur J Clin Pharmacol 1984; 26:491-498.
3. Schmäscke J, **Oellerich M**, Schumann G, Sybrecht GW. Pharmako­kinetik von Theophyllin, Proxyphyllin und Diprophyllin in einem Kombinationspräparat bei gesunden Probanden. Prax Klin Pneumol 1985; 39:19-27.
4. Neuenkirchen H, Wilkens JH, **Oellerich M**, Sybrecht GW. Noctur­nal asthma: Effect of a once per evening dose of sustained release theophylline. Eur J Respir Dis 1985; 66:196-204.
5. Kluge TBR, **Oellerich M**, Schumann G, Sybrecht GW. Enprofyl­line: Pharmacokinetics and acute effect on bronchial reacti­vity in normal subjects compared to theophylline and placebo. Eur J Clin Pharmacol 1986; 30:21-25.
6. Böttger HCh, **Oellerich M**, Sybrecht GW. Use of aminoglycosi­des in critically ill patients: Individualisation of dosage using Bayesian statistics and pharmakokinetic principles. Ther Drug Monit 1988; 10:280-286.
7. Heins M, Kurtin L, **Oellerich M**, Maes R, Sybrecht GW. Noctur­nal asthma: Slow release terbutaline versus slow release theophylline therapy. Eur Respir J 1988; 1:306-310.
8. Stein U, **Oellerich M**, Sybrecht GW, Schneider B. Evaluation of a novel Bayesian method for individualizing theophylline dosage. J Clin Chem Clin Biochem 1988; 26:405-414.
9. Raude E, **Oellerich M**, Weinel P, Freund M, Schrappe M, Riehm H, Poliwoda H. High-dose methotrexate: Pharmacokinetics in children and young adults. Int J Clin Pharmacol Ther Toxicol 1988; 26:364-370.
10. Oldhafer KJ, Schumann G, Wonigeit K, **Oellerich M**, Ringe B, Pichlmayr R. Cyclosporine A monitoring by radioimmunoassay (RIA) and high-performance liquid chromatography (HPLC) after liver transplantation: Influence of route of administration and of liver function on the RIA: HPLC ratio. Transplant Proc 1988; 20, Suppl 3:361-365.
11. Schnabel D, von Treufels S, **Oellerich M**, Böttger HCh, Sybrecht GW. Untersuchungen zur Dosistitration mit Euphylong nach vorausgegangener Serumkonzentrationsbestimmung im steady state. Pneumologie 1990; 44:287-288.
12. Martz W, **Oellerich M**, Schnabel D, Sybrecht GW. Individualiza­tion of theophylline dosage: A Bayesian method evaluated in patients with once-daily dosing. Ther Drug Monit 1991; 13:420-424.
13. Winkler M, Schumann G, Petersen D, **Oellerich M**, Wonigeit K. Monoclonal fluorescence polarization immunoassay evaluated for monitoring cyclosporine in whole blood after kidney, heart, and liver transplantation. Clin Chem 1992; 38:123-126.
14. Schütz E, Gummert J, Mohr FW, Armstrong VW, **Oellerich M**. Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation. Transplant Proc 1995; 27:1298-1300.
15. Gummert J, Schütz E, **Oellerich M**, Mohr FW, Dalichau H. Monitoring of TPMT in heart transplant recipients under immnuosuppression with azathioprine. Artif Organs 1995; 19:918-920.
16. Schütz E, Gummert J, Armstrong VW, Mohr FW, **Oellerich M**. Azathioprine pharmacogenetics: The relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem Clin Biochem 1996; 34:199-205.
17. Braun F, Lorf T, Schütz E, Christians U, Grupp C, Sattler B, Canelo R, Sewing K.-Fr, Armstrong VW, **Oellerich M**, Ringe B. Clinical relevance of monitoring tacrolimus: Comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. Transplant Proc 1996; 28:3175-3176.
18. Schütz E, Gummert J, Mohr FW, Armstrong VW, **Oellerich M**. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther Drug Monit 1996; 18:228-233.
19. von Ahsen N, Helmhold M, Schütz E, Eisenhauer T, Armstrong VW, **Oellerich M**. Cyclosporin A trough levels correlate with serum lipoproteins and apolipoproteins: implications for therapeutic drug monitoring of cyclosporin A. Ther Drug Monit 1997; 19:140-145.
20. Leipold G, Schütz E, Haas JP, **Oellerich M**. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis & Rheumatism 1997; 40:1896-1898.
21. Braun F, Schütz E, Christians U, Lorf T, Schiffmann JH, Armstrong VW, Schröter W, Sewing KF, **Oellerich M**, Ringe B. Pitfalls in monitoring tacrolimus (FK 5406). Ther Drug Monit 1997; 19:628-631.
22. Binder L, Schiel X, Binder C, Menke CFA, Schüttrumpf S, Armstrong VW, Unterhalt M, Erichsen N, Hiddemann W, **Oellerich M**. Clinical outcome and economic impact of aminoglycoside peak concentrations in febrile immunocompromised patients with hematologic malignancies. Clin Chem 1998; 44:408-414.
23. Schütz E, Armstrong VW, Shipkova M, Weber L, Niedmann PD, Lammersdorf T, Wiesel M, Mandelbaum A, Zimmerhackl LB, Mehls O, Tönshoff B, **Oellerich M** and Members of the German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. Transplant Proc 1998; 30:1182-84.
24. Schütz E, Shipkova M, Armstrong VW, Niedmann PD, Weber L, Tönshoff B, Pethig K, Wahlers T, Braun F, Ringe B, **Oellerich M**. Therapeutic drug monitoring of mycophenolic acid: comparison of hplc and immunoassay reveals new MPA metabolites. Transplant Proc 1998; 30:1185-1187.
25. Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, Zimmerhackl LB, Schütz E, Mehls O, **Oellerich M**, Armstrong VW, Tönshoff B. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998; 9: 1511-1520.
26. Armstrong VW, Schütz E, Zhang Q, Groothusien S, Scholz C, Shipkova M, Aboleneen H, **Oellerich M**. Modified pentamer formation assay for measurement of tacrolimus and its active metabolites: comparison with liquid chromatography-tandem mass spectrometry and microparticle enzyme-linked immunoassay (MEIA-II). Clin Chem 1998; 44: 2516-2523.
27. Braun F, Canelo R, Schütz E, Shipkova M, Lorf T, Hanack U, Niedmann D, Armstrong VW, **Oellerich M**, Ringe B. How to handle mycophenolate mofetil in combination with tacrolimus? Transplant Proc 1998; 30: 4094-4095.
28. Shipkova M, Schütz E, Armstrong VW, Niedmann PD, Wieland E, **Oellerich M**. Overestimation of mycophenolic acid by Emit correlates with MPA metabolite. Transplant Proc 1999; 31:1135-1137.
29. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schütz E, Brenner-Weiß G, Voihsel M, Braun F, **Oellerich M**. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. British J Pharmacol 1999; 126:1075-1082.
30. Shipkova M, Armstrong VW, Schneider T, Niedmann PD, Schütz E, Wieland E, **Oellerich M**. Stability of mycophenolic acid and mycophenolic acid glucuronide in human plasma. Clin Chem 1999; 45: 127-129.
31. Schütz E, Shipkova M, Armstrong VW, Wieland E, **Oellerich M**. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 1999; 45: 419-422.
32. Weber LT, Lamersdorf T, Shipkova M, Niedmann PD, Wiesel M, Zimmerhackl LB, Staskewitz A, Schütz E, Mehls O, **Oellerich M**, Armstrong VW, Tönshoff B and members of the German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients. Ther Drug Monit 1999; 21: 498-506.
33. Wieland E, Shipkova M, Schellhaas U, Schütz E, Niedmann PD, Armstrong VW, **Oellerich M**. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 2000; 33: 107-113.
34. Kiehl MG, Shipkova M, Basara N, Blau IW, Schütz E, Armstrong VW, **Oellerich M**, Fauser AA. Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clin Biochem 2000; 33: 203-208.
35. Holt DW, Johnston A, Kahan BD, Morris RG, **Oellerich M**, Shaw LM. New approaches to cyclosporine monitoring raise further concerns about analytical techniques. Clin Chem 2000; 6: 872-874.
36. Pickenpack A, Straub RH, Distler O, Hammond A, **Oellerich M**, Schölmerich J, Lang B, Schütz E. Safety and efficacy of an intravenous loading dose of azathioprine for treatment of non-TPMT-deficient patients with rheumatic diseases. Rheumatology 2000; 39:1435-1436.
37. Ringe B, Braun F, Wietzke P, **Oellerich M**, Ramadori G. Replacement of corticosteroids by mycophenolate mofetil in liver graft recipients on initial tacrolimus immu­nosuppression. Transplant Proc 2000; 32: 2543.
38. Shipkova M, Schütz E, Armstrong VW, Niedmann PD, **Oellerich M**, Wieland E. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 2000; 46: 365-372.
39. Braun F, Armstrong VW, Lorf T, Canelo R, Arndt C, **Oellerich M**, Ringe B. Comparison of trough level and C(2) cyclosporine blood concentration monitoring in outpatient kidney transplant recipients. Transplant Proc 2001; 33: 3108-3109.
40. Braun F, Kassuhn M, Laabs S, Streit F, Armstrong VW, **Oellerich M**, Ringe B. Intestinal biotransformation of cyclosporine A in an extracorporeal pig intestine perfusion model. Transplant Proc 2001; 33: 3145-3155.
41. Braun F, Schütz E, Peters B, Talaulicar R, Grupp C, Undre N, Schafer A, Armstrong VW, **Oellerich M**, Ringe B. Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. Transplant Proc 2001; 33: 2127-2128.
42. Wieland E, Shipkova M, Schütz E, Braun F, Niedmann PD, Armstrong VW, Ringe B, Svinarov DA, **Oellerich M**. Preliminary report on the effect of xenoperfusion with human blood on cyclosporin A metabolism and cytochrome-P-4503A4-mRNA expression in a pig liver perfusion model. Clin Biochem 2001; 34: 53-57.
43. Shipkova M, Strassburg CP, Braun F, Streit F, Gröne HJ, Armstrong VW, Tukey RH, **Oellerich M**, Wieland E. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. British J Pharmacol 2001; 132:1027-1034.
44. Armstrong VW, Shipkova M, Schütz E, Weber L, Tönshoff B, **Oellerich M**. Monitoring of mycophenolic acid in pediatric renal transplant recipients. Transplant Proc 2001; 33: 1040-1043.
45. Shipkova M, Wieland E, Schütz E, Wiese C, Niedmann PD, **Oellerich M**, Armstrong VW. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 2001; 33: 1080-1081.
46. Ringe B, Braun F, Schütz E, Füzesi L, Lorf T, Canelo R, **Oellerich M**, Ramadori G. A novel management strategy of steroid-free immu­nosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001; 71: 508 - 515.
47. von Ahsen N, Richter M, Grupp C, Ringe B, **Oellerich M**, Armstrong VW. No influence of the MDR-I C3435T polymorphism or a CYP 3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transpant recipients. Clin Chem 2001; 47: 1048-1052.
48. Shipkova M, Armstrong VW, Kiehl MG, Niedmann PD, Schütz E, **Oellerich M**, Wieland E. Quantification of mycophenolic acid in plasma samples collected during and immediately after intravenous administration of mycophenolate mofetil. Clin Chem 2001; 47: 1485 – 1488.
49. Shipkova M, Armstrong VW, Kuypers D, Perner F, Fabrizi V, Holzer H, Wieland E, **Oellerich M**. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit 2001; 23: 717-721.
50. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O, Zimmerhackl LB, **Oellerich M**, Tönshoff B. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002; 48: 517-525.
51. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O, Zimmerhackl LB, **Oellerich M**, Tönshoff B. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13: 759-768.
52. Shipkova M, Armstrong VW, Weber L, Niedmann PD, Wieland E, Haley J, Tönshoff B, **Oellerich M**. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 2002; 24: 390-399.
53. Maes B, **Oellerich M**, Ceuppens JL, Armstrong VW, Evenepoel P, Kuypers D, Messiaen T, Shipkova M, Wieland E, Vanrenterghem Y. A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener’s granulomatosis. Nephrol Dial Transplant 2002; 17: 923-926.
54. Braun F, Peters B, Schütz E, Lorf T, Undre N, **Oellerich M**, Ringe B. Therapeutic drug monitoring of tacrolimus early after liver transplantation. Transplant Proc 2002; 34: 1538-1539.
55. Wigger M, Armstrong VW, Shipkova M, Wacke R, Nizze H, Streit F, von Ahsen N, Muscheites J, Glasenapp S, Stolpe HJ, **Oellerich M**. Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. Ther Drug Monit 2002; 24:438-443.
56. Shipkova M, Armstrong VW, Wieland E, **Oellerich M**. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem 2003; 49: 260-268.
57. Johnston A, Chusney G, Schütz E, **Oellerich M**, Lee TD, Holt DW. Monitoring cyclosporin in blood: between-assay differences at trough and 2 hours post-dose (C2). Ther Drug Monit 2003; 25: 167-173.
58. Maes BD, Dalle I, Geboes K, **Oellerich M**, Armstrong VW, Evenepoel P, Geypens B, Kuypers D, Shipkova M, Geboes K, Vanrenterghem YFCh. Erosive enterocolitis in mycophenolate mofetil - treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 2003; 75: 665-672.
59. Kuypers DRJ, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, **Oellerich M**, Armstrong V, Shipkova M, Daems J. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003; 25: 609-622.
60. Indjova D, Atanasova S, Shipkova M, Armstrong VW, **Oellerich M**, Svinarov D. Phenotypic and genotypic analysis of thiopurine S-methyltransferase polymorphism in the Bulgarian population. Ther Drug Monit 2003; 25:631-636.
61. Indjova D, Shipkova M, Atanasova S, Niedmann PD, Armstrong VW, Svinarov D, **Oellerich M**. Determination of thiopurine methyltransferase phenotype in isolated human erythrocytes using a new simple nonradioactive HPLC method. Ther Drug Monit 2003; 25: 637-644.
62. Weber LT, Shipkova M, Armstrong VW, Mehls O, **Oellerich M**, Tönshoff B, for the German Study Group Pediatric Renal Transplantion. C2 monitoring and absorption profiling of cyclosporine for optimization of immunosuppressive therapy in pediatric renal transplant recipients. Transplant Proc 2003; 35:2128-2130.
63. Barten MJ, Streit F, Boeger M, Dhein S, Tarnok A, Shipkova M, Armstrong VW, Mohr FW, **Oellerich M**, Gummert JF. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immu­nosuppression on lymphocyte proliferation and activation in rat whole blood. Transplantation 2004; 77: 1154-1162.
64. Shipkova M, Spielbauer B, Voland A, Gröne HJ, Armstrong VW, **Oellerich M**, Wieland E. cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. Transplantation 2004; 78: 1145-1152.
65. Weber LT, Armstrong VW, Shipkova M, Feneberg R. Wiesel M, Mehls O, Zimmerhackl LB, **Oellerich M**, Tönshoff B and members of the German Study Group on Pediatric Renal Transplantation. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. Ther Drug Monit 2004; 26: 415-424.
66. Heller T, **Oellerich M**, Armstrong VW, von Ahsen N. Rapid detection of ITPA 94C>A and IVS2 + 21A>C gene mutations by real-time fluorescence PCR and in vitro demonstration of effect of ITPA IVS2 + 21A>C polymorphism on splicing efficiency. Clin Chem 2004; 50: 2182-84.
67. Kenkel JM, Lipschitz AH, Shepherd G, Armstrong VW, Streit F, **Oellerich M**, Luby M, Rohrich RJ, Brown SA. Pharmacokinetics and safety of lidocaine and monoethylglycinexylidide in liposuction: a microdialysis study. Plast Reconstr Surg 2004; 114: 516-524.
68. Atanasova SY, von Ahsen N, Toncheva DI, Dimitrov TG, **Oellerich M**, Armstrong VW. Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN). Clin Biochem 2005; 38: 223-228.
69. Barten MJ, Shipkova M, Bartsch P, Dhein S, Streit F, Tarnok A, Armstrong VW, Mohr FW, **Oellerich M**, Gummert JF. Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo. Ther Drug Monit 2005; 27: 123-131.
70. Armstrong VW, Tenderich G, Shipkova M, Parsa A, Koerfer R, Schröder H, **Oellerich M**. Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. Ther Drug Monit 2005; 27: 315-321.
71. El Desoky ES, AbdelSalam YM, Salama RH, El Akkad MA, Atanasova S, von Ahsen N, Armstrong VW, **Oellerich M**. NAT2\*5/\*5 genotype (341T>C) is a potential risk factor for schistosomiasis-associated bladder cancer in Egyptians. Ther Drug Monit 2005; 27: 297-304.
72. Kamdem LK, Streit F, Zanger UM, Brockmöller J, **Oellerich M**, Armstrong VW, Wojnowski L. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005; 51: 1374-1381.
73. von Ahsen N, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, Stein J, Bias P, Adler G, Shipkova M, **Oellerich M**, Kruis W, Reinshagen M. Association of inosine triphosphatase 94C>A and thiopurine s-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem 2005; 51: 2282-2288.
74. Shipkova M, Lorenz K, **Oellerich M**, Wieland E, von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem 2006; 2: 240-247.
75. Wilson D, Johnston F, Holt D, Moreton M, Engelmayer J, Gaulier JM, Luthe H, Marquet P, Moscato D, **Oellerich M**, Mosso R, Streit F, Brunet M, Fillee C, Schmid R, Wallemacq, Barnes G. Multi-center evaluation of analytical performance of the microparticle enzyme immunoassay for sirolimus. Clin Biochem 2006; 39: 378-386.
76. Weber LT, Hoecker B, Armstrong VW, **Oellerich M**, Tönshoff B. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. Ther Drug Monit 2006; 28: 623-631.
77. Brandhorst G, Streit F, Goetze S, **Oellerich M**, Armstrong VW. Quantification by liquid chromatography tandem mass spectrometry of mycophenolic acid and its phenol and acyl glucuronide metabolites. Clin Chem 2006; 52: 1962-1964.
78. Naesens M, Kuypers DRJ, Streit F, Armstrong VW, **Oellerich M**, Verbeke K, Varenterghem Y. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther 2006; 80: 509-21.
79. Birnbaum F, Reis A, Böhringer D, Sokolowska Y, Meyer K, Voiculescu A, **Oellerich M**, Sundmacher R, Reinhard T. An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. Transplantation 2006; 81: 767-772.
80. Heller T, van Gelder T, Budde K, de Fijter JW, Kuypers D, Arns W, Schmidt J, Rostaing L, Powis SH, Claesson K, MacPhee IAM, Pohanka E, Engelmayer J, Brandhorst G, **Oellerich M**, Armstrong VW. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant, 2007; 7: 1822-1831.
81. van Hest RM, Doorduijn JK, de Winter BCM, Cornelissen JJ, Vulto AG, **Oellerich M**, Löwenberg B, Mathot RAA, Armstrong VW, van Gelder T. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit 2007; 29: 353-360.
82. Reinshagen M, Schütz E, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, Stein J, Bias P, Adler G, Shipkova M, Kruis W, **Oellerich M**, von Ahsen N. 6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007; 53: 1306-1314.
83. Wolff NA, Burckhardt BC, Burckhardt G, **Oellerich M**, Armstrong VW. Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney. Nephrol Dial Transpl 2007; 22: 2497-2503.
84. Brandhorst G, Tenderich G, Zittermann A, Oezpeker C, Koerfer R, **Oellerich M**, Armstrong VW. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Ther Drug Monit 2008; 30: 113-116.
85. Brandhorst G, Marquet P, Shaw LM, Liebisch G, Schmitz G, Coffing MJ, Domke I, Streit F, Luthe H, **Oellerich M**. Multicenter evaluation of a new inosine monophosphate dehydrogenase inhibition assay for quantification of total mycophenolic acid in plasma. Ther Drug Monit 2008; 30: 428 – 433.
86. Weber LT, Hoecker B, Armstrong VW, **Oellerich M**, Tönshoff B. Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant. Ther Drug Monit 2008; 30: 570-575.
87. van Agteren M, Armstrong VW, van Schaik RHN, de Fijter Hans, Hartmann A, Zeier M, Budde K, Kuypers D, Pisarski P, Le Meur Y, van der Werf M, Mamelok RD, **Oellerich M**, van Gelder T. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. Ther Drug Monit 2008; 30: 439-444.
88. van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, **Oellerich M**, Holt DW, Tönshoff B, Keown P, Campbell S, Mamelok RD. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86: 1043-1051.
89. Beckebaum S, Armstrong VW, Cicinnatti VR, Streit F, Klein CG, Gerken G, Paul A, **Oellerich M**. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil. Ther Drug Monit 2009; 31: 205-210.
90. Heller T, Asif AR, Petrova DT, Doncheva Y, Wieland E, **Oellerich M**, Shipkova M, Armstrong VW. Differential proteomic analysis of lymphocytes treated with mycophenolic acid reveals caspase-3 induced cleavage of Rho GDP-dissociation inhibitor 2. Ther Drug Monit 2009; 31: 211-217.
91. van Gelder T, Domke I, Engelmayer J, de Fijter H, Kuypers D, Budde K., Koeger R, Luthe H, **Oellerich M.** Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. Ther Drug Monit 2009; 31: 218-223.
92. Petrova DT, Heller T, Hitt R, Wieland E, **Oellerich M**, Armstrong VW, Shipkova M. Regulation of IL2 and NUCB1 in mononuclear cells treated with acyl glucuronide of mycophenolic acid reveals effects independent on inosine monophosphate dehydrogenase inhibition. Ther Drug Monit 2009; 31: 31-41.
93. Brandhorst G, Luthe H, Domke I, Knoke C, Rhode KH, Sauter H, **Oellerich M.** Therapeutic Drug Monitoring and drugs of abuse testing on the cobas® 6000 analyzer series: analytical performance under routine-like conditions. Clin Chem Lab Med 2009; 47: 854-859.
94. Jones AE, Wilson HK, Meath P, Meng X, Holt DW, Johnston A, **Oellerich M**, Armstrong VW, Stachulski AV. Convenient syntheses of the in vivo carbohydrate metabolites of mycophenolic acid: reactivity of the acyl glucuronide. Tetrahedron Lett 2009; 50: 4973 – 4977.
95. Brandhorst G, Brehmer F, Petrova DT, Gross O, Miosge N, Armstrong VW, **Oellerich M**. Mycophenolic acid predose concentrations and renal function in a mouse model for progressive renal fibrosis. Ther Drug Monit 2010; 32: 73 – 78.
96. Soldin SJ, Hardy RW, Wians FH, Balko JA, Mendu DR, Chaffin CH, Streit F, Barbarakis M, Martel J, Canfield W, Levy HR, **Oellerich M**. Performance evaluation of the new ADVIA Centaur system cyclosporine assay (single-step-extraction). Clin Chim Acta 2010; 411: 806-811.
97. Petrova DT, Brandhorst G, Brehmer F, Gross O, **Oellerich M**, Armstrong VW. Mycophenolic acid displays IMPDH-dependent and IMPDH-independent effects on renal fibroblast proliferation and function. Ther Drug Monit 2010; 32: 405-412.
98. Prémaud A, Weber LT, Tönshoff B. Armstrong VW, **Oellerich M**, Urien S, Marquet P, Rousseau A. Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. Pharmacol Res 2011; 63: 216-224.
99. van Gelder T, Silva HT, de Fijter H, Budde K, Kuypers D, Mamelok RD, Armstrong VW, **Oellerich M**. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation. Ther Drug Monit 2011; 33: 155-164.
100. Streit F, Binder L, Hafke A, Brandhorst G, Braulke F, Haase D, Armbrust T, Cameron S, Ramadori G, **Oellerich M**, Walson P. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients. Ther Drug Monit 2011; 33: 632 - 643.
101. Rother A, Glander P, Vitt E, Czock D, von Ahsen N, Armstrong VW, **Oellerich M**, Budde K, Feneberg R, Tönshoff B, Weber LT. Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid. Eur J Clin Pharmacol 2012; 68: 913 – 922.
102. Schulz-Jürgensen S, Burdelski M, **Oellerich M**, Brandhorst G. Intracellular ATP production in CD4+ T cells as a predictor for infection and allograft rejection in trough-level guided pediatric liver transplant recipients under calcineurin-inhibitor therapy. Ther Drug Monit 2012; 34: 4-10.
103. Misdaq M, Andag R, **Oellerich M,** Asif AR, von Ahsen N. Establishment of thiopurine S-methyltransferase gene knockdown in Jurkat T-lymphocytes: An in vitro model of TPMT polymorphism. Ther Drug Monit 2012; 34: 584-592.
104. Binder L, Schwörer H, Hoppe S, Streit F, Neumann S, Beckmann A, Wachter R, **Oellerich M**, Walson PD. Pharmacokinetics of meropenem in critically ill patients with severe infections. Ther Drug Monit 2013; 35: 63-70.
105. **Oellerich M**, Schütz E, Kanzow P, Schmitz J, Beck J, Kollmar O, Streit F, Walson PD. Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. Ther Drug Monit 2014; 36: 136-140.
106. Shipkova M, Petrova DT, Rosler AE, Orth M., Engelmayer J, Wieland E, Brandhorst G, **Oellerich M.** Comparability and imprecision of 8 frequently used commercially available immunoassays for therapeutic drug monitoring. Ther Drug Monit 2014; 36: 433-441.
107. Graff J, Scheuermann EH, Brandhorst G, **Oellerich M**, Gossmann J. Pharmacokinetic analysis of mycophenolate mofetil and enteric-coated mycophenolate sodium in calcineurin inhibitor-free renal transplant recipients. Ther Drug Monit 2016; 38: 388-392.

# Proteomics

1. Shipkova M, Beck H, Voland A, Armstrong VW, Gröne HJ, **Oellerich M**, Wieland E. Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics 2004; 4: 2728-2738.
2. Asif AR, **Oellerich M**, Armstrong VW, Riemenschneider B, Monod M, Reichard U. Proteome of conidial surface associated proteins of aspergillus fumigatus reflecting potential vaccine candidates and allergens. J Proteome Res 2006; 5: 954-962.
3. Köhler SC, von Ahsen N, Schlumbohm C, Asif AR, Goedtel-Armbrust U, **Oellerich M**, Wojnowski, Armstrong VW. Mamoset CYP3A21, a model for human CYP3A4: Protein expression and functional characterization of the promoter. Xenobiotica 2006; 36: 1210-1226.
4. Asif AR, Armstrong VW, Voland A, Wieland E, **Oellerich M**, Shipkova M. Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. Biochimie 2007; 89: 393-402.
5. Dihazi H, Müller GA, Lindner S, Meyer M, Asif AR, **Oellerich M**, Strutz F. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem 2007; 53: 1636-1645.
6. Petrova DT, Asif AR, Armstrong VW, Dimova I, Toshev S, Yaramov N, **Oellerich M**, Toncheva D. Expression of chloride intracellular channel protein 1 (CLIC1) and tumor protein D52 (TPD52) as potential biomarkers for colorectal cancer. Clin Biochem 2008; 41: 1224-1236.
7. Asif AR, **Oellerich M**, Armstrong VW, Hecker M, Cattaruzza M. T-786C polymorphism of the *NOS-3* gene and the endothelial cell response to fluid shear stress – a proteome analysis. J Proteome Res 2009; 8: 3161-3168.
8. Schultze FC, Petrova DT, **Oellerich M**, Armstrong VW, Asif AR. Differential proteome and phosphoproteome signatures in human T-lymphoblast cells induced by sirolimus. Cell Prolif 2010; 43: 396-404.
9. Asif AR, **Oellerich M**, Armstrong VW, Gross U, Reichard U. Analysis of the cellular Apergillus fumigatus proteome that reacts with sera from rabbits developing an acquired immunity after experimental aspergillosis. Electrophoresis 2010; 31:1947-1958.
10. Singh B, **Oellerich M**, Kumar R, Kumar M, Bhadoria DP, Reichard U, Gupta VK, Sharma GL, Asif AR. Immuno-reactive molecules identified from the secreted proteome of aspergillus fumigatus. J Proteome Res 2010, 9: 5517-5529.
11. Singh B, Sharma GL, **Oellerich M**, Kumar R, Singh S, Bhadoria DP, Katyal A, Reichard U, Asif AR. Novel cytosolic allergens of Aspergillus fumigatus identified from germinating conidia. J Proteome Res 2010; 9: 5530-41.
12. Petrova DT, Brehmer F, Schultze FC, Asif AR, Gross O, **Oellerich M**, Brandhorst G. Differential kidney proteome profiling in a murine model of renal fibrosis under treatment with mycophenolate mofetil. Pathobiology 2011; 78: 162-170.
13. Zafar S, von Ahsen N, **Oellerich M**, Zerr I, Schulz-Schaeffer WJ, Armstrong VW, Asif AR. Proteomics approach to identify the interacting partners of cellular prion protein and characterization of Rab7a interaction in neuronal cells. J Proteome Res 2011; 7: 3123-35.
14. Qasim, M, Rahman H, **Oellerich M**, Asif AR. Differential proteome analysis of human embryonic kidney cell line (HEK-293) following mycophenolic acid treatment. Proteome Sci 2011; 9: 57.
15. Rahman H, Qasim M, Schultze F, **Oellerich M**, Asif AR. Fetal calf serum heat inactivation and lipopolysaccharide contamination influence the human T lymphoblast proteome and phosphoproteome. Proteome Sci 2011; 9: 71.
16. Zahid S, **Oellerich M**, Asif AR, Ahmed N. Phosphoproteome profiling of substantia nigra and cortex regions of Alzheimer’s disease patients. J Neurochem 2012; 121: 954 - 963.
17. Nasim FF-H, Ejaz S, Ashraf M, Asif AR, **Oellerich M,** Ahmad G, Malik GA, Attiq uR. Potential Biomarkers in the sera of breast cancer patients from Bahawalput, Pakistan. Biomarkers in Cancer 2012; 4: 19-34.
18. Biswas S, Sharma S, Saroha A, Bhakuni DS, Malhotra R, Zahur M, **Oellerich M,** Das HR, Asif AR. Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach. PLoS ONE 2013; 8: e56246.
19. Zahid S, Khan R, **Oellerich M**, Ahmed N, Asif AR. Differential S-nitrosylation of proteins in Alzheimer’s disease. Neuroscience 2014; 256: 126-136.
20. Zahid S, **Oellerich M**, Asif AR, Ahmed N. Differential expression of proteins in brain regions of Alzheimer’s disease patients. Neurochem Res 2014; 39: 208-215.
21. Qasim M, Rahman H, Raees A, **Oellerich M.** Mycophenolic acid mediated disruption of the intestinal epithelial tight junctions. Exp Cell Res 2014; 322: 277-289.
22. Rahman H, Qasim M, **Oellerich M**, Asif AR. Identification of the novel interacting partners of the mammalian target of rapamycin complex 1 in human CCRF-CEM and HEK293 cells. Int J Mol Sci 2014; 15: 4823-4836.
23. Rahman H, Qasim M, **Oellerich M**, Asif AR. Crosstalk between Edc4 and mammalian target of rapamycin complex 1 (mTORC1) signaling in mRNA decapping. Int J Mol Sci 2014; 15: 23179-23195.
24. Petrova DT, Schultze FC, Brandhorst G, Luchs KD, Lenz C, Urlaub H, Rubel D, Gross O, Walson PD, **Oellerich M.** Effects of mycophenolate mofetil on kidney function and phosphorylation status of renal proteins in Alport COL4A3-deficient mice. Proteome Sci 2014; 12: 56.
25. Misdaq M, Ziegler S, von Ahsen N, **Oellerich M**, Asif AR. Thiopurines induce oxidative stress in T-lymphocytes: A proteomic approach. Mediat Inflamm 2015; Article ID 434825; doi 10.1155/2015/434825.
26. Petrova DT, Brandhorst G, Koch C, Schultze FC, Eberle C, Walson PD, **Oellerich M**. Mycophenolic acid reverses TGF beta-induced cell motility, collagen matrix contraction and cell morphology *in vitro*. Cell Biochem Funct 2015; 33: 503-508.

# Molecular diagnostics

1. von Ahsen N, Schütz E, Armstrong VW, **Oellerich M**. Rapid detection of prothrombotic mutations of prothrombin (G20210A), factor V (G1691A) and methylenetetetrahydrofolate reductase (C677T) by real time fluorescence PCR with the LightCycler. Clin Chem 1999; 45: 694-696.
2. von Ahsen N, **Oellerich M**, Armstrong VW, Schütz E. Application of a thermodynamic nearest-neighbor model to estimate nucleic acid stability and optimize probe design: prediction of melting points of different mutations of apolipoprotein B 3500 and factor V Leiden with a hybridization probe genotyping assay on the LightCycler. Clin Chem 1999; 45: 2094-2101.
3. von Ahsen N, **Oellerich M**, Schütz E. Use of two reporter dyes without interference in a single-tube rapid-cycle PCR: alpha1-antitrypsin genotyping by multiplex real-time fluorescence PCR with the LightCycler. Clin Chem 2000; 46:156-161.
4. Schütz E, von Ahsen N, **Oellerich M**. Genotyping of eight thiopurine methyltransferase mutations: three-color multiplexing, "two-color/shared" anchor, and fluorescence-quenching hybridization probe assays based on thermodynamic nearest-neighbor probe design. Clin Chem 2000; 46:1728-1737.
5. von Ahsen N, Lewczuk P, Schütz E, **Oellerich M**, Ehrenreich H. Prothrombin activity and concentration in healthy subjects with and without the prothrombin G20210A mutation. Thrombosis Research 2000; 99:549-556.
6. von Ahsen N, **Oellerich M**, Schütz E. DNA base bulge vs unmatched end formation in probe-based diagnostic insertion/deletion genotyping: genotyping the UGT1A1 (TA)n polymorphism by real-time fluorescence PCR. Clin Chem 2000; 46:1939-1945.
7. von Ahsen N, **Oellerich M**, Schütz E. A method for homogeneous color-compensated genotyping of factor V (G1691A) and methylenetetrahydrofolate reductase (C677T) mutations using real-time multiplex fluorescence PCR. Clin Biochem 2000; 33:535-539.
8. von Ahsen N, **Oellerich M**. The intronic prothrombin 19911A>G polymorphism influences splicing efficiency and modulates effects of the 20210G>A polymorphism on mRNA amount and expression in a stable reporter gene assay system. Blood 2004; 103: 586-592.
9. von Ahsen N, Armstrong VW, **Oellerich M**. Rapid, long-range molecular haplotyping of thiopurine S-methyltransferase (TPMT) \*3A, \*3B and \*3C. Clin Chem 2004; 50: 1528-1534.
10. Heller T, Kirchheiner J, Armstrong VW, Luthe H, Tzvetkov M, Brockmöller J, **Oellerich M**. AmpliChip CYP450 GeneChip®: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit 2006; 28: 673-677.
11. Atanasova S, Shipkova M, Svinarov D, Mladenova A, Genova M, Wieland E, **Oellerich M**, von Ahsen N. Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6. Ther Drug Monit 2007; 29: 6-10.
12. Petrova DT, Nedeva P, Maslyankov S, Toshev S, N, Atanasova S, Toncheva D, **Oellerich M**, von Ahsen N. No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol 2008; 134: 317-22.
13. Petrova DT, Yaramov N, Toshev S, Nedeva P, Maslyankov S, von Ahsen N, **Oellerich M**, Toncheva D. Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls. Onkologie 2007; 30: 559-63.
14. von Ahsen N, **Oellerich M**, Armstrong VW. Characterization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotype-phenotype correlation and promoter function. Ther Drug Monit 2008; 30: 16-22.
15. von Ahsen N, Tzvetkov M, Karunajeewa HA, Gomorrai S, Ura A, Brockmöller J, Davis TE, Mueller I, Ilett KF, **Oellerich M**. CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. Int J Mol Edpidemiol Genet 2010; 1: 310 – 319.
16. Schultze FC, Andag R, Alwahsh SM, Toncheva D, Maslyankov S, Yaramov N, von Ahsen N, Brandhorst G, Walson PD, **Oellerich M**, Petrova DT. FoxP3 demethylation is increased in human colorectal cancer and rat cholangiocarcinoma tissue. Clin Biochem 2014; 47: 201-205.
17. Beck J, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, Gaedcke J, Moerer O, Slotta JE, Walson P, Kollmar O, **Oellerich** M, Schütz E. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem 2013; 59: 1732-1741.
18. Brandhorst G, Petrova DT, Weigand S, Eberle C, von Ahsen N, Schmitz J, Schultze FC, Raddatz D, Karaus M, **Oellerich M**, Walson PD. Lack of correlation between Treg quantification assays in inflammatory bowel disease patients. World J Gastroenterol 2015; 21: 3325-3329.
19. Beck J, **Oellerich M**, Schulz U, Schauerte V, Reinhard L, Fuchs U, Knabbe C, Zittermann A, Olbricht C, Gummert JF, Shipkova M, Birschmann I, Wieland E, Schütz E. Donor-derived cell-free DNA is a novel universal biomarker for allograft rejection in solid organ transplantation. Transplant Proc 2015; 47: 2400-2403.
20. Billing H, Höcker B, Fichtner A, van Damme-Lombaerts R, Friman S, Jaray J, Vondrak K, Sarvary E, Dello Strologo L, **Oellerich M**, von Ahsen N, Tönshoff B. Single-nucleotide polymorphism of CYP3A5 impacts the exposure to tacrolimus in pediatric renal transplant recipients: A pharmacogenetic substudy of the TWIST trial. Ther Drug Monit 2017; 39: 21-28.
21. Schütz E, Fischer A, Beck J, Harden M, Koch M, Wuensch T, Stockmann M, Nashan B, Kollmar O, Matthaei J, Kanzow P, Walson PD, Brockmöller J, **Oellerich M**. Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. PLOS Med 2017; 14: e1002286; doi: 10.1371/journal.pmed.1002286.
22. Schirmer MA, Beck J, Leu M, **Oellerich M**, Rave-Fränk M, Walson PD, Schütz E, Canis M. Cell-free plasma DNA for disease stratification and prognosis in head and neck cancer. Clin Chem 2018; 64: 959-970.
23. **Oellerich M**, Shipkova M, Asendorf T, Walson PD, Schauerte V, Mettenmeyer N, Kabakchiev M, Hasche G, Gröne HJ, Friede T, Wieland E, Schwenger V, Schütz E, Beck J. Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. Am J Transplant 2019; 19: 3087-3099.
24. Tran JN, Günther OP, Sherwood KR, Fenninger F, Allan LL, Lan J, Sapir-Pichhadze R, Duquesnoy R, Claas F, Marsh SG, McMaster R, Keown PA & Genome Canada Transplant Consortium\* (German Working Group: Opelz G, **Oellerich M**). High-throughput sequencing defines donor and recipient HLA B-cell epitope frequencies for prospective matching in transplantation. Communications Biology 2021; 4: 583; doi.org/10.1038/s42003-021-01989-3.
25. Osmanodja B, Akifova A, Budde K, Choi M, **Oellerich M**, Schütz E, Beck J. Absolute or relative quantification of donor-derived cell-free DNA in kidney transplant recipients: case series. Transplant Direct 2021; 7: e778
26. Knüttgen F, Beck J, Dittrich M, **Oellerich M**, Zittermann A, Schulz U, Fuchs U, Knabbe C, Schütz E, Gummert J, Birschmann I. Graft-derived cell-free DNA as a noninvasive biomarker of cardiac allograft rejection: a cohort study on clinical validity and confounding factors. Transplantation 2022; 106: 615-622
27. Baumann A K, Beck J, Hartleben B, Schütz E, **Oellerich M**, Wedemeyer H, Jaeckel E, Taubert R. Elevated donor-specific cell-free DNA during subclinical graft injury after liver transplantation. Liver Transplantation 2022; 28: 1911-1919
28. Schrezenmeier E, Hector Rincon-Arevalo H, Jens A, Stefanski A-L, Hammett C, Osmanodja B, Koch N, Zukunft B, Beck J, **Oellerich M**, Pross V, Stahl C, Choi M, Bachmann F, Liefeldt L, Glander P, Schütz E, Bornemann-Kolatzki K, Lopez del Moral C, Schrezenmeier H, Ludwig C, Jahrsdorfer B, Eckardt K-U, Lachmann N, Kotsch K, Dörner T, Halleck F , Sattler A, Budde K. Temporary antimetabolite hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. JCI Insight 2022;7: e157836. doi: 10.1172/jci.insight.157836.
29. Osmanodja B, Akifova A, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E and Budde K. Donor-Derived Cell-Free DNA for Kidney Allograft Surveillance after Conversion to Belatacept: Prospective Pilot Study. J. Clin. Med. 2023, 12, 2437.
30. Akifova A, Budde K, Choi M, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E and Osmanodja B. Donor-Derived Cell-Free DNA in Biopsy-Proven Antibody-Mediated Rejection Versus Recurrent IgA Nephropathy After Kidney Transplantation. Kidney Int Rep 2023, <https://doi.org/10.1016/j.ekir.2023.07.011>.
31. Osmanodja B, Budde K**, Oellerich M.** Zellfreie Transplantat-DNA zur Diagnose und Monitoring bei antikörpervermittelter Abstoßung nach Nierentransplantation. Transfusionsmedizin 2023, 13: 196-200.
32. Osmanodja B, Akifova A, Budde K, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E, Velden J, Lehmann C, Krüger BM, Bachmann A, Kowald J. Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series. Transpl Int 2024; 37:13213
33. Akifova A, Budde K, Choi M, Amann K, Buettner-Herold M, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E, Bachmann F, Halleck F, Schrezenmeier E, Seelow E, Zukunft B, Lachmann N, Stauch D, Osmanodja B. Association of blood donor-derived cell-free DNA levels with Banff scores and histopathological lesions in kidney allograft biopsies: results from an observational study. Transplant direct 2025; 11: e1794
34. Akifova A, Budde K, Amann K, Buettner-Herold M, Choi M, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E, Bachmann F, Halleck F, von Hoerschelmann E, Koch N, Schrezenmeier E, Seelow E, Waiser J, Zukunft B, Eckardt K-U, Halbritter J, Kettritz R, López Del Moral C, Lachmann N, Stauch D, Niemann M, Schmidt D, Halloran P F, Osmanodja B. Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial; Nephrol Dial Transplant 2025; 0: 1-12
35. Hansmann H, Fante M A, Harrer D C, Heidemannns S, **Oellerich M**, Beck J, Schütz E, Perl M, Zartner B, Wolff D, Edinger M, Herr W, Banas B, Zecher D, Hansmann L. CD19 CAR-T-cells mediate sustained tolerance of a kidney allograft despite discontinued conventional immunosuppression. Am J Transplant 2025; submitted
36. Knödel L, Büttner-Herold M, Götz M, Luber M, Spriewald B, **Oellerich M,** Beck J, Banas B, Zecher D. Acute rejection with DSA-negative severe microvascular inflammation in a kidney transplant recipient with an isolated DPB1\*04-mismatch successfully stabilized with daratumumab. Am J Transplant 2025; submitted

# BOOK CHAPTERS

1. Haeckel R, **Oellerich M**. Enzymimmunotests zum Nachweis von Arzneimitteln im Serum und Harn. In: Engelhardt A, Lommel H, Hrsg. Akute Syndrome. Weinheim: Verlag Chemie, 1978: 281-286.
2. **Oellerich M**, Haeckel R. Rationalisierung von Enzymimmuno­tests. In: Haeckel R, Hrsg. Rationalisierung des medizini­schen Laboratoriums, 2 Aufl. Darmstadt: GIT-Verlag, 1979: 188-195.
3. **Oellerich M**. Die vollmechanisierte Bestimmung von Theophyllin mit dem homogenen Enzymimmunotest. In: Vogt W, Hrsg. Prakti­sche Anwendung des Enzymimmunoassays in der Klinischen Chemie und Serologie. Stuttgart: G.Thieme Verlag, 1979: 85-90.
4. **Oellerich M**. Anwendung der EMIT-Technik beim Drogenscreening. In: Vogt W, Hrsg. Praktische Anwendung des Enzymimmunoassays in der Klinischen Chemie und Serologie. Stuttgart: G.Thieme Verlag, 1979: 66-75.
5. **Oellerich M**. Die Bestimmung von Methotrexat mit einem vollme­chanisierten, homogenen Enzymimmunotest. In: Sommer R, Hrsg. Kontrolle der Plasmaspiegel von Pharmaka. Stuttgart: G. Thieme Verlag, 1980: 61-66.
6. **Oellerich M**. Methodik der Theophyllin-Bestimmung. In: Wetten­gel R, Hrsg. Asthma-Therapie mit Theophyllin. Optimierung durch Blutspiegel-Bestimmung. München-Deisenhofen: Dustri-Verlag Dr. K. Feistle, 1980: 66-82.
7. **Oellerich M**. Drug Monitoring mit Enzymimmunotests. In: Vogt W, Hrsg. Radioaktivitätsfreie, quantitative Immunoassays in der klinischen Chemie. Stuttgart: G. Thieme Verlag, 1981: 81-101.
8. **Oellerich M**. Monitoring therapeutic drugs in clinical chemi­cal laboratories. In: Kaiser E, Gabel F, Müller MM, Bayer M, eds. XI. International Congress of Clinical Chemistry. Ber­lin, New-York: W. de Gruyter & Co., 1982: 897-910.
9. **Oellerich M**, Böhm MM, Tietjen HG, Sybrecht GW. Klinische Er­fahrungen mit der Bestimmung der Theophyllin-Konzentration im Serum bei Patienten mit obstruktiven Ventilationsstörungen. In: Rietbrock N, Woodcock BG, Staib AH, Hrsg. Theophylline and other methylxanthines. Braunschweig, Wiesbaden: Vieweg Verlag, 1982: 255-266.
10. **Oellerich M**, Külpmann WR, Beneking M, Haindl H, Müller-Vahl H. Future of drug monitoring: new developments for drug measurement. In: Masson, ed. Biologie prospective. 5e Colloque International de Pont-à-Mousson. 1983: 1169-1173.
11. **Oellerich M**. Principles of enzyme-immunoassays. In: Bergmeyer HU, ed. Methods of enzymatic analysis, 3rd ed. Weinheim: Ver­lag Chemie, 1983: 233-260.
12. Sybrecht GW, **Oellerich M**. Antiallergische - antiobstruktive Therapie durch Mastzellenprotektion: Theophyllin. In: Schmidt OP, Hrsg. Mastzellenproduktion, Antiallergische/ antiobstruk­tive Therapie. München-Deisenhofen: Dustri-Verlag Dr. Karl Feistle, 1983: 77-86.
13. **Oellerich M**, Sybrecht GW. Drug Monitoring und Dosisvorher­sage. In: Oellerich M, Sybrecht GW, Wettengel R, Hrsg. Theo­phyllin, Optimierung der Therapie in Klinik und Praxis. Neu-Isenburg: I.M.P. Verlag, 1983: 85-98.
14. Sybrecht GW, **Oellerich M**. Therapie mit Theophyllin: Charakte­ristik verschiedener Theophyllin-Präparate, Indikation und individuelle Dosierung. In: Oellerich M, Sybrecht GW, Wetten­gel R, Hrsg. Theophyllin, Optimierung der Therapie in Klinik und Praxis. Neu-Isenburg: I.M.P. Verlag, 1983: 127-139.
15. **Oellerich M**, Schmäschke J, Schumann G, Sybrecht GW. Biover­fügbarkeit von Theophyllin, Proxyphyllin und Diprophyllin in einer oral applizierten Lösung und einem Retard-Präparat. In: Nolte D, Krejci G, Hrsg. Methylxanthine bei obstruktiven Atemwegserkrankungen. München-Deisenhofen: Dustri-Verlag Dr. Karl Feistle, 1984: 49-69.
16. **Oellerich M**, Thomas L. Pharmaka (Drug Monitoring). In: Thomas L. Hrsg. Labor und Diagnose, 2. Aufl. Marburg: Die Medizinische Verlagsgesellschaft, 1984: 838-850.
17. Müller-Vahl H, **Oellerich M**. Zum klinischen Wert der Bestim­mung der Serumkonzentration des freien, nicht eiweißgebun­denen Phenytoin. Epilepsie 84. Reinbeck: Einhorn-Presse Ver­lag, 1985: 335-343.
18. **Oellerich M**. Theophylline. In: Bergmeyer HU, ed., Oellerich M, ed. consultant. Methods of enzymatic analysis, Vol. XII, Drugs and Pesticides, 3rd ed., Weinheim: VCH Verlagsgesell­schaft, 1986: 5-23.
19. Evans WE, **Oellerich M**. Drugs monitored during therapy. Intro­duction. In: Bergmeyer HU, ed., Oellerich M, ed. consultant. Methods of enzymatic analysis, Vol. XII, Drugs and Pestici­des, 3rd ed., Weinheim: VCH Verlagsgesellschaft, 1986: 2-4.
20. **Oellerich M**. Influence of protein binding commentary. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokine­tics, priciples of therapeutic drug monitoring. Spokane: Applied Therapeutics, Inc., 1986: 220-228.
21. **Oellerich M**. Clearancewerte und Metabolitenkinetik in der Leberdiagnostik. In: Seidel D, Lang H, Hrsg. Funktion und Funktionsdiagnostik der Leber. Merck-Symposium der Deutschen Gesellschaft für Klinische Chemie 1985. Berlin, Heidelberg: Springer-Verlag, 1987: 53-55.
22. **Oellerich M**. Allgemeine Grundlagen der Therapiekontrolle durch Bestimmung der Serumkonzentrationen von Pharmaka. In: Greiling H, Gressner AM, Hrsg. Lehrbuch der Klinischen Chemie und Pathobiochemie. Stuttgart: Schattauer, 1987: 1089-1095.
23. **Oellerich M**. Pharmaka und deren klinisch-chemische Bestim­mungsmethoden. In: Greiling H, Gressner AM, Hrsg. Lehrbuch der Klinischen Chemie und Pathobiochemie. Stuttgart: Schattauer, 1987: 1096-1114.
24. **Oellerich M**, Sybrecht GW, Raude E, Schulz M, Ringe B, Schmidt FW, Wilkens JH. Drug Monitoring im Notfall-Labor. In: Henkel E, Hrsg., Kleinkonferenz der Dt. Ges. für Klin. Chemie 1985, Darmstadt: GIT Verlag, 1987: 78-87.
25. Schumann G, **Oellerich M**, Olthafer KJ, Leirich C, Wonigeit K. Entwicklung eines spezifischen HPLC-Routineverfahrens zur Bestimmung von Ciclosporin im Blut. In: Königsteiner Chroma­tographie-Tage 1987. Eschborn: Waters, Division of Milli­pore, 1987.
26. **Oellerich M**. Pharmaka (Drug monitoring). In: Thomas L. Hrsg. Labor und Diagnose, 3. Aufl. Marburg: Die Medizinische Ver­lagsgesellschaft, 1988: 1192-1211.
27. **Oellerich M**. Bestimmung von Antiepileptika mittels radioakti­vitätsfreier homogener Immunoassays. In: Schliak H, Hopf HC, Hrsg. Diagnostik in der Neurologie. Stuttgart: Georg Thieme Verlag, 1988: 263-275.
28. **Oellerich M**, Schwabe H, Stein U, Schwarting H, Sybrecht GW. Theophyllin im Speichel. In: Haeckel R, Hrsg. Speicheldiagno­stik. Darmstadt: GIT Verlag, 1988: 57-63.
29. **Oellerich M**. Diagnostik des Drogenabusus mittels klinisch-chemischer Methoden. In: Hellbrügge T, Pachler JM, Hrsg. Dro­gen im Kindes- und Jugendalter. Lübeck: Hansisches Verlags­kontor, 1988: 31-43.
30. **Oellerich M**, Schumann G. Is there a need for standardization in drug monitoring? In: Ashby JP, ed. Towards improving labo­ratory economics and working practice. Lund: Proceedings of the 7th ECCLS Annual Conference Salzburg 1987, The European Committee for Clinical Laboratory Standards, 1988: 169-201.
31. **Oellerich M**, Schneider B. Single-point and Bayesian approach for individualizing theophylline dosage. In: Keller H, Tren­delenburg Ch, eds, Curtius HCh, Roth M, series eds. Clinical biochemistry, 2. Data presentation, interpretation. Berlin: W. de Gruyter & Co., 1989: 403-423.
32. **Oellerich M**, Böttger HCh, Sybrecht GW, Raude E. Anwendung der Bayes-Statistik zur Vorhersage des individuellen Serum­konzentrationsverlaufs von Pharmaka. In: Gibitz HJ, Geldma­cher von Mallinckrodt M, Hrsg. Klinisch-toxikologische Analy­tik bei akuten Vergiftungen und Drogenmißbrauch. Weinheim: DFG Deutsche Forschungsgemeinschaft, VCH Verlagsgesellschaft, 1989: 169-175.
33. **Oellerich M**. Allgemeine Grundlagen der Therapiekontrolle durch Bestimmung der Serumkonzentrationen von Pharmaka. In: Greiling H, Gressner AM, Hrsg. Lehrbuch der Klinischen Chemie und Pathobiochemie, 2. überarb. Aufl. Stuttgart: Schattauer, 1989: 1089-1095.
34. **Oellerich M**. Pharmaka und deren klinisch-chemische Bestim­mungsmethoden. In: Greiling H, Gressner AM, Hrsg. Lehrbuch der Klinischen Chemie und Pathobiochemie, 2. überarb. Aufl. Stuttgart: Schattauer, 1989: 1096-1114.
35. Schumann G, **Oellerich M**, Kohlhaw K, Wonigeit K, Leirich C. Monitoring cyclosporine (CSA) in transplantation: FPIA compared with RIA and HPLC. In: Tanaka K, Pippenger CE, Mimaki T, Walson PD, Ohgitani S, eds. Advances in therapeutic drug monitoring. Proceedings of the 1st International Con­gress of Therapeutic Drug Monitoring. Tokyo: Enterprise, 1990: 279-281.
36. Haeckel R, **Oellerich M**, Binder L. Hydrazonopropionic acid de­rivatives. In: Bailey CJ, Flatt PR, eds. New antidiabetic drugs. London: Smith-Gordon, 1990: 207-216.
37. Burdelski M, **Oellerich M**, Pippenger CE, Meng X, Rodeck B, Latta A, Binder L, Heller C. Free radical scavenging enzyme activities in erythrocytes of paediatric patients with Crohn's disease. In: Williams CN, ed. Trends in inflammatory bowel disease therapy. Dordrecht: Kluwer Academic Publishers, 1991: 393-454.
38. **Oellerich M**, Burdelski M, Ringe B, Ozaki N, Binder L, Pichl­mayr R. Assessment of donor organ function. In: Rodes J, Arroyo V, eds. Therapy in liver diseases. Barcelona: Ediciones Doyma S.A., 1992:227-236.
39. **Oellerich M**, Burdelski M, Lautz HU, Hartmann H, Ringe B, Pichlmayr R. Donor rating and assessment of pretransplant prognosis by use of the MEGX test. In: Paoletti R, ed. Drugs and the liver. Fondazione Giovanni Lorenzini 1992.
40. **Oellerich M**. Pharmaka (Drug Monitoring). In: Thomas L, Hrsg. Labor und Diagnose, 4. überarb. Aufl. Marburg: Die Medizinische Verlagsgesellschaft, 1992: 1444-1465.
41. **Oellerich M**, Burdelski M, Goeschen K, Lautz HU, Wedeking H. Drug metabolism as an index of liver function. In: Sunshine I, ed. Recent developments in therapeutic drug monitoring and clinical toxicology. New York: Marcel Dekker, Inc., 1992: 765-771.
42. Petersen D, Schumann G, **Oellerich M**, Klauke R, Wittner N. HPLC reference method for theophylline: Calibration by use of standard addition. In: Sunshine I, ed. Recent developments in therapeutic drug monitoring and clinical toxicology. New York: Marcel Dekker, Inc., 1992: 277-284.
43. Burdelski M, **Oellerich M**, Rodeck B, Latta A, Düwel J. The role of dynamic liver function tests in liver transplantation. In: Paediatric Cholestasis. Novel Approaches to Treatment. Ed. M Lentze, J Reichen. Kluwer Academic Publishers, Dordrecht, Boston, London, 1992: 215-224.
44. **Oellerich M**, Burdelski M, Beyrau R, Ringe B, Lamesch P, Gubernatis G, Pichlmayr R. Assessment of liver function in donors by use of the MEGX test. In: G.Brunner, M.Mito, eds. Artificial Liver Support, 2nd ed. Springer-Verlag Berlin Heidelberg 1992: 132-139.
45. **Oellerich M**, Kaltefleiter M, Luy M, Armstrong VW, Schütz E, Binder L, Ringe B. Use of drugs of assess liver function. In: Biologie prospective. Comptes rendus du 8e Colloque de Pont-à-Mousson. Ed. MM Galteau, G Siest, J Henry. John Libbey Eurotext, Paris. 1993: 411-416.
46. **Oellerich M**. Current status of the use of liver function tests in transplantation. In: III Simposio Nazionale. Monitoraggio farmaci e droghe d'abuso. ATTI. Antonio Delfino Editore, Roma 1993: 55-67.
47. **Oellerich M**. Allgemeine Grundlagen der Therapiekontrolle durch Bestimmung der Serumkonzentrationen von Pharmaka. In: Greiling H, Gressner AM, Hrsg. Lehrbuch der Klinischen Chemie und Pathobiochemie, 3. überarb. Aufl. Stuttgart: Schattauer, 1995: 1353-1359.
48. **Oellerich M**. Pharmaka und deren klinisch-chemische Bestim­mungsmethoden. In: Greiling H, Gressner AM, Hrsg. Lehrbuch der Klinischen Chemie und Pathobiochemie, 3. überarb. Aufl. Stuttgart: Schattauer, 1995: 1360-1376.
49. Armstrong VW, Zielmann S, **Oellerich M**, Therapeutic drug monitoring in critical care medicine. In: Dellinger RP, ed. Current Topics in Intensive Care, No. 3, London: Saunders, 1996: 1-22.
50. Armstrong VW, **Oellerich M**, Practical aspects of TDM. In: Kaplan LA, Pesce AJ, eds. Clinical Chemistry, 3rd ed., St.Louis: Mosby, 1996, 1098-1102.
51. **Oellerich M**, Schütz E, Armstrong VW, Wieland E, Ringe B,. Liver transplantation: Assessment of liver function in both transplant candidates and recipients. In: Kleesiek K, Heubner A, eds., Transplantation of organs and cells, Berlin: Blackwell, 1997, 22-34.
52. Schütz E, Armstrong VW, **Oellerich M**. Drug Monitoring nach Organtransplantation. In: Bruhn, Fölsch Hrsg., Labormedizin, Schattauer Verlagsgesellschaft, 1999: 124-131.
53. **Oellerich M**. Pharmaka (Drug Monitoring). In: Thomas L, Hrsg., Labor und Diagnose, 5. überarb. Aufl. Frankfurt/Main: TH-Books Verlagsgesellschaft, 1998: 1170-1183.
54. **Oellerich M**. Therapeutic drug monitoring. In: Thomas L, ed., Clinical laboratory diagnostics. Use and assessement of clinical laboratory results, 1. edition. Frankfurt/Main: TH-Books Verlagsgesellschaft, 1998:1145-1157.
55. **Oellerich M**. Pharmaka (Drug Monitoring). In: Thomas L., Hrsg., Labor und Diagnose, 5. erweiterte Aufl., Frankfurt/Main: TH-Books Verlagsgesellschaft, 2000:1170-1183.
56. **Oellerich M**. Drug-Monitoring: Absorptionsprofile – individuelle Pharmakokinetik. In: Land W., Hrsg., Ciclosporin in der Transplantationsmedizin. 1. Aufl., Stuttgart/New York: Thieme, 2001:62-72.
57. **Oellerich M**. Biomarkers of hepatic disease. In: Trull AK, ed., Biomarkers of Disease, An evidence-based approach. 1. edition., Cambrigde: University Press Cambridge, 2002; 167-174.
58. **Oellerich M**, Armstrong VW. Therapeutic Drug Monitoring (TDM). Part 2: Practical aspects of TDM. In: Kaplan LA, Pesce AJ, Kazmierczak SC., eds., Clinical Chemistry. Theory, Analysis, Correlation. 4. edition., St. Louis: Mosby, 2003; 1086-1091.
59. Armstrong VW, Schwab M, **Oellerich M**. Metabolismus von Xenobiotika und Drug Monitoring. In: Renz H., Hrsg., Integrative Klinische Chemie und Laboratoriumsmedizin. 1. Aufl., Berlin/ New York: Walter de Gruyter, 2003; 615-631.
60. **Oellerich M**. Therapeutic drug monitoring. In: Thomas L, ed., Clinical laboratory diagnostics. Use and assessement of clinical laboratory results, 1. Chinese edition. Frankfurt/Main: TH-Books Verlagsgesellschaft, 2004:1140-1151.
61. Tönshoff B, Weber LT, Armstrong VW, **Oellerich M**. Mycophenolate mofetil in pediatric patients. Pharmacokinetics and pharmacodynamics of mycophenolic acid. A CME monograph. Roche Pharmaceuticals 2004: 35-48.
62. **Oellerich M**. Pharmaka (Drug Monitoring). In: Thomas L, ed., Labor und Diagnose. Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik. 6. Aufl., Frankfurt/Main: TH-Books Verlagsgesellschaft, 2005:1552-1568.
63. Armstrong VW, **Oellerich M**. Critical evaluation of methods for therapeutic drug monitoring. In: Burton ME, Shaw L, Schentag JJ, Evans WE eds. Applied Pharmacokinetics and Pharmacodynamics. Principles of Therapeutic Drug Monitoring, 4th edition. Philadelphia: Lippincott, Williams & Wilkins, 2006: 30-39.
64. **Oellerich M**, Streit F, Schütz E. Ciclosporin: Formulierungsabhängige Pharmakokinetik. In: Petersen KU, Abendroth D. Austauschbarkeit von Pharmaka kritischer Dosierung: Bestandsaufnahme am Beispiel Ciclosporin. Lengerich: Pabst Science Publishers, 2008: 42-53.
65. Armstrong VW, Schütz E, **Oellerich M**. Drug Monitoring nach Organtransplantation. In: Bruhn HD, Fölsch UR, Schäfer H, Hrsg. Labormedizin, 2. überarbeitete Aufl., Schattauer, 2008: 145 – 155.
66. **Oellerich M**. Pharmaka (Drug Monitoring). In: Thomas L, ed., Labor und Diagnose. Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik. 7. Aufl., Frankfurt/Main: TH-Books Verlagsgesellschaft, 2008: 1552 - 1568.
67. **Oellerich M**, Ritschel WA, Armstrong VW. Therapeutic Drug Monitoring. In: Kaplan LA, Pesce AJ, eds., Clinical Chemistry. Theory, Analysis, Correlation. 5. edition, St. Louis: Mosby Elsevier, 2010: 263 – 280.
68. Brandhorst G, Armstrong VW, Schütz E, **Oellerich M**. Drug Monitoring nach Organtransplantation. In: Bruhn HD, Junker R, Schäfer H, Schreiber S, Hrsg. Labormedizin, 3. überarbeitete Aufl., Schattauer, 2011: 139 – 150.
69. **Oellerich M,** Brandhorst G, Shipkova M, Wieland E. Biomarkers: The link between therapeutic drug monitoring and pharmacodynamics of immunosuppressants. In: Dasgupta A, ed., Therapeutic drug monitoring: newer drugs and biomarkers, 1. edition, San Diego. Elsevier, 2012: 349 - 372.
70. **Oellerich M**. Pharmaka (Drug Monitoring). In: Thomas L, ed., Labor und Diagnose. Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik. 8. Aufl., Frankfurt/Main: TH-Books Verlagsgesellschaft, 2012: 1899 - 1917.
71. Singh B, Sharma GL, Singh S, Reichard U, **Oellerich M**, Bhadoria DP, Asif AR. Aspergillosis: a major challenge for public health. In: Kappas M, Groß U, Kelleher D, eds. Global Health. A challenge for interdisciplinary research. Göttingen: Universitätsverlag Göttingen, 2012: 191-208.
72. **Oellerich M**, Beck J, Kanzow P, Schmitz J, Kollmar O, Walson PD, Schütz E. Graft-derived cell-free DNA as a marker of graft integrity after transplantation. In: Oellerich M, Dasgupta A, eds., Personalized immunosuppression in transplantation: Role of biomarker monitoring and therapeutic drug monitoring, 1. edition, San Diego. Elsevier, 2016; 153-176.
73. **Oellerich M**, Schütz E, Beck J, Kollmar O, Kanzow P, Blum A, Walson PD. Graft-derived cell-free DNA as a biomarker in liver transplantation. In: Patel VB, Preedy VR, eds., Biomarkers in Disease: Methods, Discoveries and Applications. Biomarkers in Liver Disease. 1. edition. Springer, 2016; doi: 10.1007/978-94-007-7742-2\_10-1.
74. Beck J, **Oellerich M,** Schütz E. A universal droplet digital PCR approach for monitoring of graft health after transplantation using a preselected SNP set. In: Karlin-Neumann G, Bizouarn F, eds., Digital PCR. Methods in Molecular Biology (vol. 1768). Humana Press, New York, NY, 2018. doi: 10.1007/978-1-4939-7778-9\_19.
75. **Oellerich M**, Budde K, Bornemann-Kolatzki K, Sherwood K, Osmanodja B, Melter M, Beck J, Schütz E, Keown P, Walson PD. Donor-derived cell-free DNA as a marker of graft injury after solid organ transplantation. In: Dasgupta A ed., Therapeutic drug monitoring: newer drugs and biomarkers. 2. edition, San Diego, Elsevier, 2024; 475-498.

# REVIEWS

1. Haeckel R, **Oellerich M**. Enzymimmunotests für die Routinediag­nostik. Lab med 1977; 1:121-131.
2. **Oellerich M**, Haeckel R. Diagnostischer Wert klinisch-chemi­scher Untersuchungen. Kriterien und deren praktische Anwen­dung. Med Welt 1978; 29:866-872.
3. **Oellerich M**. Überwachung der Serumkonzentrationen von Arznei­mitteln mit Hilfe von Enzymimmunotests. Nieders Ärzteblatt 1978; 24:852-854.
4. **Oellerich M**, Haeckel R. Einsatz von Enzymimmunotests beim Drogenscreening. Lab med 1979; 3:65-70.
5. Haeckel R, **Oellerich M**. Die Bestimmung der Transferrin-Eisen­bindungskapazität. Lab med 1979; 3:163-166.
6. **Oellerich M**. Enzyme immunoassays in clinical chemistry - pre­sent status and trends. J Clin Chem Clin Biochem 1980; 18:197-208.
7. **Oellerich M**. Praktikabilität und Zuverlässigkeit des enzym-immunologischen Opiatnachweises. Med Labor 1980; 33:199-206.
8. Diehl V, Kotz R, Salzer M, Winkler K, Baumgärtner G, Sekera J, Ramach W, Illinger J, Janka GE, Pralle H, Mc Vie JG, Willoughby MLN, Engelhardt P, **Oellerich M**. Report on various clinical studies on high dose methotrexate in Europe (non-EORTC). Onkologie 1981; 4:308-319.
9. **Oellerich M**, Sybrecht GW. Indikation und Methodik der Bestim­mung des Theophyllinspiegels im Serum. Therapiewoche 1981; 31:5110-5116.

Indications and methods for determining theophylline levels in serum. Brit J Clin Pract., Suppl. 10:22-27.

1. Sybrecht GW, **Oellerich M**. Stellenwert des Theophyllins in der Asthmatherapie unter Berücksichtigung der Blutspiegel. Atemw.-Lungenkrkh. 1981; 7:269-276.
2. **Oellerich M**. Neuere Entwicklungen der Mechanisierung von En­zymimmunotests. MTA-Zeitschrift d. dvta 1981; 27:316-320.
3. **Oellerich M**. Diagnostik und Drogenabusus mit klinisch-chemi­schen Methoden. Deutsches Ärzteblatt 1982; 79:41-49.
4. **Oellerich M**, Sybrecht GW, Klein H. Therapieüberwachung durch Bestimmung von Pharmaka-Konzentrationen im Serum. Methodik und klinische Bedeutung. Internist 1982; 23:174-181.
5. **Oellerich M**. Das Konsilium im Rahmen der klinischen Toxikolo­gie und des Drug Monitoring. Dt Ges f Klin Chem e.v.- Mittei­lungen 1983; 14:206-214.
6. **Oellerich M**. Enzymimmunotests zur in-vitro Schilddrüsen­diagnostik. Akt Endokr Stoffw 1984; 5:6-12.
7. **Oellerich M**. Enzyme-immunoassay - a review. J Clin Chem Clin Biochem 1984; 22:895-904.
8. Maes RAA, **Oellerich M**, Enders PW. Thephylline profile. Report V of the Senate Commission for Clinical-Toxicilogical Analy­sis. DFG Deutsche Forschungsgemeinschaft. Weinheim: VCH Ver­lagsgesellschaft, 1985.
9. **Oellerich M**, Beneking M, Schumann G, Sybrecht GW. Überwachung der Serumkonzentration unter Theophyllin- und Digoxinthera­pie. Therapiewoche 1986; 36:1114-1124.
10. Wilkens JH, Wilkens H, Meins M, Kurtin L, **Oellerich M**, Sybrecht GW. Treatment of nocturnal asthma: the role of sustained-release theophylline and oral ß-2-mimetics. Chrono­biology International 1987; 4:387-396.
11. Maes RAA, **Oellerich M**. Tobramycin profile. Report IX of the Senate Commission for Clinical-Toxicological Analysis. DFG Deutsche Forschungsgemeinschaft. Weinheim: VCH Verlagsgesell­schaft, 1988.
12. **Oellerich M**, Schumann G, Raude E. Sources of errors in diffe­rent protein binding assay systems - pharmacology and toxico­logy. Scand J Clin Lab Invest, 49 Suppl. 1989: 193:62-71.
13. Pichlmayr R, Lautz HU, **Oellerich M**, Gubernatis G. Functional studies in assessment of donor and recipient selection. Eur J Gastroenterol Hepatol 1989; 1:87-91.
14. Uges DRA, von Clarmann M, Geldmacher von Mallinckrodt M, van Heijst Ad NP, Ibe K, **Oellerich M**, Schütz H, Stamm D, Wunsch F. Orientierende Angaben zu therapeutischen und toxischen Konzentrationen von Arzneimitteln und Giften in Blut, Serum oder Urin. Mitteilung XV der Senatskommission für klinisch-toxikologische Anayltik. DFG Deutsche Forschungsgemeinschaft. Weinheim: VCH Verlagsgesellschaft, 1990.
15. **Oellerich M**. Drug metabolism as an indicator of liver function. Clinical Chemistry News, Special Issue, Frontiers in therapeutic drug monitoring and clinical toxicology, Miceli J and Wong SH eds., American Association for Clinical Chemistry, 1992, p 16-19.
16. **Oellerich M**. Therapeutic drug monitoring and pharmacokinetic dose prediction methods. Wien Klin Wochenschr 1992; 104:12-15.
17. **Oellerich M**. Leberfunktionstests bei Lebertransplantation. Prognose heute besser beurteilbar. Krankenhaus Arzt 1993; 66:163-168.
18. **Oellerich M**, Armstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R, Lindholm A, Halloran P, Gallicano K, Wonigeit K, Schütz E, Schran H, Annesley T. Lake Louise Consensus Conference on Cyclosporin Monitoring in Organ Transplantation: Report of the Consensus Panel. Ther Drug Monit 1995; 17:642-654.
19. Potter JM, **Oellerich M**. The use of lidocaine as a test of liver function in liver transplantation. Liver Transplantation and Surgery 1996; 2: 211-224.
20. **Oellerich M**, Schütz E, Armstrong VW. Monitoring of cyclosporin and azathioprine in organ transplantation. Drug Metabolism and Drug Interactions 1997; 14:17-31.
21. **Oellerich M**, Armstrong VW, Schütz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Clin Biochem 1998; 31: 309-316.
22. Shaw LM, Nicholls A, Hale M, Armstrong VW, **Oellerich M**, Yatscoff R, Morris RE, Holt DW, Venkataramanan R, Haley J, Halloran P, Ettenger R, Keown P, Morris RG. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 1998; 31: 317-322.
23. **Oellerich M**, Shipkova M, Schütz E. Wieland E, Weber L, Tönshoff B, Armstrong VW and members of the German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. Ther Drug Monit 2000; 22: 20-26.
24. Armstrong VW, **Oellerich M**. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus and azathioprine. Clin Biochem 2001; 34: 9-16.
25. **Oellerich M**, Armstrong VW. The MEGX test: A tool for the real-time assessment of hepatic function. Ther Drug Monit 2001; 23: 81-92.
26. Shaw LM, Holt DW, **Oellerich M**, Meiser B, van Gelder T. Current Issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305-315.
27. **Oellerich M**, Armstrong VW. Two-hour cyclosporine concentration determination: an appropriate tool to monitor Neoral therapy? Ther Drug Monit 2002; 24: 40-46.
28. Shipkova M, Armstrong VW, **Oellerich M**, Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 2003; 25: 1-16.
29. Dresing K, Pouwels C, Bonsack S, **Oellerich M**, Schwörer H, Uy A, Stürmer KM. HCV-, HBV- und HIV-Infektionen – Gefahren für Arzt und Pflegepersonal. Chirurg 2003; 74: 1026-1033.
30. Armstrong VW, Shipkova M, von Ahsen N, **Oellerich M**. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit 2004; 26: 220-226.
31. **Oellerich M**, Armstrong VW, Streit F, Weber L, Tönshoff B. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clin Biochem 2004; 37: 424-428.
32. Tönshoff B, Weber LT, Höcker B, Köpf S, Zimmerhackl LB, Armstrong VW, **Oellerich M**. Der Stellenwert des Immunsuppressivums Mycophenolatmofetil bei pädiatrischen Nierentransplantatempfängern. Tx Med 2004; 16: 26-37.
33. Johnston A, Belitsky P, Frei U, Horvath J, Hoyer P, Helderman JH, **Oellerich M**, Pollard S, Riad H, Rigotti P, Keown P, Nashan B. Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients. Eur J Clin Pharmacol 2004; 60; 389-395.
34. Shipkova M, Armstrong VW, **Oellerich M**, Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin. Drug Metab. Toxicol. 2005; 1: 505-526.
35. **Oellerich M**, Barten MJ, Armstrong VW. Biomarkers. The link between therapeutic drug monitoring und pharmacodynamics. Ther Drug Monit 2006; 1: 35-38.
36. van Gelder T, Le Meur Y, Shaw LM, **Oellerich M**, DeNorfrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Tönshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: 145-154.
37. **Oellerich M**, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. Ther Drug Monit 2006; 28: 720-725.
38. Davies NM, Grinyó J, Heading R, Maes B, Meier-Kriesche HU, **Oellerich M**. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transpl, 2007; 22: 2440-2448.
39. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, Kuypers D, Le Meur Y, Marquet P, **Oellerich M**, Thervet E, Toenshoff B, Undre N, Weber LT, Westley IS, Mourad M. Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European Consensus Conference. Ther Drug Monit 2009; 31: 139-152.
40. von Ahsen N, Binder C, Brockmöller J, **Oellerich M**. CYP2D6 und Tamoxifen: pharmakogenetische Neuentdeckung eines etablierten Medikaments? J Lab Med 2009; 33: 293-302.
41. Wieland E, Olbricht CJ, Süsal C, Gurragchaa P, Böhler T, Israeli M, Sommerer C, Budde K, Hartmann B, Shipkova M, **Oellerich M**. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit 2010; 32: 560-572.
42. **Oellerich M**. The future of pathology and laboratory medicine. BJCL 2011; 19:9-14.
43. Israeli M, Klein T, Brandhorst G, **Oellerich M**. Confronting the challenge: individualized immune monitoring after organ transplantation using the cellular immune function assay. Clin Chim Acta 2012; 413: 1374 - 1378.
44. Singh B, Singh S, Asif AR, **Oellerich M**, Sharma GL. Allergic aspergillosis and the antigens of Aspergillus fumigatus. Curr Protein Pept Sci 2014; 15: 403-423.
45. **Oellerich M**, Walson PD, Beck J, Schmitz J, Kollmar O, Schütz E. Graft-derived cell-free DNA as a marker of transplant graft injury. Ther Drug Monit 2016; 38 (Suppl. 1): S75-S79.
46. Brunet M, Shipkova M, van Gelder T, Wieland E, Sommerer C, Budde K, Haufroid V, Christians U, López-Hoyos M, Barten MJ, Bergan S, Picard N, Millán López O, Marquet P, Hesselink DA, Noceti O, Pawinski T, Wallemacq P, **Oellerich M**. Barcelona Consensus on biomarker-based immunosuppressive drugs management in solid organ transplantation. Ther Drug Monit 2016; 38 (Suppl 1): S1-S20.
47. Shipkova M, Hesselink DA, Holt DW, Billaud EM, van Gelder T, Kunicki PK, Brunet M, Budde K, Barten MJ, De Simone P, Wieland E, López OM, Masuda S, Seger C, Picard N, **Oellerich M**, Langman LJ, Wallemacq P, Morris RG, Thompson C, Marquet P. Therapeutic drug monitoring of everolimus: A consensus report. Ther Drug Monit 2016; 38: 143-169.
48. Seger C, Shipkova M, Christians U, Billaud EM, Wang P, Holt DW, Brunet M, Kunicki PK, Pawinski T, Langman LJ, Marquet P, **Oellerich M**, Wieland E, Wallemacq P. Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. Ther Drug Monit 2016; 38: 170-189.
49. Price CP, John AS, Christenson R, Scharnhorst V, **Oellerich M**, Jones P, Morris HA. Leveraging the real value of laboratory medicine with the value proposition. Clin Chim Acta 2016; 462: 183-186.
50. **Oellerich M**, Kanzow P, Walson PD. Therapeutic drug monitoring – Key to personalized pharmacotherapy. Clin Biochem 2017; 50: 375-379.
51. **Oellerich M**, Schütz E, Beck J, Kanzow P, Plowman PN, Weiss GJ, Walson PD. Using circulating cell-free DNA to monitor personalized cancer therapy. Crit Rev Clin Lab Sci 2017; 54: 205-218.
52. **Oellerich M,** Schütz E, Beck J, Walson PD. Circulating cell-free DNA – diagnostic and prognostic applications in personalized cancer therapy. Ther Drug Monit 2019; 41: 115-120.
53. Eiben B, Glaubitz R, Schütz E, Beck J, Eiben C, Teubert A, Wagner H, Winkler T, Kupatt W, **Oellerich M.** Die Untersuchung zellfreier DNA durch Liquid Biopsy in der Medizin (The investigation of cell-free DNA by liquid biopsy in medicine). Deutsche Zeitschrift für Onkologie 2019; 51: 60-64.
54. **Oellerich M,** Christenson RH, Beck J, Walson PD. Plasma *EGFR* mutation testing in non-small cell lung cancer: A value proposition. Clin Chim Acta 2019; 495: 481-486.
55. O’Kane M, Porter D, McCann M, Juelicher P, Christenson R, **Oellerich M**, Price CP, St John A. A value proposition for natriuretic peptide measurement in the assessment of patients with suspected acute heart failure. Clin Chim Acta 2020; 500: 98-103
56. **Oellerich M,** Christenson RH, Beck J, Schütz E, Sherwood K, Price CP, Keown PA, Walson PD. Donor-Derived Cell-Free DNA Testing in Solid Organ Transplantation: A Value Proposition. JALM 2020; 5: 993-1004.
57. Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, Marquet P, Molinaro M, Noceti O, Pattanaik S, Pawinski T, Seger C, Shipkova M, Swen JJ, van Gelder T, Venkataramanan R, Wieland E, Woillard JB, Zwart TC, Barten MJ, Budde K, Dieterlen MT, Elens L, Haufroid V, Masuda S, Millan O, Mizuno T, Moes DJ, **Oellerich M**, Picard N, Salzmann L, Tönshoff B, van Schaik RH, Vethe NT, Vinks A, Wallemacq P, Asberg A, Langman LJ. Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit 2021; 43: 150-200.
58. **Oellerich M,** Sherwood K, Keown P, Schütz E, Beck J, Stegbauer J, Rump LC, Walson PD. Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury. Nat Rev Nephrol 2021; 17: 591-603.
59. Danesi R, Lo YMD, **Oellerich M**, Beck J, Galbiati S, Del Re M, Lianidou E, Neumaier M, van Schaik RHN. What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology?- Considerations on pre-analytical aspects by the IFCC workgroup cfDNA. Clin Chim Acta 2021; 520: 168-171
60. St John A, O`Kane M, Christenson R, Jülicher P, **Oellerich M,** Price CP. Implementation of medical tests in a Value-Based healthcare environment: A framework for delivering value. Clin Chim Acta 2021; 521: 90-96.
61. **Oellerich M**, Budde K, Osmanodja B, Bornemann-Kolatzki K, Beck J, Schütz E, Walson PD. Donor-derived cell-free DNA as a diagnostic tool in transplantation. Front. Genet. 2022; 13:1031894.
62. **Oellerich M**, Budde K, Osmanodja B, Bornemann-Kolatzki K, Beck J, Schütz E, Walson PD. Donor-derived cell-free DNA for personalized immunosuppression in renal transplantation. Ther Drug Monit 2023; 45: 20-25.
63. Akifova A, Budde K, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E, Osmanodja B. Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications. Transpl Int 2024; 37:13239.
64. Masuda S, Lemaitre F, Barten MJ, Bergan S, Shipkova M, van Gelder T, Vinks S, Wieland E, Bornemann-Kolatzki K, Brunet M, de Winter B, Dieterlen MT, Elens L, Ito T, Johnson-Davis K, Kunicki PK, Lawson R, Lloberas N, Marquet P, Millan O, Mizuno T, Moes DJ, Noceti O, **Oellerich M,** Pattanaik S, Pawinski T, Seger C, van Schaik R, Venkataramanan R, Walson P, Woillard JB Langman LJ. Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit 2025; 47: 4-31

# MULTICENTRE STUDIES

1. Bernutz C, Horn K. Ergebnisse der gemeinsamen Erprobung eines Enzymimmunoassays für Thyrotropin (TSH). J Clin Chem Clin Biochem 1986; 24:659-666.
2. Knedel M, Assmann G, Courbe A, van Impe L, Kattermann R, Keller H, **Oellerich M**. Investigation of the performance of the ES 600 Enzym-TestR system. A multicenter study. J Clin Chem Clin Biochem 1988; 26:149-162.
3. Klein G, Castiñeiras MJ, Collinsworth W, Courbe A, Delavenne M, Hänseler E, Hannak D, Kaspar P, Kattermann R, Knoke A, Mastropaolo W, Moia F, Nelson P, **Oellerich M**, Suigo E, Swanson R, Torralba A, Valdes R, Jr., Wilders-Truschnig M, Wu AHB. Results of the multicenter evaluation of the CEDIA theophylline assay. Wien Klin Wochenschr 1992; 104:31-37
4. Klein G, Collinsworth W, Courbe A, Fuentes-Arderiu X, Graham J, Hänseler E, Hannak D, Kattermann R, Knoke A, Lehmann P, Mastropaolo W, Moia F, Nelson P, **Oellerich M**, Suigo E, Torralba A, Wilders-Truschnig M, Wu AHB. Results of the multicenter evaluation of the CEDIA phenytoin assay. Wien Klin Wochenschr 1992; 104:38-42.
5. Klein G, Collinsworth W, Courbe A, Diez O, Domke I, Hänseler E, Haux P, Kattermann R, Knoke A, Lehmann P, Moia F, Nelson P, **Oellerich M**, Suigo E, Torralba A, Valdes R, Jr., Wilders-Truschnig M, Wu AHB. Results of the multicenter evaluation of the CEDIA phenobarbital assay. Wien Klin Wochenschr 1992; 104:43-47.
6. Horn K, Haux P, Kattermann R, **Oellerich M**, Knoke A, Sommer R, Weißmann A, Vockenhuber M, Clark D, Ng RH, Glick MR, Collinsworth W, Schröder S, Dubois H. Results of the multicenter evaluation of the CEDIA cortisol assay. Wien Klin Wochenschr 1992; 104:80-85.
7. Horowitz GL, Zaman Z, Blanckaert NJC, Chan DW, DuBois JA, Golaz O, Mensi N, Keller F, Stolz H, Klingler K, Marocchi A. Prencipe P, McLawhon RW, Nilsen OL, **Oellerich M**, Luthe H, Orsonneau JL, Richeux G, Recio F, Roldan E, Rymo L, Wicktorsson AC, Welch SL, Wieland H, Busse Grawitz A, Mitsumaki H, McGovern M, Ng K, Stockmann W. Modular Analytics: a new approach to automation in the clinical laboratory. J Autom Method Manag 2005; 1: 8-25 .
8. Brandhorst G, Streit F, Kratzsch J, Schiettecatte J, Roth HJ, Luppa PB, Körner A, Kiess W, Binder L, **Oellerich M,** von Ahsen N. Multicenter evaluation of a new automated electrochemiluminescence immunoassay for the quantification of testosterone compared to liquid chromatography tandem mass spectrometry. Clin Biochem 2011; 44: 264-267.
9. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, **Aldo-DHF Investigators.** Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013; 309: 781-791.

# BOOKS EDITED

1. **Oellerich M**, Sybrecht GW, Wettengel R. Theophyllin, Optimie­rung der Therapie in Klinik und Praxis. Neu-Isenburg: I.M.P. Verlag, 1983.
2. Evans WE, **Oellerich M**. Therapeutic drug monitoring clinical guide, (dtsch., franz., ital., span., holländ. Übersetzung 1984) Abbott Laboratories, 1984.
3. Bergmeyer HU, ed. **Oellerich M**, ed. consultant. Methods of en­zymatic analysis, Vol. XII, Drugs and Pesticides, 3rd ed., Weinheim: VCH Verlagsgesellschaft, 1986.
4. Taylor WJ, Diers Caviness MH, eds., **Oellerich M**, ed. consul­tant. A textbook for the clinical application of therapeutic drug monitoring. Irving: Abbott Laboratories, 1986.
5. Diers Caviness M, Mac Kichan J, Bottorff MB, Taylor WJ, ed., **Oellerich M**, ed. consultant. Therapeutic drug monitoring: a guide to clinical application. Irving: Abbott Laboratories, 1987.
6. Sunshine I, ed., **Oellerich M**, ed. board. Recent developments in therapeutic drug monitoring and clinical toxicology. New York: Marcel Dekker Inc., 1992.
7. Evans WE, **Oellerich M**, Holt DW. Therapeutic drug monitoring clinical guide: (dtsch., ital., franz. Übersetzung 1994), 2nd ed., Abbott Laboratories, 1994.
8. Evans WE, Schentag JJ, Jusko WJ, eds., **Oellerich M**, ed. consultant. Applied pharmacokinetics, 3rd ed., Vancouver: Applied Therapeutics, 1996.
9. Evans WE, **Oellerich M**. Therapeutic drug monitoring clinical guide, (dtsch., ital. Übersetzung 1994) Abbott Laboratories, 1994.
10. Evans WE, **Oellerich M**. Surveillance Thérapeutique par le dosage des médicaments. Guide pratique, 3ème éd. Abbott Laboratories, 1994.
11. Burtis CA, Ashwood ER, Bruns DE. Eds.; associate editors: Ann Gronowski, Greg Miller, **Oellerich M**,Francois Rousseau, Mitch Scott, Karl Voelkerding. Tietz textbook of clinical chemistry and molecular diagnostics. 5th ed., St. Louis: Elsevier Saunders, 2012.
12. **Oellerich M**, Dasgupta A. Personalized immunosuppression in transplantation: Role of biomarker monitoring and therapeutic drug monitoring. 1. edition, San Diego. Elsevier, 2016.

# EDITORIALS, LETTERS TO THE EDITOR, QUESTIONS AND ANSWERS

1. **Oellerich M**. Theophyllin allein oder kombiniert mit N-substi­tuierten Derivaten? Selecta 1980; 37:3246.
2. **Oellerich M**. Workshop conference of the German Society for Clinical Chemistry, Immunological Diagnostics, Guest Edito­rial. J Clin Chem Clin Biochem 1984; 22:845.
3. **Oellerich M**, Sybrecht GW. Pharmacokinetics and theophylline. Brit J Clin Pract 1984; 38, Suppl. 35:3-4.
4. **Oellerich M**. Leserbrief zur Frage des therapeutischen Berei­ches von Lithium. Lab med 1985; 9:338.
5. Haeckel R, Kaiser R, **Oellerich M**, Siliprandi N. Workshop con­ference on carnitine. Preface. Carnitine: Metabolism function and clinical application. J Clin Chem Clin Biochem 1990; 28:291-295.
6. Schütz E, Gummert J, Mohr F, **Oellerich M**. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341:436.
7. Armstrong VW, Wieland E, Diedrich F, Renner A, Rath W, Kreuzer H, Kuhn W, **Oellerich M**. Serum antibodies to oxidised low-density lipoprotein in pre-eclampsia and coronary heart disease. Lancet 1994; 343:1570.
8. **Oellerich M**. Editorial. Ther Drug Monit 1996; 18:321.
9. **Oellerich M**. Klinisch-chemische Forschung im Spannungsfeld zwischen Medizin und Naturwissenschaften (Emeritierung von Prof.Dr.Dr.J.Büttner). DG Klinische Chemie Mitteilungen 1996; 27:55-59
10. Shaw LM, **Oellerich M**. The role of therapeutic drug monitoring in disease management: introduction. Clin Chem 1998; 44:369.
11. Schütz E, Shipkova M, Armstrong VW, **Oellerich M**. Monoethylglycinexylidide (MEGX) liver function test is not compromised by 3-hydroxy MEGX in humans. Hepatology 1998; 28:1439-1440.
12. Ivanova A, von Ahsen N, Adjarov D, Krastev Z, **Oellerich M**, Wieland E. C282Y and H63D mutations in the HFE gene are not associated with porphyria cutanea tarda in Bulgaria. Hepatology 1999; 30: 1531-1532.
13. Schütz E, Shipkova M, Wieland E, Niedmann P, Armstrong VW, **Oellerich M**. Evaluation of an immunoassay for mycophenolic acid. Ther Drug Monit 2000; 22:141-142.
14. **Oellerich M**. Laboratory evaluation and monitoring of transplant recipients. Ther Drug Monit 2000; 22:640.

**Oellerich M**. Laboratoriumsmedizinische Diagnostik und Verlaufskontrolle bei Transplantat­empfängern. DG Klinische Chemie Mitteilungen 2000; 31:167-169.

1. Hummel KM, von Ahsen N, Kühn R-B, Kaboth U, Grunewald RW, **Oellerich M** Müller GA. Pseudohypercreatininemia due to positive interference in enzymatic creatinine measurements caused by monoclonal IgM in patients with Waldenström’s macroglobulinemia. Nephron 2000; 86: 188-189.
2. **Oellerich M**, Shaw L. Proceedings of the Analytica Conference 2000 symposium on laboratory evaluation and monitoring of transplant recipients Munich, Germany, April 11, 2000. Clin Biochem 2001; 34:1.
3. **Oellerich M**, Armstrong VW. Prodrug metabolites: implications for therapeutic drug monitoring. Clin Chem 2001; 5: 805 - 806.
4. von Ahsen N, Wieland E, Adjarov D, Krastev Z, **Oellerich M**, Ivanova A. The HFE gene S65C polymorphism is rare among Bulgarian porphyria cutanea tarda patients. J Hepatol 2001; 34: 484-488.
5. von Ahsen N, **Oellerich M**, Schütz E. Limitations of genotyping based on amplicon melting temperature. Clin Chem 2001; 7: 1331-1332
6. **Oellerich M**. Editorial zur Fusion der Deutschen Gesellschaft für Laboratoriumsmedizin und der Deutschen Gesellschaft für Klinische Chemie. J Lab Med 2003; 27: 6-7.
7. **Oellerich M**. Editorial. J Lab Med 2004; 28: 2.
8. **Oellerich M**, Kohse KP. Editorial Klinische Chemie Mitteilungen 2004; 35: 81-82.
9. von Ahsen N, **Oellerich M**. Prothrombin 19911A>G as a functional noncoding variant: the evidence remains. Blood 2005; 105: 2995-6.
10. Meier-Kriesche HU, Davies NM, Grinyó J, Heading R, Mamelok R, Wijngaard P, **Oellerich M**, Maes B. Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil. Am J Transplant 2005; 5: 1164.
11. von Ahsen N, **Oellerich M**. Chip-Based Genotyping: Translation of pharmacogenetic research to clinical practice. Clin Chem 2007; 53: 1186-1187.
12. Brandhorst G, **Oellerich M** (moderators), Brunet M,Kowalski R, Vinks A, Wallemaacq P (experts). Q & A: Individually tailored immunosuppression: is there a role for biomarkers? Clin Chem 2011; 57: 376-381.
13. Brandhorst G, **Oellerich M**, Maine G, Taylor P, Veen G, Wallemacq P. Liquid chromatography-tandem mass spectrometry or automated immunoassays: what are the future trends in therapeutic drug monitoring? Clin Chem 2012; 58: 821-825.
14. Wieland E, Shipkova M, **Oellerich M**. Biomarkers in transplantation medicine: Guide to the next level in immunosuppressive therapy. Clin Chim Acta 2012; 413: 1309.
15. Kanzow P, Kollmar O, Schütz E, **Oellerich M**, Schmitz J, Beck J, Walson PD, Slotta JE. Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver. Transplantation 2014; 98: e43-e45.
16. Scott MG, Rifai N (moderators), Smith B, **Oellerich M**, Panteghini M, Apple F, Sikaris K, Young I (experts). Q & A: The changing face of laboratory medicine: a more service and less academically oriented profession? Clin Chem 2015; 61: 322-329.
17. **Oellerich M**, Koren G. In memoriam: Offie Soldin, PhD, MBA. Ther Drug Monit 2015; 37: 555-556.
18. Christenson RH, Grenache DG, **Oellerich M.** Preamble.Special Collection on the Value of Laboratory Medicine. JALM 2020; 5: 841-843.
19. **Oellerich M**: Zellfreie Tumor-DNA in der molekularen Diagnostik bei Kopf-Hals-Karzinomen. HNO 2021; 69: 324; doi.org/10.1007/s00106-021-01009-0.
20. Agbor-Enoh S (moderator), **Oellerich M,** Wu A, Halloran P F, De Vlaminck I, Keller M (experts). Q&A: Novel approaches for transplant monitoring; is the horizon here? Clin Chem 2021; 67: 1443-1449

# GUEST EDITOR

1. **Oellerich M,** Wieland E, Shipkova M (eds.).Special issue: Peripheral biomarkers as a complementary tool to TDM for individualizing immunosuppression in transplantation medicine. Clin Chim Acta 2012; 413: 1309-1418.
2. Christenson R, Grenache D, **Oellerich M** (eds.). Special collection: Value of laboratory testing and the value proposition, JALM 2020; doi.org/10.1093/jalm/jfaa120GENE BANK ENTRIES
3. Schütz E, Andag R, Wieland E, **Oellerich M**. Porcine Cytochrome-P450 with high protein homology to human CYP3A4 (Nifedipine oxidase J04449). GenBank, Acc.no. AF 109068; 23-Nov-1998.
4. Atansova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. AY966403: Marmoset glultathione peroxidase 1 mRNA, complete cds.
5. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. AY966404: Marmoset glutathione peroxidase 4 mRNA, complete cds.
6. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. DQ164097: Callithrix jacchus gamma-glutamylcysteine synthetase regulatory subunit mRNA, complete cds.
7. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. DQ241811: Callithrix jacchus catalase mRNA, complete cds.
8. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. DQ486898: Callithrix jacchus glutathione synthetase mRNA, complete cds.
9. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. EF059744: Callithrix jacchus eukaryotic translation elongation factor EF2 mRNA, complete cds.
10. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. EF203010: Callithrix jacchus glutathione reductase (GSR) mRNA, complete cds.

# PROTEOME ENTRIES

1. Allergome Platform Entries

(<http://www.allergome.org>)

Immuno-reactive molecules identified from the secreted proteome of Aspergillus fumigatus. Singh B, **Oellerich M**, Kumar R, Kumar M, Bhadoria DB, Reichard U, Gupta VK, Sharma GL, Asif AR. J Proteome Res 2010; 9: 5517-5529.

Immuno-reactive molecules identified from the secreted proteome of Aspergillus fumigatus. Singh B, **Oellerich M**, Kumar R, Kumar M, Bhadoria DB, Reichard U, Gupta VK, Sharma GL, Asif AR. J Proteome Res 2010; 9: 5530-5541.

Asp f AT V

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8983

Asp f Catalase

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-08-09 8987

Asp f Chitosanase

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8985

Asp F CP

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8994

Asp f DPPV

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-08-13 8984

Asp f FDH

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8992

Asp f gamma Actin

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-04-29 9533

Asp f Glucosidase

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8995

Asp f GPI

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-05-15 2543

Asp f GT

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-07-02 8986

Asp f IAO

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8996

Asp f IPMI

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-05-20 9531

Asp f LPL1

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-07-02 8989

Asp f LPL3

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-07-02 8988

Asp f Mannosidase

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8990

Asp f MDH

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-04-29 8993

Asp f PL

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8991

Asp f PUP

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8982

Asp f RPS3

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-04-29 9532

Asp f SXR

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-04-29 9530

# COMMITTEE RECOMMENDATIONS

1. Guder WG, Groß J, Jaroß J, Kattermann R, Katz N, **Oellerich M**. Kommission für die Ausbildung der Deutschen Gesellschaft für Klinische Chemie e.V.: Empfehlungen zur ärztlichen Ausbildung im Fach Klinische Chemie. Dt Ges f Klin Chem e.V. - Mitteilungen 1993; 24: 200-207.
2. Levy G, Thervet E, Lake J, Uchida K on behalf of the CONCERT group. Patient management by Neoral C2 monitoring: an international consensus statement. Transplantation 2002; 73: S12-S18.
3. Pollard S, Nashan B, Johnston A, Hoyer P, Belitsky P, Keown P, Helderman H. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Clin Ther 2003, 25: 1654-1669.
4. Kuypers DR; Le Meur Y, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, Tönshoff B, Holt DW, Chapman J, Gelder T, Transplantation Society (TTS) Consensus Group on TDM of MPA. Clin J Am Soc Nephrol 2010; 5: 341-58.

# NEWSLETTER

1. **Oellerich, M**. Challenges of Transplantation in Children. IATDMCT Newsletter. Ther Drug Monit 2002; 24: 322.
2. **Oellerich, M.** Individualisierte Arzneimitteltherapie

Zertifizierte Fortbildung in Zusammenarbeit mit der Bayerischen Landesärztekammer. Der Internist 2006, 1 (Beilage): 1-8.

1. **Oellerich M**, von Ahsen N. Nachruf Victor William Armstrong. Klinische Chemie Mitteilungen. Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin e.V. 2010; 41: 133 – 135.
2. **Oellerich M**. Obituary. Prof. Dr. Victor William Armstrong 1948 – 2010. Ther Drug Monit 2010; 32:379.
3. **Oellerich M**. Obituary. Prof. Dr. rer. nat. Victor William Armstrong. J Lab Med 2010; 34: 237-238.
4. **Oellerich M**. Internationale Fachgesellschaften beteiligen sich an einer einzigartigen Initiative für eine neue Sichtweise auf die Laboratoriumsmedizin. Klinische Chemie Mitteilungen 2011; 42: 6-7.
5. **Oellerich M**. XXVI. WASPaLM Weltkongress in Las Vegas. Klinische Chemie Mitteilungen 2012; 43: 21-22.
6. **Oellerich M.** Neue Entwicklungen bei WASPaLM. Klinische Chemie Mitteilungen 2013; 44: 49.
7. **Oellerich M.** Liquid Biopsy in der Transplantationsmedizin. DIATRA 2019; 29: 46-47.
8. **Oellerich M**, Beck J, Bauer C, Schütz E. Zellfreie DNA als Biomarker in der Transplantationsmedizin. transplant campus, 07.01.2020; https://www.transplant-campus.de/nierentransplantation-lebertransplantation-herztransplantation-highlights/allgemein/wissen-kompakt/zellfreie-dna-und-liquid-biopsy-nach-transplantation/

# ABSTRACTS

1. Kley HK, **Oellerich M**, Wiegelmann W, Herrmann J, Rudorff KH, Nieschlag E, Krüskemper HL. Pituitary and peripheral glandu­lar functions in male drug addicts at the end of the metha­done maintenance program. Acta Endocrinol 1977; Suppl. 212:162.
2. **Oellerich M**, Haeckel R, Schumann G. Hydrazonoverbindungen - eine neue Gruppe von blutglucosesenkenden Substanzen. Aktu­elle Endokrinologie und Stoffwechsel 1980; 1:214-215.
3. Külpmann WR, **Oellerich M**. Determination of therapeutic serum concentrations of antiepileptic drugs by a newly developed gas chromatographic procedure and enzyme immunoassay: a com­parative study. J Clin Chem Clin Biochem 1980; 18:720.
4. **Oellerich M**, Böhm MM, Sybrecht GW. Klinische Bedeutung der Kontrolle der Theophyllinserumkonzentration bei Patienten mit Asthma brochiale. Verhandlungen der Deutschen Gesellschaft für Innere Medizin 1982; 88:426-427.
5. Külpmann WR, **Oellerich M**, Gey S, Beneking M, Heyer R. Deter­mination of phenytoin in serum by non-isotopic immunoasays (EMIT, FPIA, NIIA, SLFIA) and gaschromatography. J Clin Chem Clin Biochem 1982; 20:665-666.
6. Steenken Ch, **Oellerich M**, Werner PC, Klein H, Lichtlen PR. Klinische Wertigkeit der Bestimmung von Disopyramid-Serum­spiegeln bei antiarrhythmischer Therapie. Zeitschrift für Kardiologie 1984; Suppl 1, 73:78.
7. Wrenger M, **Oellerich M**, Sybrecht GW. Determination of enprofylline by HPLC using column switching. J Clin Chem Clin Biochem 1985; 23:615.
8. Schulz M, **Oellerich M**, Raude E, Freise J, Schmidt FW. Unter­suchungen zur Kinetik des Lidocainmetaboliten und Patienten mit Leberzirrhose. Z Gastroenterol 1987; 25:1-2.
9. Burdelski M, **Oellerich M**, Raude E, Ringe B, Kämmerling L, Worm M, Scheruhn M, Raith H, Bortfeld St, Westphal C. Erste Erfahrungen mit quantitativen Leberfunktionstesten zur Erfas­sung von Leberschäden bei Organspendern. WZ Gastroenterol 1987; 25:79-80.
10. Lamesch P, Blumhardt G, Ringe B, Burdelski M, **Oellerich M**, Schmidt E, Pichlmayr R. Wertigkeit von Funktionstests zur Beurteilung von Lebertransplantaten. Z Gastroenterol 1987; 25:80.
11. Beneking M, **Oellerich M**, Haeckel R, Binder L. Untersuchungen zur Hemmung der Carnitin-Acylcarnitin-Translocase an Mito­chondrien der Meerschweinchenleber. Z Gastroenterol 1987; 25:63-64.
12. Wrenger M, **Oellerich M**, Riedmann M. Development of HPLC methods using column switching technqiues and automatic mobile phase adjustment for the determination of disopyramide and antiepileptic drugs. J Clin Chem Clin Biochem 1987; 25:636-637.
13. Burdelski M, **Oellerich M**, Ringe B, Raith H, Scheruhn M, Lamesch P, Rodeck B, Pichlmayr R. Prognostische Bedeutung quantitativer Leberfunktionsteste (MEGX-, ICG-, GEK- und Coffein-Test) bei Lebertransplantierten. Z Gastroenterol 1988; 26:12-13.
14. **Oellerich M**, Burdelski M, Lautz HU, Raude E, Ringe B, Lamesch P, Gubernatis G, Beneking M, Rodeck B, Pichlmayr R. Effi­ciency of the MEGX formation test in liver transplantation. Hepatology 1988; 8:1220.
15. **Oellerich M**, Burdelski M, Lautz HU, Lamesch P, Herrmann H, Raude E, Ringe B, Gubernatis G, Beneking M, Schulz M, Schmidt FW, Pichlmayr R. Prognostische Wertigkeit des MEGX-Tests bei Transplantations-Kandidaten und lebertransplantierten Patien­ten. Z Gastroenterol 1989; 27:50-51.
16. Lautz HU, **Oellerich M**, Schulz M, Knoke A, Raude E, Burdelski M, Bürger M, Schmidt FW. Zur klinischen Bedeutung der Mono­ethylglycinxylidid (MEGX) Bestimmung bei hepatischen und bili­ären Leberzirrhosen. Z Gastroenterol 1989; 27:42.
17. **Oellerich M**, Burdelski M, Lautz HU, Rodeck B, Duevel J. Prognostic value of the MEGX liver function test in trans­plant candidates. Clin Chem. 1989; 35:1135.
18. **Oellerich M**, Burdelski M, Lautz HU, Rodeck B, Schmidt FW. Assessment of short-term prognosis in transplant candidates with cirrhosis. J Hepatol 1989; 9, Suppl 1:67.
19. **Oellerich M**, Burdelski M, Lautz HU. Prognostic sensitivity and specificity of the monoethylglycinexylidide liver func­tion test in transplant candidates. J Clin Chem Clin Biochem 1989; 27:757.
20. **Oellerich M**, Burdelski M, Beyrau R, Ringe B, Lamesch P, Wonigeit K, Lautz HU, Gubernatis G, Taki Y, Pichlmayr R. Lidocaine metabolite formation as a measure of early post-transplant liver function. Hepatology 1989; 10:625.
21. Duewel J, Burdelski M, **Oellerich M**, Rodeck B. Evaluation of liver function tests as prognostic indicators in chronic pediatric liver disease. Hepatology 1989; 10:660.
22. Kohlhaw K, Hoeft R, Muraca M, Ringe B, Bunzendahl H, Schumann G, Sonntag O, **Oellerich M**, Pichlmayr R. Serum esterified bilirubin (EB) and serum total bile acids (BA) in episodes of cholestasis after orthotopic liver transplantation (OLT). Hepatology 1989; 10:662.
23. Lamesch P, Rabe C, Ringe B, **Oellerich M**, Burdelski M, Guber­natis G, Pichlmayr R. Efficiency of MEGX and ICG-test for the prediction of postoperative complications after hepatic resections. Hepatology 1989; 10:663.
24. **Oellerich M**. Sources of error in protein binding assay systems, pharmacology and toxicology. Biochem Clin. 1989; 13:25-26.
25. **Oellerich M**, Sonntag O, Burdelski M. Decentralized perfor­mance of clinical chemical analysis: methodological aspects. Biochem Clin 1990; 14, Suppl 1:35.
26. Burdelski M, **Oellerich M**, Düwel J, Rodeck B, Herrmann H. Prognostische Wertigkeit von Leberfunktionstesten und klini­schen Befunden bei pädiatrischen Transplantationskandidaten. Z Gastroenterol 1990; 28:73.
27. Kohlhaw K, Muraca M, Hoeft R, Sonntag O, Villei T, Ringe B, Bunzendahl H, Schumann G, **Oellerich M**, Pichlmayr R. Differen­tialdiagnostische Bedeutung von Bilirubin-Fraktionen und Gallensäuren bei Leberfunktionsstörungen nach orthotoper Lebertransplantation (OLT). Z Gastroenterol 1990; 28:72-73.
28. **Oellerich M**. Lidocaine metabolite formation as measure of pretransplant liver function. Hepatitis Digest 1990; 1:20-21.
29. Rieß U, Binder L, Gulba DC, **Oellerich M**, Lichtlen P. Herzmus­kelspezifisches Troponin T: Ein neuer Reperfusionsmarker? Z Kardiol 1990; 79, Suppl 1:116.
30. **Oellerich M**, Burdelski M, Lautz HU, Rodeck B, Herrmann H. Lidocaine metabolite formation as a prognostic indicator in transplant candidates with cirrhosis. Clin Chem 1990; 36:1170.
31. Burdelski M, **Oellerich M**, Rodeck B. Prognostic indicators in liver cirrhosis. Pediatric Research 1990; 27:535.
32. **Oellerich M**. Drug metabolism as an index of liver function. Quimica Clinica 1990; 9:314.
33. Schumann G, **Oellerich M**, Petersen D. HPLC reference method for theophylline: calibration by use of standard addition. Quimica Clinica 1990; 9:352.
34. Burdelski M, **Oellerich M**, Düwel J, Rodeck B, Brodehl J. Pre­dictors of one-year survival in pediatric liver cirrhosis. Hepatology 1990; 12:858.
35. **Oellerich M**, Goeschen K, Wedeking H, Elling D, Burdelski M. Lidocaine metbolite formation as a measure of liver function in pregnancy. Hepatology 1990; 12:1011.
36. Binder L, **Oellerich M**, Haeckel R. Untersuchungen zur Hypo­glykämischen Wirkung von 2-(3-Phenylpropoxyimino)-butyrat. DG Klinische Chemie Mitteilungen 1990; 21:239.
37. **Oellerich M**. Drug metabolism as an indicator of liver func­tion. Clin Chem 1991; 37:1099.
38. Petersen D, Schumann G, **Oellerich M**, Demertzis S. Monitoring 5-fluorocytosine serum concentrations in immunocompromized patients with severe fungal infections. Clin Chem 1991; 37:1004.
39. Schumann G, Kunze K, **Oellerich M**, Petersen D, Hoyer P, Filler G, Offner G. Determination of cyclosporine in capillary blood by an affinity column mediated immunoassay (ACMIA) on the ACAR. Clin Chem 1991; 37:998.
40. **Oellerich M**, Burdelski M, Lautz HU, Pichlmayr R. Assessment of one-year pretransplant survival by flow-dependent dynamic liver function tests and Pugh score. Hepatology 1991; 14:286A.
41. **Oellerich M**, Hartmann H, Burdelski M, Lautz HU, Binder L. Prognostische Wertigkeit der Kombination von Pugh-Score und MEGX-Test bei Lebertransplantations-Kandidaten. Z Gastro­enterol 1992; 30:74.
42. Kynast B, Binder L, Marx D, Zoll B, **Oellerich M**, Schmoll HJ, Schauer A. p185-Überexpression beim Mammakarzinom. Nachweis mit ICA und ELISA. Verh.Dtsch.Ges.Path. 1992; 76:278.
43. Wieland E, Armstrong VW, **Oellerich M**. Probleme der Bestimmung oxidierter Lipoproteine in vitro und in vivo. Dt.Ges.f.Klin.Chemie e.V. - Mitteilungen 1992; 23:127-128.
44. Binder L, **Oellerich M**. Influence of 2-(3-phenylpropoxyimino)-butyrate on glucose transport in 3T3-L1 adipocytes. Eur J Clin Chem Clin Biochem 1993; 31:A16.
45. Schütz E, Gummert J, Jendras I, Mohr F, **Oellerich M**. Erythrocyte thiopurine methyltransferase as a predictor of potential azathioprine intolerance in heart transplantation. Eur J Clin Chem Clin Biochem 1993; 31:A46.
46. Wieland E, David A, Armstrong VW, **Oellerich M**. Enzymatic determination of aldehydic lipid peroxidation products using bacterial bioluminescence: Application to oxidized low density lipoproteins. Eur J Clin Chem Clin Biochem 1993; 31:A54.
47. Schütz E, Polzien F, Ringe B, Armstrong VW, **Oellerich M**. Differences in cytochrome P-450-mediated lidocaine metabolite formation between normal subjects and liver donors. Hepatology 1993; 18:343A.
48. Wieland E, Schütz E, Küthe F, Heller C, Armstrong VW, **Oellerich M**. Supplementation of organ preservation solutions with idebenone (QSA-10) protects liver microsomes against oxygen-radical-mediated damage. Hepatology 1993; 18:64A.
49. Wieland E, Schütz, E, Armstrong VW, **Oellerich M**. Oxygen radical mediated damage of hepatic microsomal lipids and proteins: protective effects of benzoquinones and α-tocopherol compared. Z Gastroenterol 1994; 32:64.
50. Binder L, Marx D, Kynast B, Meden H, Schauer A, **Oellerich M**. Determination of c-erb-2 oncoproteins in primary tumor and serum from breast cancer patients: prognosis and relapse. J Cancer Res Clin Oncol 1994; Suppl 120:R3.
51. Petersen D, Freund M, Poliwoda H, Schöffski P, Paaz U, Knoche MF, Schumann G, **Oellerich M**. Monitoring serum concentrations of 5-fluorocytosine and dosage individualization in cancer patients. J Cancer Res Clin Oncol 1994; Suppl 120:R61.
52. Schütz E, Kaltefleiter M, Luy-Kaltefleiter M, Ringe B, Armstrong VW, Burdelski M, **Oellerich M**. Prediction of early graft survival and complications by serial determination of MEGX and hyaluronic acid after OLT. Hepatology 1994; 20:126A.
53. Wieland E, Schütz E, Hensel A, Niedmann PD, Armstrong VW, **Oellerich M**. Antioxidant defense and lipid peroxidation during extended cold storage of pig livers in UW and HTK organ preservation solutions. Hepatology 1994; 20:414A.
54. Binder L, Wiemann S, **Oellerich M**. Effects of hydrazonopropionic acid derivates on glucose transport in 3T3-LI adipocytes. Diabetologia 1994; 37:A125.
55. Binder C, Binder L, **Oellerich M**, Hiddemann W. Proliferative activity and expression pattern of glucose transporter mRNA'S in human tumors and cell lines. Onkologie 1994; Suppl.2 17:10.
56. Wieland E, Schütz E, Hensel A, Niedmann PD, Nebendahl K, Armstrong VW, **Oellerich M**. Antioxidantienstatus und Lipidperoxidation während ausgedehnter kalter Ischämie in UW- und HTK-Organprotektionslösung am Modell der explantierten Schweineleber. Z Gastroenterol 1995; 33:57.
57. Schütz E, Wieland E, Hensel A, Dietrich K, Nebendahl K, Armstrong VW, Ringe B, **Oellerich M**. Idebenon unterdrückt den leukozytenvermittelten Hyaluronsäureanstieg im Ischämie/ Reperfusionsmodell der isoliert perfundierten Schweineleber. Z Gastroenterol 1995; 33:59-60.
58. Schütz E, Gummert J, Armstrong VW, Mohr FW, **Oellerich M**. Azathioprine pharmacogentics: The relationship of TPMT and 6-TGN in heart and kidney transplant recipients. Ther Drug Monit 1995; 17:429.
59. Schütz E, Dietrich D, Weyland W, Ringe B, **Oellerich M**. Does high-flow ascites compromise the MEGX-test? Ther Drug Monit 1995; 17:428.
60. von Ahsen N, Armstrong VW, Helmhold M, Schütz E, Eisenhauer T, **Oellerich M**. Cyclosporin trough levels correlate with serum lipoproteins and apolipoproteins in renal transplant recipients. Ther Drug Monit 1995; 17:430.
61. Heller C, Schütz E, Armstrong VW, **Oellerich M**. Improved EMIT assay for semiautomated cyclosporine determination. Ther Drug Monit 1995; 17:416.
62. Braun F, Schütz E, Grupp C, Canelo R, Armstrong VW, **Oellerich M**, Ringe B. Interaction of tacrolimus (FK-506) and fluconazole. Ther Drug Monit 1995; 17:397.
63. Schütz E, Wieland E, Heine L, Hensel A, Schmiedl A, Armstrong VW, Richter J, Günther E, **Oellerich M**. Heat-shock protein 70 gene expression in a pig liver cold ischemia/reperfusion model: influence of storage time and gadolinium chloride. Hepatology 1995; 22:218A.
64. Schettler V, Wieland E, Methe H, Schuff-Werner P, **Oellerich M**, Müller GA. Granulocyte glutathione peroxidase and gluathione reductase activities are significant changes during dialysis treatment: hemofiltration and hemodialysis compared. JASN 1995; 6:561.
65. Schettler, V, Wieland E, Schuff-Werner P, Kreuzer H, **Oellerich M**, Müller GA. Modified erythrocyte free radical scavenging enzymes activities (FRSEA) in patients suffering from coronary heart disease (CHD) undergoing LDL-apheresis (HELP). Nieren- und Hochdruckkrankheiten 1995; 24:526.
66. Schettler, V, Wieland E, Schuff-Werner P, Kreuzer H, **Oellerich M**, Müller GA. Modified erythrocyte free radical scavenging enzymes activities (FRSEA) in patients suffering form coronary heart disease (CHD) undergoing LDL-apheresis (HELP). Nephrol. Dial. Transplant 1996; 11: 1476.
67. Schettler V, Wieland E, Methe H, Schuff-Werner P, **Oellerich M**, Müller GA. Oxidative stress in granulocytes of patients undergoing hemodialysis and hemofiltration. Nieren- u.Hochdruckkrankheiten 1996; 25:400.
68. Schettler V, Wieland E, Iven H, Schuff-Werner P, **Oellerich M**, Müller M. Free radical scavenging enzyme activities (FRSEA) in granulocytes from renal transplant recipients (RTR) under cyclosporine therapy. JASN 1996; 7: 1922.
69. Schütz E, Wieland E, Hensel A, Heine L, Günther E, **Oellerich M**. Expression von HSP70, c-fos, TNF-alpha und iNOS mRNA in einem Schweineleberperfusionsmodell: Einfluß der kalten Ischämie in HTK-Organprotektionslösung. Z Gastroenterol 1996; 33:74.
70. **Oellerich M**, Armstrong VW. Assessment of liver function by the use of MEGX- and ICG-tests. Clinical Intensive Care 1996; Suppl, 7:29-30.
71. Wieland E, Schütz E, Armstrong VW, **Oellerich M**. QSA-10 (idebenone) protects the sinusoidal endothelium from oxygen radical mediated damage in a pig liver ischemia / reperfusion model. Hepatology 1996; 24:430A.
72. Schütz E, Wieland E, Armstrong VW, **Oellerich M**. Early ischemia/reperfusion damage after cold storage in a pig liver model is not related to TNF-α and iNOS mRNA expression. Hepatology 1996; 24:432A.
73. Delinikolas A, Binder L, Luthe H, Heller C, **Oellerich M**. Evaluation of the Stratus cardiac troponin I immunoassay. Laboratoriumsmedizin 1996; 20: 676.
74. **Oellerich M**. Stellenwert des MEGX-Tests in der Leberfunktionsdiagnostik. DG Klinische Chemie Mitteilungen 1996; 27:68-69.
75. Schütz E, Wieland E, Heine L, Günther E, **Oellerich M**. Die hepatozytäre Energiedefizienz in der frühen Reperfusionsphase nach kalter Leberischämie ist an der Auslösung der Hitzeschock Protein 70 Expression beteiligt. Z Gastroenterol 1997; 1: 79.
76. Wieland E, Schütz E, Andreeva M, Zwerger B, **Oellerich M**. Effekt der Reperfusion auf die Cytochrom P-450 3A Aktivität und mRNA Expression in der Schweineleber nach kalter Ischämie in HTK-Organprotektionslösung. Z Gastroenterol 1997; 1: 79.
77. Binder L, Schiel X, Fernandes A, Menke C, Schüttrumpf S, Armsstrong VW, Unterhalt M, Hiddemann W, **Oellerich M**. Clinical outcome and economic impact of therapeutic drug monitoring: an outcome and economic study of aminoglycoside TDM in immmunoscompromised patients with hematologic malignancies. Clinical Chemistry 1997; 6:83-84.
78. Schettler V, Wieland E, Methe H, Schuff-Werner P, **Oellerich M**, Müller GA. Oxidative stress in granulocytes during extracorporeal treatment: free radical scavenging enzymes and glutathione in hemodialysis and LDL apheresis compared. Nieren- und Hochdruckkrankheiten 1997; 26:485.
79. Burdelski M, Helmke K, Schütz E, Knoke A, **Oellerich M**. MEGX formation depends on liver blood flow rather than on liver CYP 3A4 content in pediatric patients with chronic end stage liver disease. Hepatology 1997; 26:281A.
80. Schütz E, Wieland E, Wagner A, Armstrong VW, Hecker M, **Oellerich M**. Supppression of IL-6 and TNF-α receptor mRNA expression during liver reperfusion after cold preservation with idebenone. Hepatology 1997; 26:353A.
81. Wieland E, Schütz E, Andreeva A, Zwerger B, Armstrong VW, **Oellerich M**. Oxygen radicals (OR) mediate the effect of white blood cells (WBC) on cytochrome P-450-3A4 (CYP3A4)-activity and -mRNA expression in a pig liver cold storage/perfusion model. Hepatology 1997; 26:629A.
82. Braun F, Lorf T, Schütz E, Hanack U, Bockhoff I, Canelo R, Klinge B, Schulze FP, Armstrong VW, **Oellerich M**, Ringe B. Clinical experience of mycophenolic acid (MPA) monitoring following liver (LTX) and kidney transplantation (KTX). Ther Drug Monit 1997; 19:552.
83. Armstrong VW, Schütz E, Meinecke I, Andreeva M, Niedmann PD, Weber L, Lamersdorf T, Wiesel M, Mandelbaum A, Mehls O, Zimmerhackl LB, Tönshoff B, **Oellerich M**. Noncompartmental pharmacokinetic analysis of mycophenolic acid concentrations in pediatric renal transplant recipients. Ther Drug Monit 1997; 19:554.
84. Armstrong VW, Schütz E, Groothuisen S, Scholz C, Andreeva M, Niedmann PD, **Oellerich M**. Pentamer formation assay for determination of tacrolimus and its active metabolites in whole blood. Ther Drug Monit 1997; 19:554.
85. Schütz E, Armstrong VW, Andreeva M, Niedmann PD, Weber L, Tönshoff B, **Oellerich M**. Prediction of mycophenolic acid plasma AUC by a three point model in pediatric kidney recipients. Ther Drug Monit 1997; 19:555.
86. Andreeva M, Niedmann D, Schütz E, Armstrong VW, **Oellerich M**. An HPLC procedure for simultaneous determination of mycophenolic acid and its glucuronide in human plasma. Ther Drug Monit 1997; 19:565.
87. Schütz E, Andreeva M, Niedmann PD, Armstrong VW, Weber L, Braun F, Tönshoff B, Ringe B, **Oellerich M**. Mycophenolic acid determination after solid organ transplantation: RP-HPLC and EMIT™ compared. Ther Drug Monit 1997; 19:566.
88. Engelmayer U, Engelmayer J, Binder L, Kölch M, **Oellerich M**. Evaluation of the digoxin assay for the Immulite® chemiluminescent immunoassay system. Ther Drug Monit 1997, 19:575.
89. Engelmayer J, Engelmayer U, Binder L, Ringe B, **Oellerich M**. False positive digoxin levels in sera from liver-transplanted patients. Ther Drug Monit 1997; 19:575.
90. Schütz E, Wieland E, Andag R, Armstrong VW, **Oellerich M**. Partial sequence of a pig gene with high homology to human CYP3A4. Ther Drug Monit 1997; 19:593.
91. El Desoky ES; Ahmed AM, Nafeh MA, El-Aty Ahmed HA, Schütz E, Armstrong VW, **Oellerich M**. Monoethylglycinexylidide (MEGX) formation in patients with liver cirrhosis and schistosomal hepatic fibrosis. Ther Drug Monit 1997; 19:601.
92. Burdelski M, Knoke A, Schütz E, **Oellerich M**. MEGX formation and expression of liver CYP3A4 mRNA compared in pediatric patients with chronic end stage liver disease. Ther Drug Monit 1997, 19:601.
93. Schütz E, Andreeva M, Niedmann PD, Armstrong VW, **Oellerich M**. Determination of monoethylglycinexylidide (MEGX) by FPIA in serum samples with high bilirubin: modified precipitation procedure and HPLC compared. Ther Drug Monit 1997; 19:602.
94. Tönshoff B, Weber L, Armstrong VW, Lamersdorf T, Andreeva M, Niedmann PD, Schütz E, Wiesel M, Mandelbaum A, Zimmerhackl LB, Mehls O, **Oellerich M**. Pharmacokinetic analysis of mycophenolic acid (MPA), free MPA and MPA-glucuronide (MPAG) in pediatric renal transplant recipients - a multicenter study. J Am Soc Nephrol 1997; 8:706A.
95. Wieland E, Schütz E, Andreeva M, Zwerger B, Armstrong VW, **Oellerich M**. Einfluß von Sauerstoffradikalen auf die CYP3A-Aktivität und Genexpression während der Reperfusion am Modell der isoliert perfundierten Schweineleber. Z Gastroenterol 1998; 36:79.
96. Armstrong VW, Schütz E, Zhang Q, Groothuisen S, Scholz C, Andreeva M, Aboleneen H, **Oellerich M**. Pentamer formation assay for determination of tacrolimus compared with hplc tandem mass spectrometry and microparticle enzyme immunoassay. Clin Chem 1998; 44:A100.
97. Engelmayer U, Binder L, Armstrong VW, Nguyen T, **Oellerich M**. Comparison of the Abbott Axsym® Digoxin II assay with the Stratus and the ACS:180 assays. Clin Chem 1998; 44:A104.
98. Schütz E, Svinarov D, Andreeva M, Niedmann PD, **Oellerich M**. CEDIA, EMIT and mFPIA (AxSYM) for cyclosproin A(CsA) determination compared to HPLC. Clin Chem 1998; 44:A105.
99. Luthe H, Binder L, Meyer T, Greber T, Buchwald A, Kreuzer H, **Oellerich M**. Emergency room triage of patients with acute chest pain by determination of cardiac troponin I. Clin Chem 1998; 44:A132.
100. Braun F, Lorf T, **Oellerich M**, Ramadori G, Ringe B. Liver transplantation without steroids. Hepatology 1998; 28: 263A.
101. Shipkova M, Wieland E, Schütz E, Armstrong VW, Niedmann PD, Braun F, Svinarov DA, **Oellerich M**. New metabolites of mycophenolic acid identified in human plasma specimens are formed by human liver microsomes. Hepatology 1998; 28:383A.
102. Wieland E, Shipkova M, Niedmann PD, Braun F, Schütz E, Armstrong VW, **Oellerich M**, Svinarov DA. Species related difference in cyclosporin a (CSA) metabolism: pig and human liver microsomes compared. Hepatology 1998; 28:606A.
103. Schütz E, Shipkova M, Armstrong VW, Wieland E, **Oellerich M**. Identification of an active metabolite of mycophenolic acid in plasma of liver transplantation recipients. Hepatology 1998; 28:739A.
104. Weber LT, Schütz E, Lamersdorf T, Andreeva M, Niedmann PD, **Oellerich M**, Zimmerhackl LB, Mehls O, Armstrong VW, Tönshoff N and the German Study Group on Mycophenolat Mofetil (MMF) Therapy. Therapeutic drug monitoring of mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in pediatric renal transplant recipients. Pediatr Nephrol 1998; 12:C204.
105. Weber LT, Lamersdorf T, Andreeva M, Niedmann PD, **Oellerich M**, Zimmerhackl LB, Mehls O, Armstrong VW, Tönshoff B and the German Study Group on Mycophenolat Mofetil (MMF) Therapy. Pharmacokinetics (PK) of mycophenolic acid (MPA) and free MPA in pediatric renal transplant recipients - a multicentre study. Pediatr Nephrol 1998; 12:C205.
106. Binder C, Schulz M, Hagemann T, Hiddemann W, **Oellerich M**. Induction of inducible NO-synthase in relation to caspase-activation during TNFα-induced apoptosis. Ann Hematol 1998; 77(Suppl II):S36.
107. **Oellerich M**. Lidocaine metabolism as an index of liver function. BJCL 1998; 2:32.
108. Burdelski M, Schütz E, Badur N, Knoke A, **Oellerich M**. Correlation of monoethylglycineexylidide (MEGX) in vivo test results with hepatic CPY3A4 content in pediatric transplant candidates. BJCL 1998; 2:36.
109. Schütz E, **Oellerich M**. Pharmacogenetics:thiopurine methyltransferase (TPMT) in the immunosuppressive treatment with azathiopurine. BJCL 1998; 2:101.
110. Shipkova M, Wieland E, Schütz E, Braun F, **Oellerich M**, Svinarov DA. Cyclosporin A (CsA) metabolism in human and pig liver microsomes compared. BJCL 1998; 2:104.
111. Koleva V, Niedmann PD, **Oellerich M**. A modified high-performance liquid chromatographic method for determination of methotrexate in human plasma. BJCL 1998; 2:107.
112. Wieland E, Vogl I, Pollok R, Schuff-Werner P, **Oellerich M**. Lipidperoxidation im Plasma und mRNA Expression antioxidativer Enzyme in Leukozyten während der Behandlung mit der Herz-Lungen-Maschine (HLM). J Lab Med 1998; 11:655.
113. Schütz E, Stürzenhofecker B, **Oellerich M**. A non-isotopic electrophoretic mobility shift assay (EMSA) for NFxB and CREB using the LI-COR DNA sequencer. J Lab Med 1998; 11: 674-675.
114. Schütz E, Shipkova M, Niedmann PD, Armstrong VW, Wieland E, **Oellerich M**. Bedeutung neu entdeckter Metabolite für das Drug Monitoring von Mycophenolsäure. J Lab Med 1998; 11:683.
115. Schütz E, Wieland E, Stürzenhofecker B, **Oellerich M**. Identifikation eines porcinen hepatischen CYP3A mit hoher Homologie zum humanen CYP3A4: Abhängigkeit der Expression vom Transkriptionsfaktor NFKB. Z Gastroenterol 1999; 37:59-111.
116. Wieland E, Schütz E, Bonitz M, v. Ahsen N, **Oellerich M**. Effekt der Reperfusion nach kalter Ischämie auf die Aktivität und Genexpression der Superoxiddismutase im Model der isolierten Schweineleber. Z Gastroenterol 1999; 37:59-111.
117. Schütz E, Armstrong VW, Weber L, Shipkova M, Tönshoff B, **Oellerich M**. Abbreviated AUC for monitoring of mycophenolic acid in pediatric kidney recipients. Clin Chem Lab Med 1999; 37: S317.
118. Binder L, Schiel X, Binder C, Schüttrumpf S, Armstrong VW, Hiddemann W, **Oellerich M**. Substantial cost savings by individualized aminoglycoside therapy in febrile neutropenic patients with underlying malignant hematologic disorders. Clin Chem Lab Med 1999; 37: S304.
119. Armstrong VW, Shipkova M, Schütz E, Weber L, Niedmann PD, Zimmerhackl LB, Mehls O, Tönshoff B, **Oellerich M**, et al. Area under the plasma concentration-time curve for total but not for free mycophenolic acid increases in the stable phase post renal transplantation. Clin Chem Lab Med 1999; 37: S 42.
120. Binder L, Luthe H, Schettler V, Hanack U, Lorf T, Dittig J, Warnecke G, Müller GA, **Oellerich M**. Cardiac Troponin T – a powerful marker to predict early cardiac death in patients with end-stage renal disease? Clin Chem Lab Med 1999; 37: S 88.
121. von Ahsen N, Schütz E, Armstrong VW, **Oellerich M**. Genetic thrombophilia screening: rapid detection of the prothrombin (G20210A) mutation by real time fluorescence PCR with the LightCycler. Clin Chem 1999; 45: A43.
122. Luthe H, Binder L, Martetschläger I, **Oellerich M**. WBC Differentials, flagging performance and reticulocyte quantification on the Abbott Cell-DYN 4000 in comparison to the coulter STKS and the reticulocyte analyzer sysmex R-1000. Clin Chem 1999; 45: A62.
123. Wieland E, Shipkova M, Schütz E, Wiese C, Bonitz U, Niedmann PD, Armstrong VW, **Oellerich M**. The acyl glucuronide metabolite of the immunosuppressant mycophenolic acid induces release of proinflammatory cytokines and TNF-alpha mRNA expression. Clin Chem 1999; 45: A127.
124. Shipkova M, Niedmann PD, Schneider T, Schütz E, Armstrong VW, Wieland E, **Oellerich M**. Determination of the newly detected pharmacologically active acyl glucuronide metabolite of mycophenolic acid by HPLC. Clin Chem 1999; 45: A128.
125. Armstrong VW, Shipkova M, Schütz E, Weber L, Zimmerhackl LB, Tönshoff B, **Oellerich M**. Pharmacokinetic – pharmacodynamic relationships of free and total mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 1999; 21: 434.
126. Wieland E, Shipkova M, Schellhaas U, Schütz E, Niedmann PD, Armstrong VW, **Oellerich M**. Effect of mycophenolic acid and its metabolites on TNF-α, IL-1β and IL-6 liberation from human mononuclear leukocytes. Ther Drug Monit 1999; 21: 435.
127. Ringe B, Braun F, Schütz E, Ramadori G, **Oellerich M**. Therapeutic window of tacrolimus in liver transplantation. Ther Drug Monit 1999; 21: 438.
128. Braun F, Schütz E, Peters B, Lorf T, Armstrong VW, **Oellerich M**, Ringe B. Pharmacokinetics of tacrolimus during the early phase after liver transplantation. Ther Drug Monit 1999; 21: 438.
129. Shipkova M, Wieland E, Braun F, Gröne HJ, Schütz E, Armstrong VW, Ringe B, **Oellerich M**. Extrahepatic glucuronidation of mycophenolic acid in human gut and kidney. Ther Drug Monit 1999; 21:441.
130. Braun F, Shipkova M, Christians U, Laabs S, Elias K, Bothur P, Schütz E, Armstrong VW, **Oellerich M**, Ringe B. Influence of tacrolimus on mycophenolate mofetil metabolism in an ex vivo isolated small bowel perfusion model. Ther Drug Monit 1999; 21: 445.
131. Ringe B, Braun F, Lorf T, Canelo R, Schütz E, **Oellerich M**. Clinical experience with tacrolimus in kidney and liver transplant recipients. Ther Drug Monit 1999; 21: 446.
132. Wieland E, Shipkova M, Schütz E, Niedmann PD, Svinarov DA, **Oellerich M**. Effect of ischemia/reperfusion on mycophenolic acid metabolism in a pig liver model. Ther Drug Monit 1999; 21: 448.
133. Armstrong VW, Roth S, Brady AT, Jeong HJ, Schütz E, Kasper KC, **Oellerich M**. Evaluation of an Emit ® tacrolimus antibody: comparison with pentamer formation assay and tacrolimus II MEIA. Ther Drug Monit 1999; 21: 448.
134. Binder L, Schiel X, Binder C, Behre G, Menke C, Armstrong VW, Hiddemann W, **Oellerich M**. Clinical and economic benefit by optimized aminoglycoside therapy in neutropenic patients with fever of unknown origin. Ther Drug Monit 1999; 21: 454.
135. Engelmayer J, Engelmayer U, Armstrong VW, **Oellerich M**. Comparison of the Roche elecsys® digoxin assay with the chiron ACS: 180 plus. Ther Drug Monit 1999; 21: 458.
136. Schütz E, Pickenpack A, Lang B, **Oellerich M**. Pharmacokinetics of 6-thioguanine nucleotides under i.v. therapy with azathioprine. Ther Drug Monit 1999; 21: 476.
137. Schütz E, Shipkova M, Armstrong VW, **Oellerich M**. Time-stratified correlation analysis of Emit and HPLC for TDM of MPA. Ther Drug Monit 1999; 21: 479.
138. Schütz E, Armstrong VW, Weber L, Shipkova M, Tönshoff B, **Oellerich M**. MPA-AUC models in relation to outcome in pediatric KTx. Ther Drug Monit 1999; 21: 479.
139. Schütz E, von Ahsen N, **Oellerich M**, Wieland E. Early reperfusion injury of cold preserved pig liver is associated with an inflammatory response and apoptosis and can be ameliorated by A2 receptor stimulation. Hepatology 1999; 4: 224A.
140. Weber LT, Schütz E, Lamersdorf T, Shipkova M, Niedmann PD, **Oellerich M**. Pharmacokinetics of mycophenolic acid (MPA) and free MPA in paediatric renal transplant recipients – a multicentre study. Nephrol Dial Transplant 1999; 14: 33-34.
141. Weber LT, Schütz E, Lamersdorf T, Shipkova M, Niedmann PD, **Oellerich M**. Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. Nephrol Dial Transplant 1999; 14: 34-35.
142. Streit F, Schütz E, Armstrong VW, **Oellerich M**. Quantification of tacrolimus and five metabolites by API tandem mass spectrometry. Clin Chem 2000; 6: A195.
143. Schütz E, Diaz VC, Ilett KF, LeGatt DF, Prohanka E, Wagner O, Wong PY, **Oellerich M**. Multicenter evaluation of the new CEDIA CsA PLUS assay for whole blood cyclosporine. Clin Chem 2000; 6: A195.
144. von Ahsen N, **Oellerich M**, Hartung S, Schütz E. Thermodynamically optimizing PCR setup: a method for homogenous color compensated genotyping of the factor V (G1691A) and methylenetetrahydrofolate reductase (C677T) mutations by real time multiplex fluorescence PCR with the LightCycler. Clin Chem 2000; 6: A202.
145. Schütz E, von Ahsen N, **Oellerich M**. Total genotyping of thiopurine methyltransferase with the LightCycler: examples for anchor sharing, three colour multiplexing and thermodynamic model based probe design. Clin Chem 2000; 6: A202-203.
146. von Ahsen N, Schütz E, **Oellerich M**. Thermodynamische Optimierung der Detektion von Punktmutationen mittels Hybridisierungssonden. DG Klinische Chemie Mitteilungen 2000; 31: 56-57.
147. Armstrong VW, **Oellerich M**. Immunosuppressive drug monitoring. J Lab med 2000; 24:445.
148. Armstrong VW, **Oellerich M**. Therapeutic drug monitoring for the intensive care unit. Journal für Anästhesie und Intensivbehandlung 2001; I.Quartal 7-8.
149. Schütz E, Braun B, Ringe B, **Oellerich M**, Wieland E. Expression der Stressgene c-fos und Egr-1 in einem Ischämie-Reperfusions-Modell der Schweineleber und Effekt der Stimulierung von Adenosin-A2-Rezeptoren mit CGS 21680. Z Gastroenterol 2000; 39:108.
150. Johnston A, Lee TD, Chusney GD, Cowper AL, Schütz E, **Oellerich M**, Holt DW. New approaches to Neoral ® monitoring: methodological implications. Ther Drug Monit 2001; 23: 465.
151. Luthe H, Engelmayer J, Engelmayer U, Streit F, Rickers A, Ulbricht B, **Oellerich M**. Comparison between LC/MS/MS and three immunoassays for cyclosporine. Ther Drug Monit 2001; 23: 467.
152. Schütz E, Streit F, Dias VC, Lewer M, Illett KF, LeGatt DF, Pohanka E, Wagner O, Wong PY, **Oellerich M**. CsA immunoassays in comparison to LC-MS/MS, is there a difference between trough (C0) and C2 levels? Ther Drug Monit 2001; 23: 471.
153. Streit F, **Oellerich M**, Schütz E. A LC-MS/MS method for the rapid quantification of CsA and metabolites. Ther Drug Monit 2001; 23: 471.
154. Shipkova M, Armstrong VW, Haley J, Tönshoff B, Weber L, Niedmann PD, Wiese C, **Oellerich M**, Wieland E. The mycophenolic acid acyl glucuronide forms covalent adducts with albumin in plasma of kidney transplant recipients. Ther Drug Monit 2001; 23: 472.
155. Shipkova M, Armstrong VW, Kuypers D, Perner F, Fabrizi V, Holzer H, Wieland E, **Oellerich M**. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriotating renal function. Ther Drug Monit 2001; 23: 472.
156. Shipkova M, Rapondijeva A, Armstrong VW, Lazarov V, Delijska B, Wieland E, Nedialkov A, Nikolov D, Tishkov I, **Oellerich M**. Pharmacokinetics of mycophenolic acid (MPA) and its phenolic glucuronide (MPAG) in patients with immune nephropathies. Ther Drug Monit 2001; 23: 472.
157. Streit F, Armstrong VW, **Oellerich M**. A simple rapid lc-ms/ms method for simultaneous quantification of sirolimus, tacrolimus, everolimus and CsA. Ther Drug Monit 2001; 23: 473.
158. Schettler V, Cordes C, Müller GA, **Oellerich M**, Wieland E. Effect of cylcosporin A and tacrolimus on free radical enzyme gene expression in leukocytes of kidney transplant recipients. Ther Drug Monit 2001; 23: 475.
159. Wieland E, Shipkova M, Armstrong VW, **Oellerich M**. Effect of mycophenolic acid and its glucuronide metabolites on MCP-I and ICAM-1 gene expression in human mononuclear leukocytes. Ther Drug Monit 2001; 23: 475.
160. Engelmayer J, Luthe H, Engelmayer U, Kyriatsoulis A, Schenk J, **Oellerich M**. Comparison of the Roche Elecsys® Digitoxin assay with two commercial immunoassays. Ther Drug Monit 2001; 23: 481.
161. Igonin AA, Armstrong VW, Shipkova M, Kukes VG, **Oellerich M**. The monoethylglycinexylidide (MEGX) test as a marker of hepatic dysfunction in septic patients with pneumonia. Ther Drug Monit 2001; 23: 497.
162. von Ahsen N, Ehrlich B, Riggert J, **Oellerich M**. Positive cryoglobulin interference with automated optical or impedance platelet counts but not with the CD-61 immunoplatelet count. Clin Chem and Lab Med 2001; 39:A80.
163. **Oellerich M**. Therapeutic drug monitoring of cyclosporin and tacrolimus in transplant patients/progress and pitfalls. Diagnostyka Laboratoryjna 2001; 37: 218-219.
164. Atanasova S, von Ahsen N, Dimitrov T, **Oellerich M**, Toncheva D. NAT polymorphisms in Bulgerian patients with Balkan Endemic Nephropathy (BEN). European Journal of Human Genetics 2002; 10: 179
165. Binder L, Hoppe S, Grüning H, Beckmann A, Puls M, Niedmann PD, Binder C, **Oellerich M**, Schwörer H. Variability of meropenem plasma levels in febrile intensive care patients. Clin Chem 2002; 48: A67.
166. Hon K, Bertholf R, Cobbaert M, Engelmayer J, Johannsen L, LeGatt DF, Luthe H, **Oellerich M**, Domke I. Multicenter evaluation of acetaminophen on Roche/ Hitachi analyzers. Clin Chem 2002; 48: A141.
167. Indjova-Hristova D, Shipkova M, Niedmann PD, Svinarov DA, **Oellerich M**. A simple high-performance liquid chromatographic method for determination of thiopurine methyltransferase (TPMT) activity in erythrocytes. J Lab Med 2002; 26: 521.
168. von Ahsen N, Schütz E, Hartung S, Andag R, **Oellerich M**. Thiopurine methyl transferase (TPMT) \*3A, \*3B and \*3C haplotyping by combined long range PCR, intramolecular ligation and real time ASA-PCR. J Lab Med 2002; 26: 522.
169. von Ahsen N, Grupp C, **Oellerich M**, Armstrong VW. The C3435T and G2677 polymorphisms of the MDR1 gene as well as the G69 866A polymorphism of the CYP3A5 gene do not influence cyclosporine C2 concentrations in renal transplant recipients. J Lab Med 2002; 26: 522.
170. Hoppe S, Schwörer H, Beckmann A, Grüning H, Niedmann PD, Binder C, Schiel X, **Oellerich M**. Binder L. Pharmakokinetik von Meropenem bei neutropenischen Patienten mit Fieber. J Lab Med 2002; 26: 519-520.
171. **Oellerich M**, Armstrong VW, Shipkova M, von Ahsen N. Thiopurine methyltransferase: do we need to genotype, phenotype or both to optimise azathioprine therapy? Clin Chem Lab Med 2002, 40: S 77.
172. Luthe H, Bertholf R, Cobbaert CM, Domke I, Engelmayer J, Hon K, Legatt DF, **Oellerich M**. Multicenter evaluation of an enzymatic acetaminophen assay on Roche/Hitachi analyzers. Clin Chem Lab Med 2002; 40: S 187.
173. von Ahsen N, **Oellerich M**. In vitro evidence against a functional role of the intronic prothrombin G19911A polymorphism. Clin Chem Lab Med 2002; 40: S 196.
174. **Oellerich M**, von Ahsen N, Shipkova M, Armstrong VW. Genotypic and phenotypic evaluations in connection with azathioprine toxicity. The Toxicologist 2003; 72 Suppl.1: 3.
175. Streit F, Armstrong VW, Dresing K, Leip CL, Burchardi H, **Oellerich M**. Real-time assessment of hepatic function is related to clinical outcome in critically ill patients after polytrauma. Clin Chem 2003; 49, Suppl: A52.
176. Binder LE, Beckmann A, Pouwels C, Hoppe S, Gruening H, Niedmann D, Binder C, Nacke A, **Oellerich M**, Schwoerer H. Variable biliary ceftriaxone levels under antibiotic prophylaxis prior to ERC. Clin Chem 2003; 49, Suppl: A58.
177. Lilje DJ, Flexer J, Bertholf RL, Coffing M, Domke I, Engelmayer J, Johannsen L, Luthe H, Minon J, **Oellerich M**, Wuertemberger M. Multicenter evaluation of Roche Gentamicin OnLine TDM on Hitachi systems. Clin Chem 2003; 49, Suppl: A121.
178. Binder LE, Pouwels C, Puls M, Beckmann A, Hoppe S, Niedmann D, Binder C, Nacke A, **Oellerich M**, Schwoerer H. Determination of free and total ceftriaxone concentrations in plasma and bile. Clin Chem 2003; 49, Suppl: A123 – A124.
179. Bertholf RL, Johannsen L, Coffing M, Domke I, Engelmayer J, Flexer J, Lilje D, Luthe H, Minon J, **Oellerich M**. Theophylline measured by kinetic interaction of microparticles in solution (KIMS) homogenous immunoassay: Results of a multi-site evaluation. Clin Chem 2003; 49, Suppl: A124 – A125.
180. **Oellerich M**, Armstrong VW. Analytical and clinical aspects of monitoring sirolimus, everolimus and C2 cyclosporin concentrations. Clin Chem Lab Med 2003; 41, Special Suppl: S46.
181. Armstrong VW, **Oellerich M**. Pharmacogenetics: impact on immunosuppressive drug dosing. Clin Chem Lab Med 2003; 41, Special Suppl: S46.
182. Luthe H, Bertholf RL, Coffing MJ, Domke I, Engelmayer J, Flexer J, Johannsen L, Lilje D, Minon J, **Oellerich M**. Multicenter evaluation of new online TDM assays for determination of gentamicin and theophylline on Roche/Hitachi systems. Clin Chem Lab Med 2003; 41, Special Suppl: S541.
183. Röddiger R, Luthe H, Rhode K, **Oellerich M**, Bertholf R, Verstraete A, De Bel A, Jones J, Coffing MJ, Sauter H. Multicenter evaluation of the new Roche phenytoin online® TDM assay developed for use on RD/Hitachi analyzer systems. Clin Chem Lab Med 2003; 41, Special Suppl: S544.
184. Shipkova M, Beck H, Voland A, Armstrong VW, Gröne HJ, **Oellerich M**, Wieland E. Identification of protein targets for mycophenolic acid acyl glucuronide (AcMPAG) in rat liver and colon tissue using 2D page and MALDI-TOF-MS. Clin Chem Lab Med 2003; 41, Special Suppl: S545.
185. Shipkova M, Spielbauer B, Voland A, Gröne HJ, Armstrong VW, **Oellerich M**, Wieland E. cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. Clin Chem Lab Med 2003; 41, Special Suppl: S546.
186. Binder L, Puls M, Niedmann PD, Pouwels C, Nacke A, **Oellerich M**, Binder C. A simple and rapid HPLC method for the determination of meropenem – preanalytical and analytical aspects. Ther Drug Monit 2003; 25: 496.
187. Engelmayer J, Bertholf RL, Coffing MJ, Domke I, Flexer J, Johannsen L, Lilje D, Luthe H, Minon JM, **Oellerich M**. Online TDM gentamicin and theophylline assays – results of the multicenter evaluation. Ther Drug Monit 2003; 25: 497.
188. Luthe H, Rhode K, **Oellerich M**, Bertholf R, Verstraete A, DE Bel A, Jones J, Coffing MJ, Sauter H, Roeddiger R. Multicenter evaluation of the new Roche phenytoin online® TDM assay on RD/Hitachi systems. Ther Drug Monit 2003; 25: 499.
189. Shipkova M, Maes B, Armstrong VW, Wieland E, **Oellerich M**. Pre-dose plasma concentrations of the reactive acyl glucuronide of mycophenolic acid (AcMPAG) in kidney transplant recipients under therapy with mycophenolate mofetil (MMF), tacrolimus and steroids. Ther Drug Monit 2003; 25: 505.
190. Streit F, Shipkova M, Armstrong VW, **Oellerich M**. Quantification of plasma total MPA and free MPA using liquid chromatography tandem mass spectrometry. Ther Drug Monit 2003; 25: 506.
191. Streit F, Armstrong VW, **Oellerich M**. Mass interferences in quantification of cyclosporine using tandem mass spectrometry without chromatography. Ther Drug Monit 2003; 25: 506.
192. Engelmayer U, Pouwels C, Engelmayer J, Streit F, **Oellerich M**. Comparison of the Dade Behring Dimension® XPAND ACMIA cyclosporine assay with Emit and LC/MS-MS. Ther Drug Monit 2003; 25: 510.
193. Indjova D, Atanasova S. Shipkova M, Armstrong VW, **Oellerich M**, Svinarov D. Phenotypic and genotypic analysis of thiopurine s-methyltransferase polymorphism in the Bulgarian population. Ther Drug Monit 2003; 25: 524.
194. Shipkova M, Voland A, Gröne HJ, Armstrong VW, **Oellerich M**, Wieland E. Relationship between plasma concentrations of mycophenolic acid (MPA) and its acyl glucuronide (AcMPAG) and intestinal damage in Wistar rats treated with mycophenolate mofetil (MMF). Ther Drug Monit 2003; 25: 537.
195. Tönshoff B, Weber LT, Armstrong VW, Zimmerhackl LB, **Oellerich M**. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. Am J Transplant 2004; 4, Suppl 8: 208.
196. Roeddiger R, Luthe H, Rhode KH, **Oellerich M**, Bertholf RL, Johannsen L, Verstraete A, De Vleeschauwer A, De Bel A, Kroll M, Coffing MJ, Sauter H. Multicenter evaluation of the new Roche Carbamazepine OnLine® TDM assay developed for use on Roche Diagnostics/Hitachi analyzer systems. Clin Chem 2004; 50, Suppl 6: A128.
197. Bertholf R, Johannsen L, Verstraete A, De Bel A, Jones J, Sargent D, Luthe H, **Oellerich M**, Rhode KH, Roeddiger R, Sauter H, Coffing MJ. Phenytoin measured by kinetic interaction of microparticles in solution (KIMS) homogeneous immunoassay: multisite evaluation of the Roche OnLine® TDM method. Clin Chem 2004; 50, Suppl 6: A133.
198. Pouwels C, Streit F, von Ahsen N, Fiedler M, Armstrong VW, **Oellerich M**. Positive interference due to a plasma component causes overestimation of whole blood cyclosporine concentrations measured with the Dimension ACMIA cyclosporine assay. Clin Chem 2004; 50, Suppl 6: A134.
199. Luthe H, Averdunk R, Busse Grawitz A, Claudius C, Domke I, Engelmayer J, Nauck M, **Oellerich M**. Roche ONLINE TDM Digitoxin – results of the multicenter evaluation. Clin Chem 2004; 50, Suppl 6: A135.
200. Binder LE, Schüttrumpf S, Binder C, Hagemann T, Trümper L, Armstrong VW, **Oellerich M**. Discrimination of elevated CRP concentrations by PCT in patients with suspected infection and underlying malignant disease. Clin Chem 2004; 50, Suppl 6: A157.
201. **Oellerich M**, Armstrong VW, von Ahsen N. Impact of pharmacogenetics on therapeutic drug monitoring. The Clinical Biochemist Reviews, Supplement 2004; S 19.
202. El Desoky E, AbdelSalam YM, Salama RH, ElAkkad MA, Atanasova S, von Ahsen N, Armstrong VW, **Oellerich M**. NAT2 genotypes and their relation to schistosomiasis associated bladder cancer in Egyptians. Ther Drug Monit 2005; 27: 217.
203. Engelmayer J, Engelmayer U, Streit F, Boyd J, Arabshahi L, Armstrong VW, **Oellerich M**. Comparison of the Seradyn Innofluor® Certican® assay on TDXFLX® system with LC/MS-MS. Ther Drug Monit 2005; 27:217.
204. Heller T, Kirchheiner J, Armstrong VW, Luthe H, Brockmöller J, **Oellerich M**. Assessment of Amplichip CYP450 based CYP2D6-genotyping and phenotype prediction compared to PCR-RFLP-genotyping and phenotyping by metoprolol pharmacokinetics. Ther Drug Monit 2005; 27: 221.
205. Luthe H, **Oellerich M**, Coffing M, Domke I. Multicenter evaluations of the Roche online® tdm assays for use on Roche/hitachi analyzer systems. Ther Drug Monit 2005; 27: 233.
206. Armstrong VW, Reinshagen M, von Ahsen N, Behrens Ch, Shipkova M, von Tirpitz Ch, Malchow H, Stallmach A, Herfath H, Stein J, Bias P, Adler G, Kruis W, **Oellerich M**. A prospective evaluation of the association between adverse drug reactions to azathioprine therapy and polymorphisms in the gene encoding inosine triphosphate pyrophosphatase. Ther Drug Monit 2005; 27: 245.
207. Wang L, Binder L, **Oellerich M**, Jiang DC. Prediction accuracy of aminoglycosides between USC\*-PACK and PKS. Ther Drug Monit 2005; 27: 259.
208. **Oellerich M**. The role of therapeutic drug monitoring in immunosuppressant therapy. Clin Chim Acta 2005; 355: S43.
209. Domke I, Engelmayer J, Langmann T, Liebisch G, Streit F, Luthe H, Dorn A, Schmitz G, **Oellerich M**. Measurement of total and free mycophenolic acid with new enzyme receptor methods on COBAS INTEGRA systems. Clin Chem 2005; 51, Suppl 6: A148.
210. Binder L, Niedmann P, Streit F, Binder C, Blaschke S, Onufrejow M, **Oellerich M**. A simple and rapid HPLC method for the determination of moxifloxacin. Clin Chem 2005; 51, Suppl 6: A155.
211. Luthe H, Rhode KH, **Oellerich M**. Performance of assays for therapeutic drug monitoring and urine drugs-of-abuse screening processed in combination with clinical chemistry workload on Roche modular analytics. Clin Chem 2005; 51, Suppl 6: A217.
212. Asif AR, Armstrong VW, Wieland E, **Oellerich M**, Shipkova M. Cytosolic proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney from mycophenolate mofetil treated rats. Clin Chem Lab Med 2005; 43: A41.
213. Domke I, Engelmayer J, Langmann T, Liebisch G, Luthe H, Schmitz G, Streit F, **Oellerich M**. Measurement of total and free mycophenolic acid with new enzyme receptor methods on COBAS INTEGRA systems. Clin Chem Lab Med 2005; 43: A47.
214. Futh J, Steiner M, **Oellerich M**, Schuff-Werner P, von Ahsen N. The adult-type hypolactasia variant: epidemiological data from two populations and a comparison of two genotyping approaches. Clin Chem Lab Med 2005; 43: A51.
215. Heller T, Doncheva Y, Asif AR, Wieland E, **Oellerich M**, Shipkova M, Armstrong VW. Mycophenolic acid and its acylglucuronide metabolite modulate expression of the Rho GDP dissociation inhibitor 2 in a T-lymphoblast cell line. Clin Chem Lab Med 2005; 43: A56.
216. von Ahsen N, Andag R, **Oellerich M**. RNA pol II processivity rather than differential binding as patho-mechanism of 3’ UTR non-coding mutations in the prothrombin gene: a study using RNA-polymerase II chromatin immunoprecipitation. Clin Chem Lab Med 2005; 43: A93.
217. **Oellerich M**, Streit F, Armstrong VW. Use of LC-MS/MS in immunosuppressive drug monitoring. Clin Biochem 2005; 38: 775.
218. Heller T, Kirchheiner J, Armstrong VW, Luthe H, Tvetkov, Brockmöller J, **Oellerich M**. AmpliChip CYP450 GeneChip®: a new gene chip allows more detailed CYP2D6 genotyping than conventional PCR-RFLP. Clin Chem 2006; 52: A53.
219. Heller T, Otto M, Trenkwalder C, Armstrong VW, **Oellerich M,** Mollenhauer B. Detection of CYP2D6 mutant alleles by AmpliChip CYP450 Gene-Chip® in dementia patients with Lewy Bodies or Parkinson’s disease. Clin Chem 2006; 52: A54.
220. Domke I, Vukovich T, Engelmayer J, Kheradmand M, Luthe H, Shipkova M, Streit F, **Oellerich M**, Wieland E. Comparability between automated immunoassays and LC-MS/MS for tacrolimus determination using routine patient samples. Clin Chem 2006; 52: A61.
221. Domke I, Shipkova M, Engelmayer J, Kheradmand M, Luthe H, Pou L, Streit F, Vukovich T, **Oellerich M**, Wieland E. Cyclosporin determination with different immunoassays in four laboratories using routine patient samples from different transplant types: performance of automated immunoassays and comparability to tandem mass spectrometry. Clin Chem 2006; 52: A61.
222. von Ahsen N, Hartung S, **Oellerich M**. Pharmacogenetic factors of thiopurine intolerance: intron 2 polymorphisms associated with reduced inosine triphosphatase (ITPA) activity. Clin Chem Lab Med 2006; 44: A152.
223. von Ahsen N, Andag R, **Oellerich M**. Pharmacogenetic factors of thiopurine intolerance: inosine triphosphatase (ITPA) has a constitutive promoter driven by SP1 and SP3 transcription factors. Clin Chem Lab Med 2006; 44: A153.
224. Brandhorst G, Harloff M, **Oellerich M**, von Ahsen N. Pseudo-neutropenia: case report of a rare interference due to neutrophil agglutination and improvement by in vitro kanamycin. Clin Chem Lab Med 2006; 44: A169.
225. Streit F, Dogan A, Binder L, **Oellerich M**. Simultaneous quantification of 7 anti-retroviral drugs in serum by liquid chromatography tandem mass spectrometry. Clin Chem Lab Med 2006; 44: A186.
226. Armstrong VW, Heller T, Brandhorst G, Streit F, van Gelder T, **Oellerich M**. Relationship between free mycophenolic acid and hematologic side effects: interim results from the FDCC study. Am J Transplant and Transplantation 2006; Suppl.: 344: A821.
227. Heller T, Armstrong VW, Brandhorst G, Engelmayer J, van Gelder T, **Oellerich M**. Plasma concentrations of mycophenolic acid acyl glucuronide related to diarrhoea. Interim results from the FDCC study. Am J Transplant and Transplantation 2006; Suppl.: 344-345: A823.
228. van Agteren M, van Schaik R, de Fijter H, Hartmann A, Schmidt J, Budde K, Kuypers D, Arns W, Le Meur Y, **Oellerich M**, Holt D, Tönshoff B, van der Werf M, Gafner N, Mamelok R, van Gelder T. Polymorphisms in the uridine diphoshate (UDP)-glucuronosyltransferases (UGT) gene explain part of the inter-individual variability in mycophenolate mofetil (MMF) pharmacokinetics. Am J Transplant and Transplantation 2006; Suppl.: 478: A 1215.
229. van Agteren M, van Schaik R, de Fijter H, Hartmann A, Schmitdt J, Budde K, Kuypers D, Pisarksi P, Le Meur Y, **Oellerich M**, Holt D, Toenshoff B, Mamelok R, de Ducla B, van Gelder T. The impact of MRP2 gene polymorphism on mycophenolic acid exposure in renal transplant patients. Am J Transplant and Transplantation 2006; Suppl.: 478: A1217.
230. Naesens M, Vanrenterghem Y, **Oellerich M**, Kuypers D. Mycophenolic acid glucuronidation and elimination is influenced by interaction with UGT metabolism and/or organic anion transport. Am J Transplant and Transplantation 2006; Suppl.: 1004: A2882.
231. von Ahsen N, Hartung S, **Oellerich M**. Rat and mouse prothrombin 3´ UTRs show significant gain-of-function in the human test system despite normal plasma prothrombin activities. Hämostaseologie 2007; 27: A35.
232. **Oellerich M**, Armstrong VW. Biomarkers – The link between therapeutic drug monitoring and pharmacodynamics. Clin Chem Lab Med 2007; 45: Suppl.: S54.
233. van Schaik RHN, van Agteren M, van der Werf M, de Fijter H, Hartmann A, Schmidt J, Budde K, Kuypers D, Arns W, Le Meur Y, **Oellerich M**, Holt DW, Toenshoff B, Gafner N, Mamelok R R, van Gelder T. Genetic Polymorphisms in UGT1A9, but not in MDR1, explain part of the inter-individual variability in mycophenolate mofetil (MMF) pharmacokinetics. Clin Chem Lab Med 2007; 45: Suppl.: S160.
234. Luthe H, Domke I, Jung M, Knoke C, Rhode KH, Sauter H, **Oellerich M**. External performance evaluation of the Cobas C 501 analysis system. Clin Chem Lab Med 2007; 45: Suppl.: S188.
235. Luthe H, Domke I, Knoke C, Rhode KH, Sauter H, **Oellerich M**. Performance of therapeutic drug monitoring and urine drugs-of-abuse screening assays under routine-like conditions on Cobas C 501. Clin Chem Lab Med 2007; 45: Suppl.: S188.
236. Weber LT, Hoecker B, Armstrong VW, **Oellerich M**, Toenshoff B. Long-term (3 years) pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients. Am J Transplant 2007; 7 (Suppl.2): 366.
237. Feneberg R, Weber LT, von Ahsen N, Armstrong VW, Hoecker B, **Oellerich M**, Toenshoff B and the German Study Group on Pediatric RTx. Consequenses of CYP3A4 and MDR-1 polymorphisms on pharmacokinetic parameters of cyclosporin A and mycophenolic acid in pediatric renal transplant recipients. Am J Transplant 2007; 7 (Suppl.2): 366-367.
238. Binder L, Streit F, Engelmayer J, Götze S, Luthe H, Budde K, Beckebaum S, Doll S, **Oellerich M**. Comparison of the ADVIA Centaur® Cyclosporine Assay with tandem mass spectrometry (LC-MS/MS). Clin Chem 2007; 53 (Suppl.): A88.
239. Luthe H, Figurski M, Korecka M, Marquet P, Liebisch G, Coffing MJ, Domke I, Schmitz G, **Oellerich M**, Shaw L. Multicenter evaluation of the Roche total mycophenolic acid assay on Cobas Integra® Systems. Clin Chem 2007; 53 (Suppl.): A93.
240. Luthe H, Domke I, Jung M, Knoke C, Rhode KH, Sauter H, **Oellerich M**. External evaluation of assays for clinical chemistry, serum proteins, drugs-of-abuse and therapeutic drug monitoring on cobas c 501 analyzer. Clin Chem 2007; 53 (Suppl.): A95.
241. Brandhorst G, Streit F, Goetze S, Rhode KH, Engelmayer J, Luthe H, **Oellerich M**. Quantification of mycophenolic acid by an optimized LC-MS/MS method compared to a new IMPDH inhibition assay on the cobas c 501 analyzer. Clin Chem 2007; 53 (Suppl.): A96.
242. Soldin SJ, Hardy RW, Wians FH, Barbarakis M, Connolly PB, Martel J, Canfield WJ, **Oellerich M**. The ADVIA Centaur® Cyclosporine (CsA): results of a multicenter clinical evaluation. Clin Chem 2007; 53 (Suppl.): A97.
243. Streit F, Dogan A, Binder L, **Oellerich M**. Measurement of serum testosterone using a Waters Quattro Premier XE Micromass® System with an APPI interface. Clin Chem 2007; 53 (Suppl.): A199.
244. Dogan A, Streit F, Binder L, **Oellerich M**. Simultaneous quantification of 9 anti-retroviral drugs in serum using a Waters Quattro Micro® System with an ESI interface. Ther Drug Monit 2007; 29: 467-468.
245. van Hest RM, Doorduijn JK, de Winter BCM, Cornelissen JJ, Vulto AG, **Oellerich M**, Löwenberg B, van Gelder T, Armstrong VW, Mathot RAA. Pharmacokinetics of mycophenolate mofetil in stem cell transplant recipients. Ther Drug Monit 2007; 29: 471.
246. Heller T, Geide A, Bonitz U, Wegner U, Gröne HJ, Armstrong VW, **Oellerich M**. Effect of the antioxidant idebenone on adverse events under mycophenolate mofetil therapy in a rat model. Ther Drug Monit 2007; 29: 490-491.
247. Brandhorst G, Streit F, Goetze S, Rhode KH, Engelmayer J, Luthe H, **Oellerich M**. A new IMPDH inhibition assay für the quantification of mycophenolic acid on the Roche Cobas c 501 analyzer compared to liquid chromatography tandem mass spectrometry. Ther Drug Monit 2007; 29: 512.
248. Luthe H, Domke I, Engelmayer J, Koeger R, van Gelder T, **Oellerich M**. Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. Ther Drug Monit 2007; 29: 512.
249. Streit F, Dogan A, Binder L, **Oellerich M**. Simultaneous determination of clozapine, olanzapine and quetiapine using the Waters Quattro Micro® System with a ESI interface. Ther Drug Monit 2007; 29: 518.
250. van Gelder T, Silva HT, de Fijter H, Budde K, Kuypers D, van Hest R, Mamelok R, Armstrong VW, **Oellerich M**. How delayed graft function impacts on exposure to mycophenolic acid in patients following renal transplantation. Ther Drug Monit 2007; 29: 527.
251. Luthe H. Figurski M, Korecka M, Marquet P, Liebisch G, Coffing MJ, Domke I, Schmitz G, Engelmayer J, **Oellerich M**, Shaw L. Multicenter evaluation of the Roche total mycophenolic acid assay on COBAS INTEGRA® Systems. Ther Drug Monit 2007; 29: 547.
252. Heller T, van Gelder T, **Oellerich M**, Armstrong VW. MRP-2 mediated biliary excretion but not renal function is a major determinant of exposure to mycophenolic acid acyl glucuronide. Ther Drug Monit 2007; 29: 548
253. **Oellerich M**. Immunosuppressive Drug Monitoring. Malaysian J Pathol 2007; 29 (Suppl. A): 63.
254. **Oellerich M**. Pathology education and research in Germany. Malaysian J Pathol 2007; 29 (Suppl. A): 73-74.
255. Luthe H, Knoke C, Rhode KH, **Oellerich M**. External performance evaluation of the COBAS c 501 analysis system. Malaysian J Pathol 2007; 29 (Suppl. A): 126.
256. Shipkova M, Heller T, Petrova DT, Hitt R, Wieland E, **Oellerich M**, Armstrong VW. A microarray investigation on the effect of the acyl glucuronide of mycophenolic acid (AcMPAG) on the expression of cell proliferation related genes in mononuclear leucocytes. Clin Chem Lab Med 2007; 45: A104.
257. van Gelder T, Domke I, Streit F, Koeger R, Luthe H, **Oellerich M**. Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. Clin Chem 2008; 54: A15.
258. von Ahsen N, Hartung S, **Oellerich M**. Comparison of TPMT activity measured by HPLC in washed red blood cells, whole blood, and plasma exchangesd whole blood. Clin Chem Lab Med 2008; 46: A159.
259. Zafar S, Asif AR, Armstrong VW, **Oellerich M**. One-STrEP-tagged human prion protein expression, purification, localization and identification of interacting proteins in mamalian cell line. Clin Chem Lab Med 2008; 46: A175.
260. Petrova DT, Brehmer F. Brandhorst G, Schroeder H, Armstrong VW, **Oellerich M**. Mycophenolic acid displays IMPDH-dependent and –independent effects on renal fibroblast proliferation and function. Clin Chem Lab Med 2008; 46: A195.
261. Brandhorst G. Armstrong VW, **Oellerich M**. Arithmetical correction of potassium in hemolytic samples: do or don’t? Clin Chem Lab Med 2008; 46: A204.
262. **Oellerich M**. Biomarkers – a link between therapeutic drug monitoring and pharmacodynamics. Clin Chem Lab Med 2008; 46: A204.
263. **Oellerich M**. Biomarkers – as an adjunct to immunosuppressive drug monitoring. Ann Transplant 2008; 13 (Suppl.1): 17.
264. **Oellerich M**, Armstrong VW, von Ahsen N. Impact of pharmacogenetics on therapeutic drug monitoring. Pathology 2009; 41 (Suppl.): 15-16.
265. **Oellerich M,** Armstrong VW, von Ahsen N. Impact of pharmacogenetics on therapeutic drug monitoring. J Mol Clin Pathol 2009; 40: 40.
266. Streit F, von Ahsen N, Brandhorst G, **Oellerich M.** Measurement of serum testosterone: Waters Quattro Premier XE Micromass® System versus Elecsys®Testosterone II and Elecsys®Testosterone. Clin Chem 2009; 55 (Suppl.): A186.
267. **Oellerich M**, Armstrong VW, von Ahsen N. Impact of pharmacogenetics on therapeutic drug monitoring. IJCB 2009; 24 (Suppl.):51.
268. Brandhorst G, Brehmer F, Petrova DT, Gross O, Armstrong VW, **Oellerich M**. Mycophenolic mofetil improves kidney function but not survival in a COL4A3-deficient mouse model for progressive renal fibrosis. Ther Drug Monit 2009; 31: 664.
269. **Oellerich M**, Armstrong VW, von Ahsen N. Impact of pharmacogenetics on therapeutic drug monitoring. Indian J of Clin Biochem 2009; 24 (Suppl.): 51.
270. Brandhorst G, Schulz-Jürgensen S, Burdelski M, **Oellerich M**. ATP production in CD4+ T cells as a predictor for infection and allograft rejection in pediatric liver transplant recipients. Clin Chem 2010; 56 (Suppl.): A241.
271. Qasim M, Rahman H, Armstrong VW, **Oellerich M**, Asif AR. Proteome alteration in human cell line in response to mycophenolic acid. Clin Chem Lab Med 2010; 49: A112.
272. Petrova DT, Brehmer F, Schultze FC, Asif AR, Gross O, **Oellerich M**, Brandhorst G. Differential kidney proteome profiling in a mouse model for renal fibrosis under treatment with mycophenolate mofetil: implications for epithelial-mesenchymal transition. Clin Chem Lab Med 2010; 49: A129.
273. Eberle C, Brandhorst G, **Oellerich M**, Goden S. Determination of regulatory T cell (Treg) counts by fluorescence activated cell sorting in patients with inflammatory bowel disease (IBD). Clin Chem Lab Med 2010; 49: A139.
274. von Ahsen N, Tzvetkov M, Karunajeewa H, Gomorrai S, Ura A, Brockmöller J, Davis TME, Müller L, Ilett KF, **Oellerich M**. CYP2D6 and CYP2C19 in Papua New Guinea: high frequency of previously unknown CYP2D6 alleles and heterozygote excess. Clin Chem Lab Med 2010; 49: A145.
275. Schulz-Jürgensen S, Brandhorst G, **Oellerich M**, Kohl M, Burdelski M. Further assessment of IATP (Cylex ImmuKnow®) in pediatric liver transplantation (LTX) and healthy controls. Transplant International 2010; 23 (Suppl. 2): 61.
276. Qasim M, **Oellerich M**, Rahman H, Asif A. Mycophenolic acid modulation of epithelial tight junctions – a mechachnism of gastrointestinal toxicity. Clin Chem 2011; 57 (Suppl.): A78.
277. **Oellerich M,** Brandhorst G. Use of endogenous biomarkers to achieve personalised immunosuppression in transplant recipients. Clin Chem Lab Med 2011; 49 (Special Suppl.): S144.
278. **Oellerich M**. Therapeutic drug monitoring – key to personalized pharmacotherapy. IJCB 2011; 26 (Suppl.): 2.
279. **Oellerich M**. Use of endogenous biomarkers to achieve personalised immunosuppression in transplant recipients. IJCB 2011; 26 (Suppl.): 10.
280. Shipkova M, Petrova DT, Rosler AE, Orth M, Engelmayer J, Wieland E, Brandhorst G, **Oellerich M.** Comparability and imprecision of eight frequently used commercially available immunoassays for therapeutic drug monitoring. Ther Drug Monit 2011; 33: 501 (P078).
281. Koch C, Petrova D, Eberle C, Schultze F, Brandhorst G, **Oellerich M**. The functional effect of mycophenolic acid on renal fibrosis. Clin Chem Lab Med 2012; 50: A205-A270 (P06).
282. Petrova D, Luchs K, Schultze F, Alwahsh S, Rubel D, Gross O, **Oellerich M**, Brandhorst G. Kidney function and histopathological differences induced by mycophenolate mofetil in a mouse model for progressive renal disease. Clin Chem Lab Med 2012; 50: A205-A270 (P07).
283. Beck J, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, Gaedcke J, Moerer O, Slotta J, Walson PD, Kollmar O, **Oellerich M,** Schütz E. Rapid and cost effective measurement of circulating cell free graft DNA for the early detection of liver transplant rejection. Clin Chem 2013; 59 (Suppl.): A-93.
284. **Oellerich M.** Therapeutic drug monitoring – key to personalized pharmacotherapy. Jpn J Ther Drug Monit 2013; 30 (Suppl.): 42-43.
285. Beck J, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, Gaedcke J, Moerer O, Slotta J, Walson PD, Kollmar O, **Oellerich M,** Schütz E. A simple method for quantifying graft cfDNA as an early biomarker of rejection. Clin Chem Lab Med 2013; 51: eA17-eA18.
286. Schütz E, Warnecke G, Fegbeutel C, Haverich A, **Oellerich M**. Abbreviated MPA-AUC in lung transplantation in comparison with the immune cell response. Ther Drug Monit 2013; 35: 684 (O2623).
287. **Oellerich M**. Pharmacokinetic monitoring and biomarkers as a means to improve outcome in transplantation. IJCB 2013; 28 (Supp.): 30.
288. **Oellerich M**. Future laboratory medicine – LC/MS vs immunoassays. IJCB 2013; 28 (Supp.): 43.
289. Slotta JE, Kanzow P, Beck J, **Oellerich M,** Schütz E, Kollmar O. Zirkulierende Transplantat-DNA als sensitiver Biomarker der Organintegrität nach Lebertransplantation. Z Gastroenterol 2014; 52 – KC074.
290. Slotta JE, Beck J, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, Gaedcke J, Mörer O, Walson P, **Oellerich M**, Schütz E, Kollmar O. Quantification of donor DNA in the circulation after liver transplantation as a potential universal rejection biomarker using digital droplet PCR. Liver Transpl 2014; 20 (Suppl. 1): S 107-108.
291. Slotta JE, Kanzow P, Schütz E, **Oellerich M**, Kollmar O. Graft derived cell-free DNA as an early organ integrity biomarker after liver transplantation of a HELLP syndrome donor liver. Liver Transpl 2014; 20 (Suppl. 1): S 241-242.
292. **Oellerich M.** Biomarkers to achieve personalized immunosuppression in transplantation. Clin Chem Lab Med 2014; 52 (Special Suppl.): S32.
293. **Oellerich M**. Use of endogenous biomarkers to achieve personalized immunosuppression. Malaysian J Pathol 2014; 36 (Suppl. A): 1.
294. **Oellerich M**. Biomarkers in transplantation – graft-derived circulating cfDNA and signatures of tolerance. Am J Pathol 2014; 184 (Suppl.): S30.
295. Schmitz J, Götze S, Andag R, Brockmöller J, Kollmar O, Schütz E, **Oellerich M.** Droplet digital PCR (ddPCR) for quantitative analysis of Treg-specific demethylation region (TSDR) in peripheral blood compared to Flow Cytometry (FACS). Clin Chem 2014; 60 (Suppl): S106.
296. Beck J, Schmitz J, Kanzow P, Kollmar O, **Oellerich M,** Schütz E. Absolute quantification of graft derived cell-free DNA (GcfDNA) early after liver transplantation (LTx) using droplet digital PCR. Clin Chem 2014; 60 (Suppl.): S194-S195.
297. Beck J, Schmitz J, Kollmar O, Slotta J, Kanzow P, Walson P, **Oellerich M**, Schütz E. Use of plasma GcfDNA quantification to guide personalized immunosuppression. Transpl Int 2014; 27 (Suppl. 3): 50.
298. Kanzow P, Kollmar O, **Oellerich M**, Schütz E, Schmitz J, Beck J, Slotta J, Walson P. Potential of graft-derived cell-free DNA quantification to improve outcomes with marginal donor organs – Case report of successful liver transplantation of a HELLP syndrome donor. Am J Transplant 2014; 14 (Suppl.): 713-714.
299. **Oellerich M**, Kanzow P, Beck J, Schmitz J, Kollmar O, Walson P, Schütz E. Graft-derived cell-free DNA (GcfDNA) as a sensitive measure of individual graft integrity after liver transplantation. Am J Transplant 2014; 14 (Suppl.): 874.
300. Beck J, **Oellerich M**, Schütz E. A new universal mulitplex digital PCR method with improved precision for the quantification of donor derived graft cfDNA traces. Clin Chem 2015; 61 (Suppl): S179.
301. Beck J, Reinhard L, **Oellerich** M, Schulz U, Fuchs U, Knabbe C, Gummert J, Schütz E, Birschmann I. Early detection of rejection after heart transplantation by a universal digital PCR method. Clin Chem 2015; 61 (Suppl): S180.
302. Schütz E, Blum A, Beck J, Harden M, Koch M, Wuensch T, Stockmann M, Nashan B, Kollmar O, Matthaei J, Kanzow P, Walson PD, Brockmöller J, **Oellerich M**. Graft-derived cell-free DNA – a promising rejection marker in liver transplantation – results from a prospective multicenter trial. Clin Chem 2016; 62 (Suppl): S34.
303. Beck J, Schirmer M, Rave-Fraenk M, Urnovitz H, Bornemann-Kolatzki K, Mitchell WM, **Oellerich M**, Schütz E, Canis M. Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer. J Clin Oncol 2017; 35 (suppl; abstr 6055); doi: 10.1200/JCO.2017.35.15\_suppl.6055.
304. Schütz E, Reinhard L, Knüttgen F, Beck J, Schulz U, Harden M, Fuchs U, Mettenmeyer N, Knabbe C, Zittermann A, Gummert J, Birschmann I, **Oellerich M**. Graft-derived cell-free DNA - a promising rejection marker in cardiac transplantation – results from a prospective observational trial. 69th AACC Annual Scientific Meeting Abstracts, 2017: S34.
305. **Oellerich M.** Circulating cell-free DNA in cancer and transplantation. Clin Chem Lab Med 2017; 55, Special Suppl: S1153.
306. **Oellerich M**, Shipkova M, Schauerte V, Asendorf T, Walson PD, Mettenmeyer N, Kabakchiev M, Ellenberger D, Friede T, Wieland E, Schwenger V, Schütz E, Beck J. Absolute quantification of graft-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation – results from a prospective observational trial. 70th AACC Annual Scientific Meeting Abstracts, 2018: S226-227.
307. Knüttgen F, Beck J, Reinhard L, Zittermann A, **Oellerich M**, Schulz U, Fuchs U, Knabbe C, Flieder T, von Bargen K, Schütz E, Gummert J, Birschmann I. Cell-free DNA as non-invasive biomarker of cardiac allograft rejection. J Lab Med 2018; 42: eA22.
308. **Oellerich M.** Laboratory medicine – challenges and opportunities. Clin Chem Lab Med 2018; 56: eA204.
309. Beck J, **Oellerich M**,Teubert A, Glaubitz R, Schütz E. Analytical validation of a clinical ddPCR assay for graft-derived cell-free DNA determination. 71st AACC Annual Scientific Meeting Abstracts, 2019: S189-190.
310. Schütz E, Asendorf T, Beck J, Shipkova M, Kabkachiev M, Walson PD, Wieland E, **Oellerich M**, Schwenger V, Schauerte V. Time dependent apparent increase in dd-cfDNA percentage in clinically stable patients between one and five years following kidney transplantation. 72nd AACC Annual Scientific Meeting Abstracts, 2020: S45
311. Osmanodja B, Akifova A, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E, Budde K. Longitudinal dd-cfDNA monitoring reduces time to ABMR diagnosis in dnDSA positive kidney transplant recipients: a diagnostic randomized clinical trial. ESOT Congress Abstract Book, Late Breaking Full Orals, LOS1\_3, p. 445, Transpl Int, 21st Congress of the European Society for Organ Transplantation, 2023